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Abstract 
Chikungunya virus (CHIKV) is a mosquito borne alphavirus, whose primary disease 
manifestation in humans is acute and chronic, often debilitating polyarthritis/polyathralgia.  Current 
treatments are often inadequate.  This thesis aims to elucidate the roles of several immune 
components in CHIKV disease, using a mouse model of CHIKV infection and disease, which 
recapitulates many aspects of human disease.  An improved understanding of the immunobiology of 
CHIKV is required for future development of new interventions for this recently re-emergent virus. 
 
CHIKV polyarthritis/polyathralgia is associated with a prolific monocytes/macrophage 
infiltration of musculoskeletal tissue in humans, monkeys and mice.  The infection in all species is 
associated with high levels of chemokine (C-C motif) ligand 2 (CCL2), a chemokine that binds 
chemokine (C-C motif) receptor 2 (CCR2) and is involved in recruitment of monocytes to the sites 
of infection.  Targeting CCL2 or CCR2 signalling has thus been proposed as a potential treatment 
option for CHIKV disease.  Results herein show that CHIKV infection of mice deficient in CCR2 
led to a significantly more pronounced and prolonged arthritis that was associated with cartilage 
damage.  The prominent monocytes/macrophages infiltrate seen in wild-type mice was replaced by 
a prolific neutrophil infiltrate in CCR2-/- mice.  The switch in the arthritic infiltrate was associated 
with changes in the expression of multiple inflammatory mediators, with the loss of anti-
inflammatory macrophages and their activities (e.g. efferocytosis) also implicated in the 
exacerbated inflammatory response.  These results illustrated that the recruited 
monocytes/macrophages in wild-type mice (although associated with acute disease) also have a 
protective role in CHIKV arthritis.  These results suggest caution may be warranted when 
considering therapeutic targeting of CCR2 for treatment of CHIKV arthritis (Chapter 3).   
 
To study the role of different components of the immune system in CHIKV viraemia and 
disease, mice deficient in B cells, T cells, CD4+ T cells, natural killer cells and IFN-γ were infected 
with CHIKV.  Results herein confirmed that B cells are crucial for controlling CHIKV viraemia, 
but showed that T cells also play a role, albeit secondary to antibodies.  B cell deficient mice 
experienced a life long viraemia with little overt pathology evident, supporting the view that 
CHIKV disease is largely an immunopathology.  In T and B cell deficient mice, viraemia was likely 
controlled by chronic up-regulation of tumour necrosis factor and interferon gamma, but not 
interferon alpha/beta.  Importantly, CD4+ T cells and interferon gamma were shown to play 
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important roles in acute CHIKV arthritis, with T cells previously thought not to play a significant 
role (Chapter 4).  
 
CHIKV disease in humans is often associated with chronic arthritic symptoms that persist 
for months, occasionally over a year, after CHIKV infection.  Persistence of CHIKV has been 
postulated to be responsible for the chronic arthritis.  To further investigate this issue, chronic 
infection and disease parameters were analysed in the established wild-type mouse model of acute 
CHIKV arthritis.  Viraemia is cleared day 4-5 post-infection and neutralising antibodies are 
detected as early as day 4 post-infection, and rose significantly thereafter.  Despite the high levels 
of neutralising antibodies, replication competent CHIKV could be recovered from feet of infected 
mice up to day 14 post-infection.  Importantly, significant levels of CHIKV RNA (including 
negative strand RNA) could be detected by quantitative real-time polymerase chain reaction in feet 
up to day 100 post-infection.  Interferon stimulated gene 54, a factor that is up-regulated in response 
to viral infection and double stranded RNA, was found also to be persistently up-regulated in these 
feet, suggesting ongoing replication of viral RNA.  Microarray analysis of these feet revealed that 
(i) many of the pathways up-regulated during acute arthritis were maintained during chronic 
infection, (ii) on-going local inflammatory responses were dominated by type I IFN responses, and 
(iii) many of the inflammatory pathways identified in chronically infected mouse feet were also 
found in chronic CHIKV patients.  These observations suggest that chronic disease is due to 
ongoing inflammation stimulated by persistently replicating viral RNA and viral proteins encoded 
by that RNA (Chapter 5). 
 
In conclusion, this thesis has shown, that inflammatory CCR2+ monocyte can be critical for 
preventing excessive pathology and resolving inflammation, that distinct immune factors control 
CHIKV viraemia and arthritis, and that long-term persistence of replicating CHIKV RNA might be 
the cause of protracted arthritic manifestations in CHIKV patients.  These studies will hopefully 
inform future development of intervention for CHIKV. 
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Chapter 1: Introduction 
 
1.1 Alphaviruses 
Alphaviruses belong to the Togaviridae family of spherical enveloped viruses (60–70 nm 
in diameter), which have a positive-sense single-stranded ribonucleic acid (RNA) genome (Weaver 
et al., 2000).  The alphavirus genus comprises approximately 30-40 viruses (Kuhn, 2007) that are 
commonly classified into New World and Old World alphaviruses, based on the location of their 
discovery (Schwartz and Albert, 2010).  New World alphaviruses (found in the Americas), for 
example, Venezuelan equine encephalitis virus (VEEV), Eastern equine encephalitis virus (EEEV) 
and Western equine encephalitis virus (WEEV), are generally associated with encephalitis.  Old 
World alphaviruses (found in Europe, Africa and Australasia), for example, Sindbis, Ross River, 
Barmah Forest, o’nyong-nyong and chikungunya viruses, are generally associated with fever, rash 
and polyarthritis (Table 1.1 ). 
Table 1.1 Alphaviruses associated with arthritis and/or arthralgia. 
Arhtritogenic 
alphavirus 
Geographic 
distribution 
Cases Comments 
Chikungunya South and 
East Asia, 
Africa, 
West-Pacific  
Recurrent epidemics. 2006–
2007 >260,000 cases in 
Reunion Island, >1.4 m in 
India, 200 in Italy. Travellers 
and 6,000 in Caribbean.  
Polyathritis/arthraligia is the dominant 
manifestation of symptomatic infection. 
Often severe at onset and progressively 
resolving within 3–6 months. 
Ross River Australia  ≤8,000 per year in Australia.   
West-Pacific  Pacific island epidemic 
19979/80. 
Travellers and military. 
 
Barmah Forest Australia  500–1,500 per year in 
Australia.  
Rash and arthropathy dominate.  
Sindbis Group Africa, Asia, 
Australia  
Rare. Probably all the same, or very similar, 
viruses.  
      Karelian fever  Russia  Rare. Arthropathy is the dominant 
manifestation.  
      Ockelbo disease Sweden  ≤30 per year   
      Pogosta disease Finland  ≤100–200 per year.   
Mayaro South 
America  
Small sporadic epidemics. 
Reported in travellers.  
Arthropathy is the prominent feature.  
O'nyong-nyong  Central & 
East Africa  
Small sporadic epidemics. > 2 
million in 1959–62.  
 
Igbo Ora  Central 
Africa  
Rare.  Probably a strain of chikungunya 
(Lanciotti et al., 1998).  
Adapted from Suhrbier and La Linn (2004) and Suhrbier and Mahalingam (2009).  
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1.2 hikungunya virus (CHIKV) 
CHIKV is an arthritogenic alphavirus that is transmitted by mosquitoes.  The word 
‘chikungunya’ is derived from the Makonde (Tanzania) language and can be translated as ‘that 
which bends up’, referring to the posture adopted by CHIKV-infected patients with severe joint 
pain (Charrel et al., 2007).  The typical clinical symptoms of CHIKV disease include self-limiting 
fever, headache, nausea, myalgia (muscle pain), rash, arthritis and persistent arthralgia (joint pain 
that can last for weeks to months) (Charrel et al., 2007).  Recently (2004-2013), a large epidemic 
swept across Africa and Asia.  In Reunion Island the epidemic caused 260,000 cases (one-third of 
the population), and had a 0.1% fatality rate (Mavalankar et al., 2008, Manimunda et al., 2011, 
Pialoux et al., 2006).  In India, an estimated 1.4–6.5 million cases were believed to have occurred 
(Schwartz and Albert, 2010).  Currently, there is no licensed vaccine for this pathogen, which has 
been declared a high priority by the US National Institute of Health (NIH) (Ryman and Klimstra, 
2008).  Patients are normally treated with analgesics, antipyretics and/or non-steroidal anti-
inflammatory drugs (NSAIDS) (Jaffar-Bandjee et al., 2010).  The understanding of the 
immunobiology of CHIKV disease is still limited, despite an increasing number of studies in the 
area. 
 
1.3 Epidemiology 
1.3.1 Geographic distribution 
CHIKV was first officially isolated and recorded in Tanzania (Ross, 1956).  However, the 
first known CHIKV outbreak has been tracked back to 1779 in Jakarta, where it was mistaken as a 
dengue outbreak (Carey, 1971).  Since the 1956 discovery, laboratory-confirmed autochthonous 
(local transmission) cases have been reported in approximately 40 countries spanning Africa, Asia, 
and recently in Europe (Figure 1.1) (Suhrbier et al., 2012, Powers and Logue, 2007).  During 1963, 
India experienced one of the worst CHIKV epidemics, with more than 400,000 individuals infected 
in Chennai alone (Arankalle et al., 2007).  More recent outbreaks have included Congo (50,000 
cases in 1999–2000) (Pastorino et al., 2004) and Indonesia (6,000 cases in 2001–2003) (Buonaguro 
et al., 2013).  
In late 2004, the largest-ever recorded CHIKV epidemic began in Kenya and spread to 
Reunion Island (estimated 300,000 cases in 2005–2006) (Schuffenecker et al., 2006), Malaysia 
(3,870 reported cases in 2006–2009) (Azami et al., 2013), Thailand (46,069 reported cases in 2008–
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2009) (Chusri et al., 2011), Papua New Guinea (1,590 cases in 2012) (Horwood et al., 2013) and 
the Caribbean (3,700 cases up to February 2014) (Robles, 2014).  
This recent outbreak was associated with a new clade of CHIKV that is efficiently 
transmitted by Aedes albopictus (Charrel et al., 2007, Delatte et al., 2008).  Three distinct 
phylogroups of CHIKV are recognised: (i) the eastern, central and southern Africa (ECSA) 
phylogroup, (ii) the west Africa phylogroup and (iii) the Asian phylogroup (Volk et al., 2010).  The 
new clade of CHIKV emerged from within the ECSA phylogroup (Schuffenecker et al., 2006, 
Pialoux et al., 2007). 
 
Figure 1.1: Distribution of CHIKV cases.   
CHIKV cases have been documented in many parts of the world.  In Figure 1.1, the red-coloured 
countries are those documented with autochthonous CHIKV transmission; green-coloured countries 
are those documented with imported CHIKV cases.  (Adapted from Powers and Logue (2007)). 
 
1.3.2 Mode of transmission—urban and sylvatic cycles 
CHIKV can be transmitted via one of two cycles: (i) the urban cycle and/or (ii) the sylvatic 
cycle.  The urban cycle of CHIKV transmission often occurs during epidemics, where CHIKV 
cycles between a mosquito vector and a human host.  The sylvatic cycle usually involves CHIKV 
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transmission during endemic seasons, where mosquito vector and non-human vertebrate hosts 
maintain the CHIKV reservoir. 
In Africa, CHIKV is thought to be maintained in a sylvatic cycle involving primates 
(Powers and Logue, 2007).  One study reported that in southern Africa (Rhodesia), wildlife 
including vervets (Ceropithecus aethiops pygerythrus) and baboons (Papio ursius) were found to be 
viraemic for three to four days (McIntosh et al., 1964).  The level of viraemia was said to be high 
enough to infect significant numbers of the mosquitoes that feed on infected animals (McIntosh et 
al., 1964).   
Some primates (Macaca fascicularis and Macaca nemestrina leonine) in Southeast Asia 
(Philippines, Malaysia and Thailand) were found to have antibodies against CHIKV (Marchette et 
al., 1978, Nakgoi et al., 2013, McIntosh et al., 1964), suggesting the presence of a sylvatic cycle in 
places other than Africa.  In addition, infectious CHIKV was detected in four macaques (Macaca 
fascularis) during the latest CHIKV epidemic in Malaysia (Apandi et al., 2009).  Despite this 
evidence for the sylvatic cycle in Asia, the urban cycle (human–mosquito) is still believed to be the 
primary mode of CHIKV transmission outside Africa (Powers and Logue, 2007).   
 
1.3.3 Vectors 
CHIKV, like all alphaviruses, is transmitted by invertebrate vectors, mostly mosquitoes 
(Strauss and Strauss, 1994).  Aedes aegypti and Aedes albopictus are the two main vectors involved 
in the urban cycle of CHIKV transmission (Singh and Unni, 2011). 
Aedes aegypti is prevalent in urban areas where fresh water and warmer temperatures are 
present (Juliano et al., 2002).  Aedes aegypti has been the main vector for CHIKV outbreaks in Asia 
(pre-2004), East Africa (2004–2005) and Comoros (2004–2005) (Powers and Logue, 2007). 
Aedes albopictus, commonly known as Asian tiger mosquito, is native to tropical and 
subtropical latitudes, but has spread into and has adapted to many parts of the world via 
international trade and travel (Enserink, 2008).  Aedes albopictus was the primary vector for 
CHIKV during the most recent major epidemic (Charrel et al., 2007, Delatte et al., 2008, Kumar et 
al., 2008).  Prior to this recent epidemic, Aedes albopictus was not a well recognised vector for 
CHIKV (Tsetsarkin et al., 2009).  Two mutations in the structural proteins of CHIKV, namely the 
A226V mutation on the E1 protein and the I211T mutation on the E2 protein, are believed to have 
contributed to the adaptation of CHIKV to the Aedes albopictus vector (Tsetsarkin et al., 2009, 
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Vazeille et al., 2007).  This adaptation is of some concern, as Aedes albopictus can thrive in arid 
and cold conditions (Benedict et al., 2007) and is spreading to an ever increasing number of 
countries (Enserink, 2008) including European countries between 1995 to 2012 (Schaffner et al., 
2013).  Autochthonous transmission of CHIKV may thus also spread to more and more countries 
worldwide.  
 
1.4 Clinical manifestations 
1.4.1 Acute symptoms 
CHIKV is able to infect people of any gender and age (Jaffar-Bandjee et al., 2010).  
CHIKV disease is ordinarily self-limiting and not life threatening, although in the recent epidemic, 
the disease appeared to be more severe with severe disease manifestations and occasionally 
mortality (Jaffar-Bandjee et al., 2010).  After infection with CHIKV, there is usually a two- to four-
day delay before the first disease symptoms appear.  In about 5% of ‘silent’ cases, patients do not 
experience any disease symptoms (Gerardin et al., 2008).  Patients normally experience a sudden 
onset of fever (39–40ºC), lethargy and rigor for 3 to 12 days (Nargi-Aizenman et al., 2002).  In 
some cases, the fever might resolve in one or two days, but return with the so-called ‘saddle-back 
fever’ (Hawman et al., 2013, Carey, 1971).  After the onset of fever, nearly all patients develop 
debilitating polyarthritis (Seymour et al., 2013, White et al., 2001) usually involving peripheral 
joints (interphalangeal joints, wrists and ankles), proximal joints (knees and elbows) and large joints 
(shoulders and spine) (Tisserand et al., 2011, Suhrbier et al., 2012).  Some patients also experience 
a maculopapular rash (Peck et al., 1979, Ryman et al., 2000) and oedema (Brighton et al., 1983).  
Most acute symptoms (aside from polyarthritis/polyarthralgia) usually resolve after seven to 10 
days (Ryman et al., 2000, Suhrbier et al., 2012). 
 
1.4.2 Chronic arthritic symptoms 
While most of the acute symptoms of CHIKV infection are resolved within one to two 
weeks, recent studies show that a high percentage of CHIKV-infected patients (ranging from 4.7–
75.4%), especially the elderly and patients with high viral loads (Sissoko et al., 2009, Das et al., 
2010, Chaaitanya et al., 2011), experience protracted (3–36 months) unresolved arthritic symptoms 
(Table 1.2).  These chronic symptoms include arthralgia, myalgia, asthenia, relapsing or lingering 
rheumatic musculoskeletal pain (RMSP), polyarthritis, chronic arthritic disability and joint stiffness 
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(Table 1.2).  Studies have associated CHIKV disease with the onset of autoimmune arthritides with 
cartilage erosion (Bouquillard and Combe, 2009, Ganu and Ganu, 2011).  However, these studies 
are not conclusive, as concurrent autoimmune diseases, rather than CHIKV infections, are believed 
to be the more likely causes of the autoimmune symptoms seen in these CHIKV-infected patients 
(Suhrbier et al., 2012).  This notion is supported by several studies indicating that chronic CHIKV 
arthritis does not generally trigger erosion of cartilage and bones (Das et al., 2010, Hoarau et al., 
2010, Schilte et al., 2013). 
Table 1.2: Frequency of persistent CHIKV arthritic symptoms. 
Studies conducted to identify the frequency and duration of arthritic symptoms caused by different 
CHIKV lineages at different geographic locations.  
 CHIKV 
lineages 
Frequency of protracted 
arthritis 
Duration 
(month) 
Symptoms Studies 
R
eu
ni
on
 Is
la
nd
 
ECSA* 
epidemic 
75.4% (261/346) 36 Arthralgia Gerardin et al. (2013) 
60% (n/a) 36 RMSP^ Schilte et al. (2013) 
57% (84/147) 15 A range of rheumatic 
symptoms 
Sissoko et al. (2009) 
63.6% (56/88) 18  Athralgia Borgherini et al. (2008) 
53% (56/106) 3–11 Chronic pain de Andrade et al. (2010) 
  
Fr
an
ce
 &
 It
al
y 
ECSA* 
epidemic 
52% (118/227) 
34% (78/227) 
Mean 23.2 Degenerative disc disease 
Arthritis 
Couturier et al. (2012) 
48% (17/29) 24 Arthralgia  Larrieu et al. (2010) 
66.5% (151/227) 12 Arthralgia, myalgia and 
asthenia 
Moro et al. (2012) 
  
In
di
a ECSA* 
epidemic 
4.7% (24/509) 24  Arthralgia Chopra et al. (2012) 
57% (249/437) 15 Polyarthritis  Mathew et al. (2011) 
6.1% (14/230) 36 Chronic arthritic 
disability 
Kularatne et al. (2012) 
  
Se
ne
ga
l 
Western 
Africa 12.1 %(13/107) ≥36 
Joint stiffness and 
arthralgia Brighton et al. (1983) 
*ECSA: East/Central/South Africa 
^RMSP: relapsing or lingering rheumatic musculoskeletal pain  
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1.4.3 Severe disease manifestations following CHIKV infection 
During the recent outbreak in the Indian Ocean (2006–2008), life-threatening symptoms 
such as encephalitis, meningoencephalitis, Guillain–Barré syndrome, pneumonia, severe acute 
nephritis, heart failure and myocarditis were found in some patients (Jaffar-Bandjee et al., 2010, 
Bodenmann and Genton, 2006, Lemant et al., 2008, Solanki et al., 2007, Economopoulou et al., 
2009, Lebrun et al., 2009).  These severe disease manifestations and occasional fatalities were rare 
in CHIKV disease prior to this outbreak (Economopoulou et al., 2009).  These severe 
manifestations were present in about 0.3% of total patients (Pierre et al., 2006), and these patients 
had a relatively high fatality rate (10.6–33%) (Economopoulou et al., 2009, Renault et al., 2007), 
whereas patients without severe manifestations had a much lower mortality rate (0.1%) (Pialoux et 
al., 2007, Mavalankar et al., 2008, Manimunda et al., 2011).  Studies have also shown that the 
elderly are more susceptible to these severe manifestations of CHIKV disease (Economopoulou et 
al., 2009, Renault et al., 2007).   
 
1.5 Biology of the CHIKV 
1.5.1 Genome organisation 
Several isolates of CHIKV have been fully sequenced, and these include the S27 African 
prototype (Khan et al., 2002), isolates from the 1983 Senegal outbreak (Vanlandingham et al., 
2005), and six isolates from the Reunion Island and the Seychelles (Schuffenecker et al., 2006).  
CHIKV has approximately 11,805 nucleotides that contain two open reading frames (ORFs), ORF1 
and ORF2, which encode viral proteins (Figure 1.2) (Solignat et al., 2009).  The whole genomic 49s 
RNA is organised as 5’ cap-nsP1-nsP2-nsP3-nsP4-(junction region)-C-E3-E2-6K-E1-poly(A)-3’ 
(Figure 1.2).  The 5’ end of CHIKV genome has a non-translated region (NTR) comprising 76 
nucleotides.  ORF1 starts at position 77 and terminates at position 7501, while the ORF2 starts at 
position 7,567 and terminates at position 11,301 (Solignat et al., 2009).  A junction sequence of 68 
nucleotides in size is located between ORF1 and ORF2 (Solignat et al., 2009).  ORF1 encodes the 
non-structural proteins that are essential for viral replication (Strauss and Strauss, 1994).  ORF2 
encodes the structural proteins that form the CHIKV viral particle (Strauss and Strauss, 1994).  
The 3’ NTR contains several conserved-repeated-sequence elements (RSEs) that are 
postulated to be involved in controlling RNA synthesis (Ou et al., 1983, Pfeffer et al., 1998).  For 
example, deletion of RSEs in Sindbis virus (SINV) changes the dynamics of viral replication 
(reduced or delayed virus release) (Kuhn et al., 1991, George and Raju, 2000, Hardy and Rice, 
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2005).  Different alphaviruses have 3’ NTRs of different lengths, with different numbers of RSEs.  
In CHIKV, several RSEs are similar to other alphaviruses (Solignat et al., 2009).  For example, two 
copies of RSE are similar to o'nyong'nyong virus (ONNV), and three copies of RSE are similar to 
those found in Ross River virus (RRV) (Solignat et al., 2009).  The poly (A) tail located at the 3’ 
end of NTR, has a 19-nucleotide conserved-sequence element (CSE) that is conserved across all 
alphaviruses.  This CSE acts as the core promoter for the synthesis of negative-sense RNA (Ou et 
al., 1981). 
 
Figure 1.2: The genomic organisation of CHIKV.  
The CHIKV genome comprises approximately 11,805 nucleotides that encode for two ORFs.  
ORF1 encodes the non-structural proteins; ORF2 encodes the structural proteins.  ORF: open 
reading frame; NTR: non-translating region; nsP: non-structural protein; J: junction sequence; C: 
capsid.  (Adapted from (Khan et al., 2002)). 
 
1.5.2 Viral particle structure of the CHIKV 
Alphavirus particles are spherical, with a diameter of 60 to 70 nm (Figure 1.3).  The 
alphavirus genome is encapsulated by the capsid protein.  This arrangement is called a 
nucleocapsid.  This inner nucleocapsid consists of 240 copies of the capsid protein, which are 
arranged in a T = 4 icosahedral configuration (a polyhedron with 20 identical triangle surfaces) 
(Weaver et al., 2012, Caspar and Klug, 1962).  The nucleocapsid is enclosed in an outer shell that 
consists of 80 viral spikes that are also arranged in T = 4 icosahedral configuration.  These viral 
spikes are embedded in, and protruding from, the host-cell-derived lipid bilayer.  Each of these viral 
spikes consists of a trimer of E1-E2 heterodimers (Zhang et al., 2002). 
The crystal structure of the E3-E2-E1 mature complex and the pE2-E1 precursor of 
CHIKV have been solved (Voss et al., 2010).  The E1 glycoprotein contains domains I, II and III, 
and E2 glycoprotein contains domains A, B and C (Voss et al., 2010).  The molecular structure of 
pE2-E1and E3-E2-E1 complex shows that domains A and B of E2 hide the fusion site located in 
domain II of E1 (Voss et al., 2010).  The E2 glycoprotein attaches to the host-cell membrane, then 
JnsP1 nsP2 nsP3 nsP4 C E3 E2 6K E1
1 kb 2 3 4 5 6 7 8 9 10 11 12
5’ NTR 
(76 nt)
3’ NTR 
(526 nt)
polyA
19 nt
ORF 1 ORF 2
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under acidic conditions in the endosome, the E2-E1 heterodimers disassociate, exposing the E1 
fusion site (at the tip of domain II of E1).  The fusogenic site of E1 then adheres to the cell 
membrane to form E1 trimers that drive viral and host-cell membrane fusion, resulting in uncoating 
and release of the genome from the nucleocapsid (Kielian and Rey, 2006). 
 
  
Figure 1.3: CHIKV viral particles.  
The viral particle of CHIKV is spherical with a diameter of 60 to 70 nm.  The alphavirus genome is 
encapsulated by the nucleocapsid.  The nucleocapsid is enclosed by a viral spike outer shell. The 
outer shell is comprised of 80 viral spikes.  Each viral spike consists of a trimer of E1-E2 
heterodimers(Adapted from (Akahata et al., 2010)). 
 
1.5.3 Entry of virus 
The entry of alphaviruses into cells is aided by pH-dependent receptor-mediated 
endocytosis in clathrin-coated vesicles (Sourisseau et al., 2007, Swanson et al., 2010) (Figure 
1.4A).  Receptors that bind mannose-rich carbohydrates (e.g. dendritic cell-specific ICAM-3-
grabbing nonintegrin 1 [DC-SIGN] and liver and lymph node-SIGN [L-SIGN]) are believed to be 
involved in this process (Guo et al., 2000).  The clathrin-coated vesicle delivers viral particles to the 
endosome.  The acidic environment in the endosome triggers an irreversible conformational 
reorganisation of the viral glycoproteins (Wahlberg et al., 1989) (Figure 1.4B).  The E1-E2 
heterodimer dissociates, exposing the E1 fusion domain, which leads to the fusion of viral 
membrane with endosomal membrane (Kielian and Jungerwirth, 1990, Wahlberg et al., 1992) 
(Figure 1.4B).  This fusion leads to the release of 49S RNA genome (encapsulated in nucleocapsid) 
into the cytoplasm (Powers et al., 2001) (Figure 1.4C).  
E1-E2 heterodimer
Trimer
10 nm
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1.5.4 Translation, replication and transcription of viral RNA 
The released 49S RNA genome is translated to non-structural proteins, which are involved 
in virus replication.  The 5’ ORF of CHIKV (Figure 1.2) is translated into a large polyprotein 
(P1234) and in some alphaviruses, into two polyproteins (P123 and P1234) produced by read-
through of an opal stop codon located between nsP3 and nsP4 (Figure 1.4D) .  These polyproteins 
are consecutively cleaved by the viral protease found in nsP2 into mature nsP1, nsP2, nsP3 and 
nsP4.  These mature nsPs replicate viral RNA (see below).  The nsP2 protein also promotes viral 
replication by shutting down host-cell transcription (Garmashova et al., 2006) and inhibiting 
IFNα/β responses (Fros et al., 2010).  The P1234 is first cleaved into nsP4 and P123, and then the 
P123 is subsequently cleaved into nsP1 and P23.  The nsP4, nsP1 and P23 then form a replication 
complex  (Figure 1.4; RC-) that synthesises negative strand RNA  (Figure 1.4E1).  The P23 is 
eventually cleaved into nsP2 and nsP3 (Lulla et al. 2012).  Mature nsP1, nsP2, nsP3 and nsP4 form 
a replication complex  (Figure 1.4; RC+) that synthesises two species of positive strand RNA: 26S 
subgenomic mRNA (Figure 1.4E2) and the 49S genomic RNA (Figure 1.4E3) (Fayzulin and 
Frolov, 2004, Frolov et al., 2001).  The promoter, which leads to the transcription of negative strand 
RNA into 26S mRNA, is found in the junction sequence (Figure 1.2) (Ou et al., 1982). 
The 26S mRNA is translated into the polyprotein precursor C-pE2-6K-E1 (Figure 1.4F) 
The C-terminal portion of the capsid is first cleaved by its own autoprotease (a serine-like protease) 
and this cleavage results in a new N-terminus for the remaining polyprotein pE2-6K-E1 (Garoff et 
al., 1990) (Figure 1.4G).  This N-terminus has a signal sequence for translocating the polyprotein 
into the rough endoplasmic reticulum for glycoprotein synthesis (Figure 1.4H), where E1 and pE2 
are glycosylated.  In the golgi apparatus, E1 and pE2 form heterodimers, and these heterodimers 
trimerise to form the viral spike (Figure 1.4I).  The pE2-E1 heterodimers translocate to cell 
membranes via the Golgi apparatus (Figure 1.4I and J).  The pE2 is then cleaved into E2 and E3 by 
the host protease furin during transport to the cell surface.  Some alphaviruses species retain the E3 
in the mature spike.  E2 is involved in receptor binding, and E3 helps in initial folding (Lobigs and 
Garoff, 1990).  Earlier studies suggested E3 was cleaved and not present in the CHIKV viral 
particle (Simizu et al., 1984); however, a recent study has revealed that the E3 is still intact in the 
X-ray crystal structure of E3-E2-E1 complex (mature complex in cytoplasm) (Voss et al., 2010).  
The cleaved capsid associates with the newly synthesised 49S genomic RNA to form the 
nucleocapsid (Figure 1.4K).  At the host-cell membrane, the nucleocapsid combines with viral 
spikes to form the mature structural protein and the host-cell lipid bilayer to form mature viral 
particles that bud from the cell membrane (Figure 1.4L).  This budding process is triggered by 
interaction of the E2 cytoplasmic domain with the nucleocapsid (Lopez et al., 1994). 
This page intentionally left blank.
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Figure 1.4: Alphavirus replication.   
(A) Alphavirus enters the cell with the aid of receptor mediated endocytosis.  (B) The endosome’s 
acidic condition causes the E1 fusion domain to be exposed.  (C) The exposed E1 domain 
subsequently fuses with endosomal membrane and leads to the release of the 49S RNA genome.  
(D) The genomic RNA, which encodes for the non-structural protein get translated into polyprotein 
P123 or P1234.  The polyprotein is further proteolytically processed to form RC- and RC+.  (E1) 
The RC- facilitates the replication of negative strand RNA.  (E2) The RC+ facilitates the production 
of the 26S subgenomic RNA and (E3) the replication of the 49S RNA genomic RNA.  (F) The 26S 
subgenomic RNA is translated into polyprotein precursor C-pE2-6K-E1.  The capsid is cleaved off 
from the polyprotein (G) and then the remaining (pE2-6K-E1) is cleaved and translocated into the 
ER.  (H) In the ER, E1 and pE2 are glycosylated.  (I) In the golgi apparatus, glycosylated E1 and 
pE2 form pE2-E1 heterodimer.  (J) The trimerised heterodimers (viral spike), are then translocated 
onto the plasma membrane.  (K) The cleaved capsid and genomic RNA form the nucleocapsid.  (L)  
At the plasma membrane, the nucleocapsid and viral spike combine to form the viral particle.  the 
virus then buds from the host-cell membrane.   
(Adapted from Kuhn (2007) and Schwartz and Albert (2010)). 
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1.6 Animal models of CHIKV and RRV disease 
1.6.1 Non-human primate models 
Non-human primates are a suitable animal model for CHIKV disease, with studies 
suggesting that they serve as the natural reservoirs of CHIKV in Africa and perhaps Southeast Asia 
(section 1.3.2).  The most comprehensive non-human primate model to date was reported by 
Labadie et al. (2010), who used cynomolgus macaques (Macaca fascicularis).  This model involved 
intravenous/intradermal inoculation of CHIKV.  CHIKV-infected macaques developed viral, 
clinical and pathological features that were comparable to human CHIKV disease. Importantly, in 
the same model, the infected adult macaques showed long-term persistence of CHIKV, a feature 
that may explain the protracted arthritic symptoms in humans.  The similarities with human CHIKV 
disease make this model useful for facilitating the development of new interventions for CHIKV 
disease.  For example, this model has been used to investigate the anti-CHIKV antibody’s 
specificity against ‘E2EP3’, an epitope that was considered for vaccine target (Kam et al., 2012).  In 
addition, cynomolgus macaques were also used to access the efficacy of a live-attenuated vaccine, 
with macaques vaccinated and then challenged with CHIKV via subcutaneous inoculation (Roy et 
al., 2014). 
Rhesus macaques (Macaca mulatta) have also been used to study CHIKV infection (Binn 
et al., 1967), immune responses triggered by CHIKV (Messaoudi et al., 2013) and have been used 
in CHIKV vaccine studies (Levitt et al., 1986, Akahata et al., 2010).  Cercopithecus monkeys, 
baboons and bonnet monkeys (Macaca radiata) (McIntosh et al., 1963, Paul and Singh, 1968) were 
also shown to be viraemic upon CHIKV inoculation, but there have been no further studies using 
these models. 
 
1.6.2 Mouse models 
Mice have been used extensively to study CHIKV and RRV pathogenesis and to study the 
efficacy of new interventions for CHIKV and RRV disease.  Mouse age, mouse genetic background 
and site of inoculation have been key factors that have critically affected the viral and pathology 
outcomes (especially the rheumatic manifestations) in these mouse models.  Several studies have 
used a lethal CHIKV infection model that involves neonates/young mice (Ziegler et al., 2008) or 
immune-compromised mice (Couderc et al., 2008, White et al., 2011, Werneke et al., 2011, Gardner 
et al., 2012).  Mouse models for RRV have also used young mice (14-21 days old) (Lidbury et al., 
2000; Morrison et al., 2006; Lidbury et al., 2008).  Neither  lethal CHIKV infection models nor use 
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of young or neonatal mice is ideal.  Lethal infection models are of minimal value in studying 
arthritis as the mice die before arthritic symptoms manifest. eonates are not immunological mature, 
thus making them less useful for vaccine studies.  Use of young mice also complicates vaccine 
studies as there is insufficient time for vaccination prior to challenge. 
Adult wild-type mouse models represent more realistic models of CHIKV disease, not 
least because arthritis is the main symptom in adult humans infected with CHIKV.  However, while 
viraemia can be established in most adult mice, CHIKV arthritis symptoms are largely absent in 
mice, which have inoculated intraperitoneally (i.p.) (Suckling et al., 1978), intradermally (Couderc 
et al., 2008), intranasally (Wang et al., 2008) or intravenously (i.v.) (Teo et al., 2012a).  Gardner et 
al. (2010) reported the first adult, non-lethal-infection mouse model for CHIKV infection with 
rheumatic manifestation.  The adult mice (>6 weeks old) were subcutaneously inoculated with 
CHIKV at the ventral side of both hind feet, towards the ankle.  Infected adult mice developed self-
limiting arthritis (with overt foot-swelling evident), tenosynovitis and myositis; as features observed 
in human CHIKV disease.  Foot swelling in infected mice was characterised by a significant degree 
of mononuclear lymphocytes infiltration in joint and associated tissues including muscle.  This 
prominent mononuclear lymphocytes infiltrate is also prominent in RRV and CHIKV infected 
humans (Soden et al., 2000, Hoarau et al., 2010), in CHIKV infected primates (Labadie et al., 2010) 
and RRV infected mice (Lidbury et al., 2000, Lidbury et al., 2008, Morrison et al., 2006).   
In another model that was reported later, young mice, which were infected with CHIKV 
subcutaneously into the foot, also demonstrated foot swelling, arthritis, tenosynovitis and myositis 
(Morrison et al., 2011).  However, the infected younger mice experienced more severe disease, with 
clear tendonitis, which was less severe in infected adult mice (Morrison et al., 2011, Gardner et al., 
2010), again suggesting that mouse age is a factor that influences disease characteristics.  The adult 
WT mouse model for CHIKV infection (Gardner et al., 2010) has been widely used for vaccine 
studies (Wang et al., 2011a, Prow et al., 2010, Metz et al., 2013b, Garcia-Arriaza et al., 2014), 
antibody treatment studies (Kam et al., 2012) and disease studies (Teo et al., 2012b, Rudd et al., 
2012, Nakaya et al., 2012). 
 
1.7 Immune responses to CHIKV and RRV 
CHIKV and RRV infections are rarely fatal in humans.  Immune responses in most healthy 
adults control the viraemia, with acute symptoms usually resolved in one to two weeks, although 
chronic rheumatic symptoms can last for months to years (Suhrbier et al., 2012).  Individuals with 
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suboptimal immune systems, such as neonates and the elderly, exhibit higher fatality rates (Burt et 
al., 2012).  Arthritic conditions are more severe and chronic in the elderly but are less common in 
children (Gerardin et al., 2013, Jaffar-Bandjee et al., 2010).  Little is known about how these 
pathologies arise and resolve, especially the arthritic manifestations.  CHIKV and RRV infections 
in joints can lead to a series of antiviral immune responses, including the induction of inflammatory 
mediators.  It has been proposed that these inflammatory mediators result in tissue damage and 
excessive inflammation, which ultimately leads to the arthritis (Suhrbier and Mahalingam, 2009, 
Jaffar-Bandjee et al., 2009).  The following sections discuss the roles of different arms of the 
immune system in controlling CHIKV and RRV infection and in mediating the pathology of 
CHIKV and RRV disease. 
 
1.7.1 Type I interferon (IFN) responses 
IFN was discovered more than 50 years ago by Isaacs and Lindenmann as an antiviral 
protein for influenza virus (Isaacs and Lindenmann, 1957).  Since then, IFN has been shown to 
inhibit many other viruses including CHIKV.  The type I IFN response is also a critical antiviral 
defence mechanism against CHIKV infections.  Gifford and Heller showed that CHIKV could 
trigger IFN production in chicken fibroblasts three hours after infection (Gifford and Heller, 1963).  
More recent in vitro studies have also shown that type I IFN suppresses CHIKV replication 
(Sourisseau et al., 2007).  In patients, type I IFN is up-regulated in the sera and tissues during the 
acute phase of CHIKV infection (Wauquier et al., 2011, Chow et al., 2011, Ng et al., 2009, Hoarau 
et al., 2010), indicating the critical role of type I IFN in controlling infection during the acute phase.  
Consistent with clinical observation, up-regulation of type I IFN is also seen in acute-phase 
infection in primates, mice and zebrafish (Labadie et al., 2010, Gardner et al., 2010, Rudd et al., 
2012, Messaoudi et al., 2013, Palha et al., 2013).  Mice with incomplete type I IFN responses are 
more susceptible to CHIKV infection (Schilte et al., 2010, Rudd et al., 2012, Couderc et al., 2008, 
Teng et al., 2012), with mice deficient in the IFN-α/β receptor, or IFN response factors 3 and 7 
dying within days of infection (Rudd et al., 2012, Couderc et al., 2008, Gardner et al., 2012). 
Animal studies have indicated that the up-regulation of type I IFN is rapid, but transient 
after CHIKV infection (Gardner et al., 2010, Labadie et al., 2010).  CHIKV nsP2 has also been 
shown to block JAK-STAT signalling (Fros et al., 2010), so IFN treatment before CHIKV infection 
(but not IFN treatment after CHIKV infection) reduces the CHIKV viraemia and foot swelling in 
mice (Gardner et al., 2010).  These observations clearly indicate that type I IFN is crucial for 
controlling CHIKV during the early phase of CHIKV infection. 
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1.7.2 Monocytes/macrophages 
Monocytes are generated by haematopoietic stem cells in bone marrow, and are released 
into circulation where they differentiate into dendritic cells and macrophages.  There are at least 
two phenotypes of macrophages: classically activated (M1) macrophages and alternatively activated 
(M2) macrophages (Mosser and Edwards, 2008).  M1 macrophages promote inflammation and are 
involved in antiviral defence (Murray and Wynn, 2011).  M2 macrophages suppress inflammation, 
phagocytosis and promote wound-healing (Mosser and Edwards, 2008, Martinez et al., 2009).  
Macrophage/monocyte infiltrates are prominent features in CHIKV and RRV infection in mice 
(Lidbury et al., 2000, Morrison et al., 2006, Lidbury et al., 2008, Gardner et al., 2010), monkeys 
(Labadie et al., 2010) and humans (Soden et al., 2000, Hoarau et al., 2010).  Studies also show that 
CHIKV can infect patient monocytes/macrophages (Her et al., 2010), with primary monocytes 
(from humans, mice and macaques) also infected by CHIKV in vitro (Labadie et al., 2010, Her et 
al., 2010, Gardner et al., 2010).  These studies collectively suggest the involvement of 
macrophages/monocytes in CHIKV and RRV immunopathogenesis.  The following sections 
discuss the role of macrophages in CHIKV and RRV infection. 
 
1.7.2.1 Macrophages: role in arthritic manifestations 
Prolific monocyte/macrophage infiltration is a prominent feature in the musculoskeletal 
tissues of CHIKV-infected humans, monkeys and mice (Gardner et al., 2010, Hoarau et al., 2010, 
Labadie et al., 2010, Morrison et al., 2011, Ozden et al., 2007).  Microarray analysis of mice feet 
during peak arthritis has revealed up-regulation of a series of genes associated with macrophage 
recruitment and activation (Nakaya et al., 2012), again suggesting that macrophages are key players 
in CHIKV arthritis.  This observation is in line with studies showing that the chemical depletion of 
macrophages ameliorates RRV triggered muscle damage in mice (Lidbury et al., 2000, Lidbury et 
al., 2008) and CHIKV arthritis in mice (Gardner et al., 2010).  Activated macrophages release a 
series of inflammatory mediators (including prostaglandins, tumour necrosis factor-α (TNF-α) and 
interleukin-6 (IL-6)), which result in tissue damage, inflammation and arthritis (Suhrbier and 
Mahalingam, 2009).  Consistent with this notion, TNF-α and IL-6 were also found to be up-
regulated during peak arthritis in RRV-infected mice (Stoermer et al., 2012).  In addition, anti-TNF-
α, anti-IFN-γ, or anti- monocyte chemotactic protein-1 treatment reduced the disease severity in 
RRV-infected mice (Lidbury et al., 2008).  Taken together, these studies show that macrophages 
mediate arthritis in arthritogenic alphaviruses such as CHIKV and RRV. 
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1.7.2.2 Macrophages and viral persistence 
There is convincing evidence that CHIKV and RRV can persist in macrophages.  RRV is 
able to establish persistent infections in many cell lines including mouse muscle cell (Eaton and 
Hapel, 1976), human synovial fibroblasts (Journeaux et al., 1987) and macrophages cell lines (Linn 
et al., 1996, Way et al., 2002, Lidbury et al., 2011).  CHIKV was found to have persisted in spleen 
macrophages in macaques months after CHIKV infection (Labadie et al., 2010, Messaoudi et al., 
2013).  Similarly, CHIKV was found to have persisted in the synovial fluid macrophages in a 
patient who had chronic CHIKV symptoms for 18 months (Hoarau et al., 2010); RRV was detected 
in macrophage infiltrated synovium of patients up to 5 weeks post onset of symptoms (Soden et al., 
2000).  In line with these studies, fully recovered patients have been shown to have significantly 
higher levels of a mediator that reduces the recruitment of macrophages/monocytes (Chow et al., 
2011).  This mediator is eotaxin - a natural antagonist that inhibits monocyte/macrophage 
recruitment by blocking C-C chemokine receptor type 2 (CCR2) (Chow et al., 2011), where CCR2 
is found on monocytes/macrophages).  It has been proposed that CHIKV could persist in 
macrophages via an apoptosis-assisted infection mechanism, in which CHIKV hides in apoptotic 
blebs that can infect neighbouring cells without triggering an antiviral response (Krejbich-Trotot et 
al., 2011, Joubert et al., 2012).  Another study suggests that M2 macrophages are likely to facilitate 
CHIKV persistence (Stoermer et al., 2012).  Taken together, these studies suggest that macrophages 
are associated with CHIKV and RRV persistence.  
 
1.7.3 Natural killer (NK) cells 
NK cells differentiate from common lymphoid progenitor cells in bone marrow (Sun and 
Lanier, 2011).  NK cells are known to provide protection against viral infection, including human 
cytomegaloviruses, influenza virus, hepatitis viruses and human deficiency virus-1 (HIV) (Lanier, 
2008).  NK cells exert their antiviral actions mainly by killing the infected cells with cytolytic 
mediators (perforin and granzymes) (Sun and Lanier, 2011).  NK cells also produce large amounts 
of IFN-γ (Sun and Lanier, 2011, Gerosa et al., 2002), which facilitates the maturation of other 
immune cells (including macrophages) and the activation of T helper (Th) cells as well as having 
direct anti-viral activity (Swain et al., 2012).  Cell surface molecules can activate or inhibit NK 
cells.  For example, NK cells are activated when there is up-regulation of NK-activating receptors 
(such as NKG-D) on NK cells and down-regulation of NK-inhibitory ligand (such as human 
leucocyte antigen A (HLA-A) and CD94) on targeted cells (Lanier, 2008, Lodoen and Lanier, 
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2005).  NK cells can also be activated by several pro-inflammatory cytokines such as type I IFNs, 
IL-12 and IL-15 (Lanier, 2008). 
The role of NK cells in CHIKV infection is not yet clearly defined.  A recent study has 
shown that the acute phase of CHIKV infection triggers transient expansion of NK cells expressing 
NKG-C and receptor for HLA-C (Petitdemange et al., 2011).  This rapid expansion of NK cells has 
also been seen in human RRV infection (Aaskov et al., 1981, Aaskov et al., 1987).  NK cells have 
also be found to be one of the infiltrating cells in the arthritic feet of CHIKV-infected mice 
(Gardner et al., 2010), and this is consistent with the up-regulation of IL-12 in the feet of CHIKV-
infected mice (Stoermer et al., 2012).  The role of NK in CHIKV arthritis is still not known, 
although NK cells are suspected to be implicated in rheumatoid arthritis (RA), as NK cells produce 
a range of pro-inflammatory cytokines (such as IFN-γ, receptor activator of nuclear factor kappa-B 
ligand, macrophage colony-stimulating factor) that may worsen RA pathology (Ahern and Brennan, 
2011). 
 
1.7.4 Adaptive immune responses against the CHIKV 
Innate immune responses are vital for the rapid detection of viruses, the first-line defence 
against viruses, and the stimulation of adaptive immune responses (Takeuchi and Akira, 2009).  
Adaptive immune responses, which consist of the humoral and cell-mediated responses that are 
mediated by B and T cells, respectively, are thought to be highly specific and effective responses 
against viral infection. Elderly patients, who are known to have a weaker adaptive immune system 
(Dorshkind et al., 2009), have been found to be more susceptible to CHIKV infection and can suffer 
a severe and protracted pathology (Hoarau et al., 2010, Borgherini et al., 2008, Gerardin et al., 
2013, Sissoko et al., 2009).  Despite the importance of adaptive immune responses in CHIKV 
disease being known, the precise roles of different arms of adaptive immune responses on CHIKV 
disease are not entirely established.  The potential roles of T and B cells in CHIKV disease, 
particularly on viraemia control and rheumatic manifestations, are discussed in the following 
sections. 
 
1.7.4.1 B cell responses 
B cells are known to produce antibodies to control CHIKV infection (Eckels et al., 1970, 
Lum et al., 2013).  These antibodies, dominated in humans by immunoglobulin G3 (IgG3), often 
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target an epitope within the E2 glycoprotein (Kam et al., 2012).  Pregnant women infected by 
CHIKV in the last month before giving birth have been shown to transmit CHIKV to their children 
(Jaffar-Bandjee et al., 2010).  This transmission occurred due to the inadequate time for the mother 
to generate sufficient levels of anti-CHIKV antibodies that would ordinarily prevent the mother-to-
child infection (Jaffar-Bandjee et al., 2010).  In addition, anti-CHIKV antibodies have been shown 
effectively to prevent CHIKV infection, not only in adult WT mice (Selvarajah et al., 2013), but 
also in type I IFN-deficient mice and neonates (mice), which are known to be more susceptible to 
CHIKV infection (Couderc et al., 2009, Pal et al., 2013, Selvarajah et al., 2013).  Several animal 
studies have also shown that antibody-based vaccines elicit protection against CHIKV (Eckels et 
al., 1970, Akahata et al., 2010, Metz et al., 2013a).  While it is clear that antibodies are critical and 
effective in clearing CHIKV viraemia, the effectiveness of antibodies in clearing CHIKV persisting 
in tissues is less clear.  Lum et al. (2013) reported that antibodies were essential in clearing CHIKV 
infection; conversely, Hawman et al. (2013) showed that injected antibodies could clear the CHIKV 
viraemia only, but not CHIKV RNA in tissues, in persistently viraemic mice who were deficient in 
B cells. 
The role of B cells in alphaviral arthritic disease is less clear.  Some studies have shown 
that B cells have no role in RRV disease (Morrison et al., 2007, Morrison et al., 2006), while 
another study reported that a deficiency in B cells leads to more severe arthritic disease in CHIKV-
infected mice (Lum et al., 2013).  In addition, studies have shown that patients with high levels of 
CHIKV-specific IgG were associated with long-term rheumatic manifestation, but the mechanism 
leading to this pathology was unclear (Gerardin et al., 2013, Moro et al., 2012).  Further 
investigation would be required to determine the precise roles of B cells and antibodies in the 
rheumatic manifestation of CHIKV disease. 
 
1.7.4.2 T cell responses 
T cells with αβ T cell receptor (TCR) are the mediators of adaptive immune responses.  
αβ+ T cells are divided into two groups, based on the expression of co-receptors CD4 and CD8.  
CD4+ T cells recognise the peptide antigen that is presented by the major histocompatibility 
complex-II (MHC-II); CD8+ T cells recognise the peptide antigen that is presented by MHC-I.  
Both CD4+ and CD8+ T cells are often involved in antiviral immune responses.  CD4+ T generally 
mediate antiviral activity by helping B cells to generate antibodies, CD8+ T cells to develop, as 
well as production of anti-viral cytokines such as IFN-γ and TNF.  CD8+ T cells exert their antiviral 
activity via cytotoxic activity, a process where the virus-infected cells are killed by perforin and 
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granzyme B secreted by the CD8+ T cells, and/or secretion of antiviral cytokines (e.g. IFN-γ and 
TNF) (Swain et al., 2012). 
The understanding of how T cells are involved in CHIKV disease is still unclear.  Clinical 
and animal studies have shown that CHIKV infections generate robust CHIKV-specific CD4+ and 
CD8+ T cell responses (Hoarau et al., 2010, Messaoudi et al., 2013, Gardner et al., 2010, Wauquier 
et al., 2011).  A clinical study showed that CD8+ T cells are activated at the early stages of 
infection (day 2–3) and CD4+ T cells are activated at later stages (Wauquier et al., 2011).  Another 
study showed that aged macaques mount lower levels of anti-CHIKV CD4+ and CD8+ T cell 
responses compared with adult macaques (Messaoudi et al., 2013).  This study also showed that 
CHIKV persisted in the spleen of older macaques, and postulated that this CHIKV persistence 
could be attributed to the reduced T cell responses seen in these animals. 
Studies have shown that CHIKV vaccines are able to elicit CD8+ T cells targeting the E1 
and E2 portions of CHIKV (Garcia-Arriaza et al., 2014, Chattopadhyay et al., 2013), suggesting the 
potential involvement of CD8+ T cells in combating CHIKV infections.  However, adoptively 
transferred vaccine-induced CHIKV-specific CD8+ T cells have failed to prevent CHIKV infection 
(Chu et al., 2013).  This observation is consistent with a study showing that a deficiency of CD8+ T 
cells neither aggravated nor ameliorated the viraemia in CHIKV-infected mice (Teo et al., 2012b).  
In the same study, Teo et al. (2012b) showed that arthritis level (foot swelling) was unaffected by a 
deficiency of CD8+ T cells, suggesting that CD8+ T cells are not involved in CHIKV arthritis.   
Although CD8+ T cells may have little or no role in viraemia control, CD8+ T cells may 
be involved in clearance of virus from tissues.  For example, CD8+T cells have been shown (i) to 
facilitate the clearance of SINV from the central nervous system (Binder and Griffin, 2001, Kimura 
and Griffin, 2000) and (ii) to mediate clearance of RRV from macrophages persistently infected by 
RRV in vitro (Linn et al., 1998).  These studies collectively suggest that CD8+ T cells are not 
essential for the viraemia control of alphaviruses, but may be involved in viral clearance from 
tissues.  Whether CD8+ T cells are required for recovery from chronic disease and clearance of 
viral RNA persisting in joint macrophages remain unresolved (Hoarau et al., 2010, Labadie et al., 
2010). 
CHIKV infections have been found to trigger a CD4+ response that is biased to the Th1 
response in mice (Gardner et al., 2010).  Studies have also indicated that a higher Th1 response is 
correlated with chronic arthritis (Kelvin et al., 2011, Chaaitanya et al., 2011, Hoarau et al., 2010).  
CD4+ T cells have been shown effectively to control VEEV and SINV in the central nervous 
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system via the action of IFN-γ (Brooke et al., 2010) (Burdeinick-Kerr et al., 2007).  The role of 
CD4+ T cells in CHIKV viraemia control and disease thus remains unclear. 
 
1.8 Alphavirus vaccine vectors and alphavirus vaccines  
Alphaviruses have been extensively studied as potential vaccine vectors (Lundstrom, 
2014).  For example, influenza virus genes delivered by recombinant VEE replicon vaccines 
successfully protected mice and birds from influenza infection (Pushko et al., 1997, Schultz-Cherry 
et al., 2000).   
Considerable effort have been expended in the development of alphavirus vaccines, 
including live attenuated virus vaccines, inactivated vaccines, virus-like particle (VLP) vaccines, 
virus-vectored vaccines, DNA vaccines and subunit vaccines (Spurgers and Glass, 2011).  Despite 
these efforts, there are no licensed alphavirus vaccines available for human use.  The only available 
vaccine, formalin-activated WEE, is for veterinary use (Barber et al., 1978).  The section below 
discussed the progress of CHIKV and RRV vaccine development. 
 
1.8.1 CHIKV and RRV vaccines 
There have been a range of approaches for CHIKV and RRV vaccine development (Table 
1.3); however, so far only 4 vaccines have been tested in humans (Ledgerwood, 2013, Edelman et 
al., 2000, Harrison et al., 1971, Aichinger et al., 2011).  The first clinical trial used CHIKV vaccine 
prepared from formalin-fixed virus cultured in green monkey kidney cells (Harrison et al., 1971).  
Vaccination in 16 army recruits with this formalin fixed vaccine resulted in the induction of 
haemagglutination-inhibiting, complement-fixing and neutralising antibodies (Harrison et al., 
1971).  Another vaccine trial conducted by the US army, used a live attenuated CHIKV vaccine 
(Edelman et al., 2000).  This vaccine consisted of live-attenuated CHIKV (of Asian origin, isolated 
in Bangkok in 1962) derived from the MRC5 cell line (human foetal fibroblast) (Edelman et al., 
2000).  Fifty-seven out of 58 of the vaccinated army recruits developed neutralising antibodies, and 
these persisted for one year in 85% of the recipients.  However, this clinical trial was halted due to 
the development of arthralgia in five of the recipients.  The third vaccine comprised Vero-cell 
derived formalin-inactivated and ultraviolet-inactivated RRV  (Aichinger et al., 2011; Holzer et al., 
2011).  This RRV vaccine resulted in 92.7-92.9% seroconversion in 382 healthy RRV-naive adults.  
The vaccine candidate is now undergoing Phase III clinical trial in Australia.  The fourth vaccine is 
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a virus-like particle (VLP) vaccine containing the CHIKV structural protein.  VLPs are 
immunogenic but not infectious (Buonaguro et al., 2013) and are considered safer than attenuated-
virus vaccines (Wang and Roden, 2013).  Akahata et al. (2010) developed a CHIKV VLP vaccine 
that protected monkeys against CHIKV infection.  This VLP vaccine is currently being developed 
by Bharat Biotech, India and is the only CHIKV vaccine that is currently in clinical development 
(Phase I completed, but results not reported) (Ledgerwood, 2013).   
In addition to the 4 vaccines described above, there are a number of other vaccines in 
preclinical development (Table 1.3), including live-attenuated CHIKV vaccine (Levitt et al., 1986), 
chemical-inactivated CHIKV and RRV vaccines (Tiwari et al., 2009, Gardner et al., 2010, Yu and 
Aaskov, 1994, Aaskov et al., 1997), other VLP vaccines (Metz et al., 2013a, Metz et al., 2013b), 
recombinant CHIKV vaccines with an encephalomyocarditis virus internal ribosome entry site 
(IRES) (Roy et al., 2014, Chu et al., 2013, Partidos et al., 2012, Plante et al., 2011), chimeric 
alphavirus (VEEV/EEV/CHIKV) vector-based vaccines (Chattopadhyay et al., 2013, Wang et al., 
2011b, Wang et al., 2008), other virus vector-based vaccines (Garcia-Arriaza et al., 2014, Brandler 
et al., 2013, Wang et al., 2011a), DNA vaccines (Mallilankaraman et al., 2011, Muthumani et al., 
2008) and recombinant protein-based vaccine (Kumar et al., 2012). 
 
1.9 Drug treatments for CHIKV patients 
Treatment for CHIKV disease usually involves the use of analgesics and/or NSAIDs, with 
aspirin to be avoided because of the risk of haemorrhage (Suhrbier et al., 2012) (Chopra et al., 
2014).  A clinical study suggested that treatment using NSAIDs plus steroids may also be useful in 
ameliorating the rheumatic symptoms of CHIKV disease (Padmakumar et al., 2009).  Methotrexate 
has occasionally been administered with reported benefit to patients with protracted chronic 
CHIKV disease suffering from RA-like diseases (Jaffar-Bandjee, 2010; Ganu, 2011).  Recent 
human trials have shown that chloroquine is ineffective in treating acute and chronic CHIKV 
arthritis (Delogu and de Lamballerie, 2011, Chopra et al., 2014).   
  
24 
Table 1.3: Vaccines in development for CHIKV and disease. 
Type of vaccine Phase of clinical 
research  
References 
Live-attenuated CHIKV Phase II 
Preclinical—halted 
Levitt et al. (1986) 
Edelman et al. (2000) 
Chemical-inactivated CHIKV  
 
 
 
Phase I 
Preclinical 
 
 
Harrison et al. (1971) 
White et al. (1972) 
Tiwari et al. (2009)  
Gardner et al. (2010) 
Chemical-inactivated RRV Phase I/II 
 
Preclinical 
Aichinger et al. (2011) 
Holzer et al. (2011 
Yu and Aaskov (1994) 
Askov et al. (1997) 
VLP Phase I/Preclinical Akahata et al. (2010) 
Ledgerwood (2013) 
Metz et al. (2013b) 
Metz et al. (2013a) 
Recombinant CHIVK vaccines with an 
encephalomyocarditis virus internal 
ribosome entry site (IRES)  
Preclinical Roy et al. (2014) 
Chu et al. (2013) 
Partidos et al. (2012) 
Plante et al. (2011) 
Chimeric alphavirus vector-based Preclinical Chattopadhyay et al. (2013) 
Wang et al. (2011b) 
Wang et al. (2008) 
Other virus vectors (adenovirus/modified 
vaccinia virus Ankara/measles) (targeting 
genes of structural proteins: E1, E2, E3, 
6K and C) 
Preclinical Garcia-Arriaza et al. (2014) 
Brandler et al. (2013) 
Wang et al. (2011a) 
DNA (targeting envelope proteins E1, E2 
and E3) 
Preclinical Mallilankaraman et al. 
(2011) 
Muthumani et al. (2008) 
Recombinant protein-based  (targeting E2) Preclinical Kumar et al. (2012) 
 
1.10 Neutralising antibody-based therapeutics 
Neutralising antibodies are well recognised as potential therapeutics for several virus 
infections including hepatitis A, hepatitis B, respiratory syncytial, herpes simplex, rabies, measles 
and vaccinia (Keller and Stiehm, 2000).  For CHIKV disease, anti-CHIKV neutralising antibodies 
were shown to prevent viraemia and pathology in WT mice, as well as highly susceptible 
immunocompromised mice that lack IFN-α/β receptor or IFN-α/β/γ receptor (Couderc et al., 2009, 
Gardner et al., 2010, Fric et al., 2013, Pal et al., 2013).  However, Suhrbier et al. postulated that 
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antibody treatment might not be useful for most patients, as patients would have developed anti-
CHIKV antibodies by the time they were diagnosed with CHIKV infection, which is usually 
undertaken by serological testing (Suhrbier et al., 2012).  A recent study revealed that although anti-
CHIKV antibody treatment is effective in neutralising CHIKV in vitro, anti-CHIKV antibody 
treatment can drive antibody-evading strategies namely CHIKV cell-to-cell transmission, which 
might conceivably reduce the efficacy of antibody treatment (Lee et al. 2011).  Antibody treatment 
may, nevertheless, be useful for treating patients with a suppressed immune system, such as 
newborn babies, pregnant women and the elderly, or be used as a prophylactic measure in epidemic 
settings (Suhrbier et al., 2012).   
 
1.11  Conclusions and thesis aims 
The unprecedented magnitude of the recent CHIKV epidemic, which resulted in CHIKV 
cases in more than 40 countries, has highlighted the threat posed by CHIKV disease.  Additional 
concerns have arisen in the current epidemic associated with the new vector and the relatively high 
incidence of severe disease manifestations and occasional fatalities.  Currently, there is no licensed 
human vaccine available for CHIKV.  Treatment commonly involves the use of analgesics and/or 
NSAIDS; however, the relief provided by these drugs is often inadequate.  To improve the therapies 
available for CHIKV disease, a better understanding of how viraemia and pathology are controlled 
is required.  While the role that type I IFN responses play in controlling CHIKV infection is now 
well recognised, the roles of other immune components such as adaptive immune cells (B and T 
cells), macrophages, NK cells, neutrophils and cytokines are less well defined – in particularly the 
roles of these cells in viral arthritis and CHIKV persistence.  The overall aim of this thesis is to 
explore the roles of these cells in CHIKV arthritis, and the mechanisms involved in persistence of 
CHIKV using an adult mouse model that closely mimics human CHIKV disease (see section 1.6.2). 
 
The specific aims of this project are: 
Aim 1: To determine the effect of CCR2 deficiency on the arthritis caused by CHIKV. 
Aim 2: To examine if an immune response limited to B cell response may protect against CHIKV 
disease.  
Aim 3: To gain more insights into the long-term persistence of CHIKV RNA and its role in 
driving chronic arthritic disease. 
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Chapter 2: Material and methods  
 
2.1 Propagation of Vero and C6/36 cells 
Vero cells (ATCC # CCL-1) and C6/36 (ATCC # CRL-1660) were cultured in 5% CO2 
atmosphere at 37°C and 28°C, respectively, with 15 ml of R5 media comprising of Roswell Park 
Memorial Institute-1640 (RPMI 1640) medium (Invitrogen, Carlsbad, USA) supplemented with: (a) 
2 mM L-glutamine (Invitrogen), (b) 5% foetal calf serum (FCS) with <0.05 endotoxin unit (EU)/ml 
(Invitrogen), (c) 10 mM HEPES buffer (Sigma-Aldrich, USA), (d) 100 U/ml penicillin (Invitrogen), 
and (e) 100 µg/ml streptomycin (Invitrogen).  Cells were passaged every 3-4 days.  To passage 
cells, RPMI 1650 medium was removed, and the cell monolayer washed once with 5 ml of 
phosphate buffered saline (PBS).  The cell monolayer was detached from the tissue culture flask by 
incubating cells with 3 ml of 0.05% trypsin at 37°C for 10 min and gentle tapping of the flask.  
Detached cells were then diluted in 10 ml of R5 media before seeding into tissue culture flask. 
 
2.2 Virus preparation 
CHIKV was isolated from a patient during 2006 CHIKV outbreak in Reunion Island 
(Gardner et al., 2010).  This isolate (LR2006-OPY1) was passaged twice in C6/36 cells in R5 
medium (see section 2.1).  After 24 hours of infection, virus preparations were harvested then 
aliquoted and stored at -70ºC. 
 
2.3 Virus titration by 50% cell culture infection dose (CCID50) 
Virus samples were collected and kept at row 1 (A to H) at -70ºC at a 96-well flat bottom 
plates.  The samples were thawed at room temperature (RT).  R2 media (comprising of supplements 
as in R5 media but with 2% FCS instead of 5% FCS) were dispensed into a 100 ml media reservoir 
(Vistalab technologies, NY, USA).  R2 media (100 µl) were pipetted into four 96-well-plates 
simultaneously in a row-by-row fashion i.e. pipetting R2 media into row 12 (A to H) of a maximum 
of 4 plates then continued on row 11-2 (A to H).  For row 1 (A to H), 100 µl R2 media were 
carefully added without touching the sera.  Pipette tips were changed for each plate.  The media 
reservoir was changed after dispensing the R2 media into row 1.  This procedure prevents the 
potential cross contamination that might occur during dispensing of the R2 media into the row 1.  
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Samples were then serially diluted ten-fold down the plate from row 1-12.  The media and sera 
were gently mixed (pipetted up and down 5 times) but avoiding the inclusion of bubbles.  Mixed 
samples (11 µl) from row 1 were transferred to following row that already contained 100 µl R2 
media.  The second click of the pipette was not triggered as this causes bubble formation.  The first 
click of the pipette was gently released while the pipette tip was still inside the well.  The pipette 
tips were then discarded and then viral dilution was repeated across the plate, changing tips each 
time.  C6/36 cells (2x104 cells in 100 µl in R5 media) were then added in each well.  C6/36 cells 
were added simultaneously into 4 plates (maximum) in a row-by-row fashion i.e. pipetting C6/36 
cells into highest dilution row (row 12) then continued on lower dilution rows (row 11-2).  These 
plates were then incubated in 5% CO2 atmosphere at 25°C.  The infectivity titre (log10 CCID50/ml) 
was calculated as described by Reed and Muench (1938). 
 
2.4 Ethics statement and care of animals  
All experiments were approved by the QIMR Berghofer animal ethics committee. All 
knock-out mouse strains were bred at the QIMR Berghofer animal house facility.  C57BL/6 mice 
were purchased from Animal Resources Center (Canning Vale, WA, Australia).  All experiments 
were performed in QIMR Berghofer Animal House and PC3 facility.  All animals were handled in 
accordance with good animal practice as defined by the National Health and Medical Research 
Council of Australia.  The mice are supplied with filtered air, clean water and nutritious food.  The 
mouse cages are changed every week and limited to 6 mice per cage.  Adult mice were eunthanised, 
via carbon dioxide inhalation, before performing any lethal procedures and when the mice were 
deemed excessively sick (e.g. severe hind limb weakness or repeated dragging of hind legs).  To 
achieve statistic significance, almost all experiments, consisting of 3-6 mice per group, and were 
independently performed at least two times; (see section 2.26 for statistical analyses).  The number 
of mice and experimental repeats is indicated in the figure legends of each figure.  The total number 
of wild-type mice used in this project was 150; the total number of the knock-out mice used is 
shown in Table 2.1. 
  
28 
2.5 Mouse infection  
CHIKV viral stocks were diluted in R2 media.  C57BL/6 mice and various knockout mice 
(C57BL/6 background) (Table 2.1) were infected with CHIKV (104 CCID50 in 40 µl R2 media) via 
subcutaneous injection into the dorso-lateral metatarsal region of each foot.  All mice were 6-10 
weeks old. 
Table 2.1: List of knock-out mice strains used in various experiments. 
All knockout mice were on a C57BL/6 background.   
Mice strain Deficiency No. of mice used Reference 
CCR2-/- C-C chemokine receptor 2 (CCR2) 80 Boring et al. (1997) 
IL-10-/- Interleukin-10 (IL-10) 10  Kuhn et al. (1993) 
µMT B cells 100 Kitamura and Rajewsky (1992) 
Rag-1-/- B and T cells  100 Mombaerts et al. (1992) 
RG B, T and NK cells 20 Song et al. (2010) 
MHC-IIΔ/Δ CD4+ T cells 25 Madsen et al. (1999) 
IFN-γ-/-  Interferon-γ (IFN-γ) 25 Dalton et al. (1993) 
 
2.6 Serum collection from CHIKV infected mice 
Blood was collected by tail vein bleed.  Mice were restrained in a mouse restrainer with 
tissue paper at the base to cushion mice while the tail is being pulled against the end of restrainer.  
There are two veins situated left and right (purple colour) on the tail.  One of the veins was gently 
cut across the tail (as opposed to lengthwise) using a sterile scalpel blade no. 23 (Livingstone, 
Rosebery, Australia).  A new blade was used for each group and between mice the blade was 
sprayed with 80% ethanol and dried on tissue paper.  The blood was collected using labelled 
MiniCollect 0.5 ml Z serum tubes (Greiner Bio-One GmbH, Kremsmunster, Austria).  The tails 
were massaged to collect sufficient blood (roughly 8 drops of blood = 30-40 µl).  Excessive blood 
on the tail was mopped with tissue paper and pressure was applied to the wound for 30 sec to stop 
the bleeding.  Serum tubes were then placed in a sealed container and transported to another 
Physical Containment 3 (PC3) lab facility at RT.  In the PC3 lab, the collected bloods were 
centrifuged at 7200 revolutions per minute (rpm) for 2.5 min on an Eppendorf Microcentrifuge 
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5418 (USA).  Sera were removed from above gel plug in MiniCollect tubes with 20 µl pipette.  Sera 
(in duplicate, 10 µl per well) were plated into flat bottom 96-well-plates and stored at -70°C.  
 
2.7 Isolation of infectious CHIKV from feet  
2.7.1 Mortar and pestle method 
Mice feet were excised, lacerated (with surgical blades), weighed and transferred into 
microcentrifuge tube with 1 ml R10 media (comprising of supplements as in R5 media but with 
10% FCS instead of 5% FCS).  The samples were then stored at -80ºC, thawed at RT and ground 
using a mortar and pestle.  The ground samples were transferred into microcentrifuge tubes and 
centrifuged at 1000 rpm at RT for 1 min in an Eppendorf 5418 microcentrifuge.  The supernatant 
was then transferred to a new microcentrifuge tube and the CCID50 calculated as described (see 
section 2.3 for detailed method). 
 
2.7.2 Homogeniser method 
Mice feet were excised, weighed and transferred into 2 ml snap-lock tubes (Eppendorf, 
US) containing 2 ml R10 media and stored at -80ºC.  The frozen feet samples were thawed at RT 
and, two 5mm stainless steel beads (Qiagen GmbH, Hilden, Germany) were added.  Feet samples 
were then homogenised using TissueLyser II (Qiagen GmbH, Hilden, Germany) at 25 Hertz for 3 
min, paused for 3 min on ice and homogenised again at 25 Hertz for 3 min.  The mixture was 
centrifuged at 1000 rpm at RT for 1 min in an Eppendorf 5418 microcentrifuge.  The supernatant 
was then transferred to a new microcentrifuge tube, and the virus concentrations were then 
determined by CCID50 as described (see section 2.3 for detailed method). 
 
2.7.3 Collagenase digestion method 
Mice feet were excised and transferred onto a 3 cm diameter Petri dish containing 1.5 ml 
of R10 media.  The Petri dish containing the mice feet were placed on ice. The feet samples were 
thoroughly lacerated using a surgical blade (skin was not removed), digested with 4% collagenase-
dispase (Roche, Dee Why, NSW, Australia) and incubated at 38ºC.  After 10 min, the feet samples 
were lacerated again at RT for 5 min and then incubated at 38ºC again.  The previous step 
(laceration and incubation) was again repeated.  After the incubation, the tissue suspension was 
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transferred into a 10 ml tube and centrifuged at 350 rpm for 1 min in an Eppendorf 5810R 
centrifuge.  The supernatant was transferred into a new 15 ml tube containing 5 ml of R10 media.  
The tube was placed on ice, 6 ml of Percoll (Sigma-Aldrich, USA) was gently added to the bottom 
of the tube via a glass pipette and centrifuged at 1600 rpm at 4ºC for 30 min.  The cell containing 
interphase layers were then transferred into a new 15 ml tube.  The cells were washed once with 5 
ml of 100% FCS and centrifuged at 1000 rpm for 6 min.  After the centrifugation, the supernatant 
was discarded.  The cell pellet was gently resuspended in 2 ml of ammonium-chloride-potassium 
(ACS) lysing buffer (0.15M NH4Cl, 1mM KHCO3, 0.1 mM Na2ethylenediaminetetraacetic acid 
(EDTA)) for 30 sec, 8 ml of R10 media was then added and centrifuged at 1000 rpm at 4ºC for 6 
min.  After the centrifugation, the cell pellet was resuspended in 800 µl R10 media, filtered through 
nylon mesh (38 µm pore size) (Seflar Filter Specialist, Blacktown, Australia) and plated into a 
single well on 24-well-plate.  After 24 h, 100 µl of supernatant was collected, stored at -20ºC, 
thawed at RT and the virus titres were then determined by CCID50 as described (see Chapter 2 
section 2.3 for detailed method). 
 
2.8 Blood smear 
Blood was collected by tail vein bleed, smeared and air dried on glass slides at RT.  The 
glass slides were stained with Quick Dip (Fronine Laboratory Supplies, Australia). 
 
2.9 Isolation of infectious CHIKV from various mice tissues  
Lymph mode, spleen, liver and thigh muscle were excised, weighed and transferred into 
microcentrifuge tubes containing 1 ml R10 media.  The samples were then stored at -80ºC, thawed 
at RT and homogenised using metal mesh and a syringe plunger.  The homogenised samples were 
transferred into microcentrifuge tubes and centrifuged at 1000 rpm at RT for 1 min in an Eppendorf 
5418 microcentrifuge.  The supernatants were then transferred into a new microcentrifuge tubes and 
the virus concentrations were then determined by CCID50 as described (see section 2.3 for detailed 
method). 
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2.10 Mouse vaccination  
CHIKV vaccine was prepared by Medical Innovations Australia Pty. Ltd., Brisbane, 
Australia.  Briefly, CHIKV was cultured in C6/36 cells, inactivated using binary ethylenimine 
(BEI), concentrated via polyethylene glycol and resuspended in 1X TNE buffer (50 mM Tris–HCl 
(pH 7.4), 100 mM NaCl and 0.1 mM EDTA).  Mice were vaccinated as described previously 
(Gardner et al., 2010).  Briefly, the mice were injected s.c. (at the base of the tail) once with 10 µg 
of BEI inactivated CHIKV antigen in 50 µl of RPMI 1640 medium.  
 
2.11 Anti-Ly6G antibody treatment  
Mice were treated with 0.3mg (in 75 µl RPMI1640) (clone 1A8) (Stemcell technologies, 
USA) or IgG2a control antibody (clone 2A3) (Stemcell technologies, USA) i.p. at the indicated 
time points.  
 
2.12 Foot measurement in mice 
The width and height of the hind feet were measured using digital vernier callipers 
(Kincrome, Australia) (Figure 2.1).  The percentage of increase in feet area was calculated by: 
 
 
  
Figure 2.1: Foot measurement in mice.  
The height and width of the hind feet were measured using callipers.  
feet area = feet width x feet height
% increase in feet area = Feet area of day x −Feet area of day 0Feet area of day 0
"
#
$
%
&
'x100
32 
2.13 Neutralisation assay  
Mouse sera were heat-inactivated at 60ºC for 30 min in a water bath. This incubation 
destroys complement and kills virus.  Heat-inactivated sera were serially diluted three-fold across 
flat bottom 96-well-plates in RPMI 1640 medium containing L-glutamine (Invitrogen) in a final 
volume of 50 µl.  Virus samples were thawed and diluted in R2 media, to a final concentration of 
200 CCID50/ml in 50 µl per well.  Sera and virus were then incubated in 5% CO2 atmosphere at 
37°C for 1 hr before adding 100 µl of 8x103 Vero cells (in R5 media).  After 5 days of incubation, 
plates were stained with 100 µl of 0.05% crystal violet in 10% formaldehyde-PBS.  Serum 
antibodies prevent the cell from becoming infected by virus.  The serum dilution giving 100% 
protection against cytopathic effect was visualised using crystal violet staining.  The presence of 
crystal violet stained monolayer indicated that serum antibodies protected the cell. 
 
2.14 RNA extraction from virus infected mice’s feet 
Mice feet were lacerated using surgical blades (Livingstone, Rosebery, Australia).  
Samples were stored in 1 ml of RNAlater™ (Ambion, Austin, USA) in a microcentrifuge tube for 
24 h at 4°C prior to long-term storage at -70°C.  This step ensured maximum penetration of 
RNAlater™ into the foot tissue.  Total RNA extraction was performed according to manufacturer’s 
instructions.  Frozen feet samples were thawed, removed from RNAlater™, and transferred into 
2ml snap-lock tubes (Eppendorf).  Two 5 mm, stainless steel beads and 1.5 ml of TriZol Reagent 
(Invitrogen, NY, USA) were added into each tube.  Feet samples were then homogenised using 
TissueLyser at 25 Hertz for 6 min.  The homogenised samples were centrifuged at 12000 rpm at 
4ºC for 15 min in a Profuge 14K (United Biosciences, USA).  Samples (excluding tissue remnant) 
were transferred into a fresh microcentrifuge tube, and 200 µl chloroform (Invitrogen) added.  The 
tube was shaken vigorously for 15 sec, and then incubated at RT for 3 min.  The mixture was 
centrifuged at 12,000 rpm at 4°C for 15 min in a Profuge 14K.  The resulting RNA containing 
upper aqueous phase was transferred into new microcentrifuge tube and 450 µl of isopropyl alcohol 
was added.  Samples were incubated at RT for 10 min after gentle inversion.  The precipitated RNA 
was pelleted by centrifugation at 12,000 rpm, 4°C for 15 min.  The resulting RNA pellets were 
washed with 1 ml of 75% ethanol, air dried, resuspended in RNAse-free water (Sigma-Aldrich, 
USA) and stored at -70°C. RNA purity and concentration were estimated using Nanodrop ND-1000 
spectrophotometer (Thermo Scientific, Waltham, USA).  
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2.15 Synthesis of complementary deoxyribonucleic acid (cDNA) from 
extracted RNA samples 
The first strand cDNA was synthesised in a reaction consisting of 200 ng of random 
hexamer oligonucleotides (Sigma, Australia), 500 µM deoxynucleoside triphosphates (dNTPs) 
(Promega Corporation, WI, USA), and 0.25-1.0 µg of the RNA sample made up to 12 µl in H2O.  
The samples were incubated in a thermal cycler at 65°C for 5 min, transferred on ice and 4 µL of 
5X strand buffer (Invitrogen), 2 µl of 0.1M dithiothreitol (Invitrogen) and 1 µl of H2O were added.  
The samples were transferred back to the thermal cycler preheated to 25ºC, incubated for 2 min and 
1 µL of Superscript (Invitrogen) was added.  The samples incubated at following conditions: 25°C 
for 10 min, 50°C for 50 min, and 70°C for 15 min. 
Negative strand specific cDNA was synthesised by the same procedure (as above) with the 
exception of the hemaxer oligonucleotides, which was substituted with 10 pg of CHIKV primer 
with a tag sequence: (5’-GGCAGTATCGTGAATTCGATGCGACACGGAGACGCCAACATT-
3’) (tag sequence is underlined) (adapted from Plaskon et al. 2009). 
 
2.16 Quantitative real-time PCR (qRT-PCR) 
qRT-PCR was performed in reaction consisting of 1 µl of cDNA (see section 2.15), 10 µL 
of SYBR green Super mix-UDG (Invitrogen), 1 µl bovine sera albumin, 6 µl H2O, and 1 µl of 10 
µM of forward and reverse primer (Table 2.2).  PCR cycling and product detection were performed 
using Rotorgene 6000 (Corbett Research, Mortlake, Australia).  The samples incubated at following 
cycling conditions: one cycle of 50°C for 2 min, one cycle of 95°C for 2 min, 45 cycles of 94°C for 
5 sec (DNA denaturation that separates the double-stranded DNA), 60°C for 10 sec (primer 
annealing) and 72°C for 30 sec (sequence extension and signal acquisition).  Data was analysed 
using Rotor-Gene Real Time Analysis software (Corbett Research, Australia).   
Table 2.2: List of primers used for qRT-PCR. 
Gene Sequence (5’ to 3’) Reference 
Arg-1  Forward: TGGACCTGGCCTTTGTTGA 
Reverse: GGTTGTCAGGGGAGTGTT 
Wongtrakool et al. 
(2012) 
CHIKV nsP1 
negative strand 
Forward: AATAAATCATAAGGCAGTATCGTGAATTCGATGC 
Reverse: AATAAATCATAAGTCTGCTCTCTGTCTACATGA 
Adapted from Plaskon 
et al. (2009) 
34 
CHIKV-E1 positive 
strand  
Forward: AGCTCCGCGTCCTTTACC 
Reverse: CAAATTGTCCTGGTCTTCCTG 
Designed in house 
CXCL2  Forward: GTGAAC TGCGCTGTCAATGC 
Reverse: CGCCCTTGAGAGTGGCTATG 
Feng et al. (2006) 
G-CSF forward  Forward: CTCAACTTTCTGCCCAGAGG 
Reverse: AGCTGGCTTAGGCACTGTGT 
Waight et al. (2011) 
IL-10 forward  Forward: ACAGGAGAAGGGACGCCAT 
Reverse: GAAGCCCTACAGACGAGCTCA 
Ellett et al. (2010) 
IL-1B forward  Forward: TCACAGCAGCACATCAACAAG 
Reverse: CCAGCAGGTTATCATCATCATCC 
Bakker et al. (2008) 
ISG-54  Forward: CTCTCTGGAGCAAGCCATTC 
Reverse: GCCATTGCTTGGTTTTTATG 
Designed in-house 
KC  Forward: TGTCAGTGCCTGCAGACCAT 
Reverse: CCTCGCGACCATTCTTGAGT 
Feng et al. (2006) 
Nur77  Forward: TGATGTTCCCGCCTTTGC 
Reverse: CAATGCGATTCTGCAGCTCTT 
Maxwell et al. (2005) 
ROR-γT  Forward: CCGCTGAGAGGGCTTCAC 
Reverse: TGCAGGAGTAGGCCACATTACA 
Carlson et al. (2009) 
RPL13a  Forward: GAGGTCGGGTGGAAGTACCA 
Reverse: GCAT CTTGGCCTTTTCCTT 
Mogal and Abdulkadir 
(2006) 
T-bet  Forward: ACCAGAGCGGCAAGTGGG 
Reverse: TGGACATATAAGCGGTTCCCTG 
Carlson et al. (2009) 
 
2.17 DNA gel electrophoresis  
PCR products were visualised by electrophoresis at 100 volts for 30 min on a 1.2% (w/v) 
agarose gel (Biorad, USA) containing 0.02 µg/ml ethidium bromide in 1X Tris acetate EDTA 
(TAE) Buffer (40mM Tris, 20mM sodium acetate, 1mM EDTA, pH8.2).  The gel was visualised 
using ultraviolet transilluminator.  
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2.18 Cytokine and chemokine detection by cytometric bead array assay 
Cytometric bead array (BD Biosciences, San Jose, USA) assay was performed according 
to the manufacturer’s instructions.  Briefly, in a single well of 96-well V-bottom plate, 10 µL of 
sera was incubated with 1.5 µL of individual bead (coated with capture antibodies that detect 
desired cytokine e.g. MCP-1) along with an equal volume PE-conjugate in the dark, at RT for 2 
hours.  The samples were then washed once with 100 µL wash buffer (BD Biosciences, San Jose, 
USA) per well, centrifuged at 1000 rpm for 3 min and supernatant removed.  The samples washed 
with 100 µl formalin (for CHIKV inactivation), supernatant removed and resuspended in 120 µL of 
wash buffer per well. Samples were then analysed by BD FACSArray bioanalyzer (BD 
Biosciences, USA).  The data was analysed by FCAP Array™ v2 Software (BD Biosciences, 
USA). 
 
2.19 Interferon alpha (IFN-α) detection by Mouse IFN-alpha FlowCytomix 
Simplex Kit 
Serum IFN-α was detected using Mouse IFN-alpha FlowCytomix Simplex Kit 
(eBioscience, USA).  The assay was performed according to manufacturer’s instructions.  Briefly, 
in a single well of 96-well V-bottom plate, 10 µl of sera was incubated with 5 µl of fluorescence 
beads coated with monoclonal antibody targeting mouse IFN-α and 10 µl of biotin-conjugate anti-
mouse IFN-α monoclonal antibody.  The plates were incubated in the dark for 2 hours on a 
microplate shaker at 500 rpm.  The samples were then washed once with 100 µl of assay buffer 
(eBioscience, USA), centrifuged at 1000 rpm for 5 min, supernatant removed.  Beads were washed 
with 100 µl formalin (for CHIKV inactivation), supernatant removed and the beads were then 
resuspended in 60 µl of assay buffer per well.  Samples were then analysed by BD FACSArray 
bioanalyzer (BD Biosciences, USA) and data collected was analysed by FCAP Array™ v3.01 
Software (BD Biosciences, USA). 
 
2.20 Histology and immunohistochemistry  
Histology and immunohistochemistry samples were prepared by HistoTechnology Facility 
(University of Queensland, Australia). Mouse tissue samples (feet, liver, lymph node, spleen and 
muscle) were fixed in 10% PBS-buffered formalin.  Feet were decalcified in EDTA for 3 weeks.  
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These tissues were embedded in paraffin wax.  Haematoxylin and eosin (H&E) staining was 
performed using standard methods.  
 
2.20.1 Leder Stain (for neutrophils) 
Leder Stain, which detects choloracetate esterase activity, was used to stain neutrophils 
(Bancroft and Gamble, 2001).  Formalin fixed paraffin sections were rehydrated and stained with 
Naphthol AS-D chloroacetate solution (Sigma-Aldrich, USA) for 30 min at 37ºC, counterstained 
with Mayer’s haematoxylin (Sigma-Aldrich, USA) for 3 min and rinsed with Scott’s solution 
(Sigma-Aldrich, USA) for 30 sec.  
 
2.20.2 Chromotroph 2R staining (for eosinophils) 
Chromotroph 2R staining was used to stain eosinophils (Cook, 1974).  Formalin fixed 
paraffin sections were affixed to adhesive slides, rehydrated and stained with Mayer’s haematoxylin 
for 3 minutes and stained with 0.05% chromotrope 2R (W/V) (ProSciTech, Thuringowa, Australia) 
(dissolved of 0.1% phenol (W/V)) for 30 min.  The samples were then dehydrated with ethanol.  
 
2.20.3 F4/80 immuno-stain (for macrophages) 
F4/80 immunohistochemistry was used to identify macrophages.  Fixed slides were 
rehydrated in distilled water and incubated in 2.0% hydrogen peroxide in Tris buffered saline 
(TBS).  After 10 min incubation at RT, slides were rinsed with distilled water then undergone 
antigen heat retrieval at 105ºC using the Biocare Medical decloaking chamber (Biocare, USA).  
Slides were cooled down for 15 min, washed with TBS and incubated with Biocare Medical 
Background Sniper  (Biocare, USA) for 30 min.  The sections were then incubated for 90 min with 
0.3% primary antibody (Abcam rat anti-mouse F4/80) in Biocare Medical Da Vinci Green diluent 
(Biocare, USA).  Sections were then washed with TBS, treated with Biocare Medical anti-rat Probe  
(20 min) (Biocare, USA), developed colour in 3,3 diaminobenzidine (DAB) and counterstained 
with Mayers’ haematoxylin. 
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2.20.4 Ly6G staining (for neutrophils) 
Ly6G staining was used to stain neutrophils.  Fixed slides were rehydrated in distilled 
water and incubated in 2.0% hydrogen peroxide in TBS.  After 20 min incubation at RT, slides 
were rinsed with distilled water.  Antigen heat retrieval were performed at 100ºC using the Biocare 
Medical decloaking chamber.  Slides were cooled at RT for 20 min, washed with TBS and 
incubated with Biocare Medical Background Sniper (Biocare, USA) for 15 min.  The sections were 
incubated for 18 hours with 0.85% primary antibody (Abcam purified rat anti-mouse Ly6G 
neutrophil #NMP-R14) in Biocare Medical Da Vinci Green diluent.  Sections were washed with 
TBS, incubated with Biocare Medical anti-rat Probe (20 min) followed by Biocare Medical Rat 
horseradish peroxidase (HRP) polymer (20 min).  The colour signal was developed in betazoid 
DAB (Biocare MACH 1 kit) and counterstained with Mayers’ haematoxylin. 
 
2.20.5 ApopTag staining (for apoptotic cells) 
ApopTag Kit (Millipore, Australia), which stains the 200 base pair fragmented DNA 
released during apoptosis, was used to detect apoptotic cells.  Fixed slides were rehydrated in 
distilled water then treated with 150 µl proteinase K (20 µg/ml in 0.05M Tris-HCI, 0.01M CaCl2, 
pH 8) for 10 min at RT.  In a Coplin jar, the slides were washed twice with distilled water and 
incubated with 3.0% H2O2 in PBS for 5 min.  The buffer was removed, and the sections were then 
treated with 18 µl equilibrium solution (from the the ApopTag Kit) for 10 min, 12.5 µl TdT enzyme 
(from the the ApopTag Kit) for 60 min at 37ºC and a stop wash buffer (from the the ApopTag Kit) 
for 10 min.  The slides were washed with PBS before incubated with 17.5 µl anti-digoxigenin 
conjugate for 30 min at RT.  The colour was developed with DAB and counterstained with 
haematoxylin.  
 
2.20.6 Safranin O staining (for proteoglycans) 
Safranin O staining was used to detect proteoglycan content in cartilage.  Fixed slides were 
rehydrated and stained with Weigert’s iron hematoyxlin solution (Sigma, Australia) for 10 min, 
washed with H2O for 10 min, stained with fast green solution for 5 min, rinsed with 1% acetic acid 
solution for 10 sec and stained in 0.1% safranin O solution (BDH, Poole, England) for 5 min.  The 
slides were then dehydrated and mounted using resinous medium.  
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2.21 Quantification of infiltrating cells in the joint by histology image 
analysis 
Stained whole foot sections were digitally scanned using Scan Scope XT digital slide 
scanner (Aperio, Vista, CA).  Aperio Image Scope analysis software version 11 (Aperio 
Technologies), Positive Pixel Count algorithm and Color Deconvolution algorithm were used to 
quantify the infiltrating cells on specific staining.  The detailed parameters of these algorithms were 
listed in Table 2.3. 
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Table 2.3: Parameters for algorithm detecting specific dye.  
Positive Pixel Count version 9.1 and Color Deconvolution version 9.1 were used to quantify 
specific infiltrating cells following each staining protocol.  
1. Positive Pixel Count version 9.1 
It detects a pixel at a given hue value (color code), hue width (range of hue value) and saturation. 
Staining (cell)  Quantified color Hue value Hue width Saturation  
Apotag (apoptotic cells) 
 
Brown (more red) 0.1 0.7 0.04 
Ly6G (neutrophils) 
 
Brown (more red) 0.1 0.6 0.04 
F4/80 (macrophages) Brown (more yellow) 0.15 0.6 0.04 
     
2. Color Deconvolution version 9.1  
It separates up to three-overlapped color and quantifies one color.  Color OD of each color was determined by detecting 
an area containing single color.  
 Staining Quantified color 
Color 1 OD  
 (R; G; B)  
(quantified channel) 
 
 
 
Color 2 OD  
 (R; G; B) 
Color 3 OD  
(R; G; B) 
Chromotroph 2R (eosinophils) Pink 0.44; 0.73; 0.55 0.67; 0.66; 0.32 0;0;0 
Leder (neutrophils) Red 0.05; 0.66; 0.74 0.20; 0.56; 0.76 0;0;0 
40 
2.22 T cell proliferation assay 
Mice spleens were teased through the mesh and transferred to a 10 ml centrifuge tube 
containing 5 ml of R10 media.  Erythrocytes were lysed by mixing the cells with 3 ml of ACS 
lysing buffer for 30 sec at RT.  After 2 min, cell suspensions were added with 7 ml of R10 media, 
centrifuged down at 1000 rpm for 5 min and plated at 2.5x106 cells/ml in R10 media on a U-bottom 
96-well-plate.  Splenocytes were stimulated with 10 µg/ml of BEI CHIKV antigen (section 2.10).  
Phytohemagglutinin (Sigma-Aldrich, USA) (2.5 µg/ml) was used as a positive control.  The cells 
were incubated at 37ºC and 5% CO2 atmosphere.  After 72 hours of incubation, each well was 
treated with 0.5 µCi of [3H]-thymidine for another 16 hours.  The cells were harvested the next day 
onto MicroBeta Filtermat-96 A using the FilterMateTM  Cell Harvester (PerkinElmer).  
Radioactivity was measured using the MicroBeta Liquid Scintillation Counter (PerkinElmer).  
 
2.23 Anti-CHIKV enzyme-linked immunosorbent assay (ELISA) 
BEI CHIKV antigen (1.2 µg/ml) in 0.05M pH 9.6 carbonate coating buffer (100 µl) 
(SigmaAldrich, USA) was added to Maxisorp Nunc-Immuno plates (Nunc™, Denmark).  After 
overnight incubation at 4ºC, the supernatant were gently discarded.  The antigen-coated plates were 
washed three times with PBST (PBS containing 0.01% (v/v) Tween 20).  The plates were blocked 
with 200 µl/well of 5% skim milk in PBST for 1 hr at RT.  Mouse sera were 3-fold serially diluted 
in PBST with 1% FBS.  The serially diluted sera were then transferred on to the antigen coated and 
blocked plate and incubated for 90 min at RT.  Plates were then washed 3 times with PBST.  Rat 
anti-mouse IgG2a/IgG1-biotin (BD Pharmingen, USA)(100 µl) was added to each well and 
incubated for 90 min at RT.  The plates were then washed 3 times with PBST.  Streptavidin-HRP 
was diluted to 1/10000 in PBST and added into each well.  The plates were incubated in dark for 1 
hr at RT.  The plates were washed 3 times with PBST.  The colour was developed with 100 µl of 
ABTS:H2O2 in the dark at RT for 5-15 min until green colour fully developed.  The developed 
colour was quantified by measuring the optical density at 405 nanometer (nm) wavelength using a 
VersaMax™ microplate reader (Molecular Devices, CA, USA).  
 
2.24 ELISA for detecting anti-nuclear antibody (ANA) 
ANAs were detected using Mouse ANA Total Ig ELISA kit (Alpha Diagnostic, USA) 
following manufacturer’s instructions.  
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2.25 Microarray experiments and analyses 
RNA samples for microarray experiments extracted as described (see section 2.14).  The 
prepared RNA samples were then processed by Ramaciotti Centre (Sydney, Australia) for 
microarray experiments using Mouse Gene 1.0ST arrays (Affymetrix).  With the assistance of Dr. 
Nakaya Helder, differentially expressed genes (DEGs) were identified as described (Nakaya et al., 
2012).  Briefly, robust multiarray average algorithm, which includes global background adjustment 
and quantile normalisation, was used to normalise all probe sets.  Probe sets with no annotations 
were removed.  Principal Component Analysis was performed on the remaining probe sets.  DEGs 
were then identified with the help of a described statistical framework (Ling et al., 2010).  DEGs 
were obtained for day 7 post-infection relative to day 0, separately for WT and CCR2-/- mice, using 
pooled RNA samples from feet of 4-6 mice for each time point and mouse strain.  Genes with low 
expression levels in the microarray analysis (log2 expression < 7) for both days 0 and 7 were 
removed.  Ingenuity Pathway Analysis (IPA) (Ingenuity System, USA), Ingenuity’s Canonical 
Pathway Analysis, and Ingenuity’s Upstream Regulator Analysis were used to analyse gene 
networks and functional relationship.  
 
2.26 Statistical analyses 
Statistical analysis was performed using IBM SPSS Statistics (version 19).  The choice of 
statistical analysis was dependent on whether the data was normally distributed.  The data was 
considered normally distributed when the difference in the variances was <4, skewness was > -2, 
and kurtosis was < 2).  The Student’s t-test was used to compare the mean for normally distributed 
data.  Where the data was not normally distributed and difference in variances was < 4, the Mann 
Whitney U test was used, and if the difference in variances was > 4, the Kolmogorov-Smirnov test 
was used.  The Student’s t-test, Mann Whitney U test and Kolmogorov-Smirnov test are limited for 
comparison of the mean of two groups.  Analysis of variance (ANOVA) tests or repeat measures 
ANOVA tests were not suitable as these are parametric tests and all data sets contained at least one, 
usually multiple comparisons, that were not normally distributed. 
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Chapter 3:  CCR2 deficiency promotes exacerbated 
chronic erosive neutrophil-dominated chikungunya 
virus arthritis  
 
3.1 Introduction 
CCR2 is the receptor for a number of C-C motif chemokines including Chemokine (C-C 
motif) ligand 2 (CCL2), which is also known as monocyte chemotactic protein-1 (MCP-1).  CCL2 
recruits monocytes, basophils and T cells to sites of inflammation and has been implicated as an 
important mediator in a range of inflammatory diseases including inter alia RA, multiple sclerosis, 
atherosclerosis, asthma, neuropathic pain (Subasinghe et al., 2013), obesity, diabetes (Panee, 2012) 
and cancer (Zollo et al., 2012).  A range of therapeutic agents that target CCR2 or CCL2 are being 
developed (Subasinghe et al., 2013, Panee, 2012, Zollo et al., 2012), although initial trial results for 
CCR2 blockade in RA patients have been disappointing (Lebre et al., 2011).  Nevertheless, 
CCR2/CCL2 inhibition may ultimately find utility in the treatment of a range of conditions 
(Subasinghe et al., 2013, Panee, 2012, Zollo et al., 2012).  Elevated CCL2 and 
monocyte/macrophage infiltrates are also prominent features in several viral arthritides, and are 
well described for alphaviral arthropathies (Suhrbier and Mahalingam, 2009), including CHIKV 
disease in mice, monkeys and humans (Gardner et al., 2010, Labadie et al., 2010, Suhrbier et al., 
2012, Hoarau et al., 2010).  Treatments with anti-CCL2 antibody or bindarit, a new drug purported 
to target CCL2 production, were shown to be effective at ameliorating rheumatic disease in CHIKV 
and RRV mouse models (Rulli et al., 2011).  As CCL2 generally appears to have no direct anti-viral 
activity (Suhrbier and Mahalingam, 2009, Guabiraba et al., 2010, Lin et al., 2011, Rulli et al., 
2011), targeting this chemokine and/or its receptor would appear attractive for treatment of viral 
arthritides.   
 The inflammation biology of CCR2/CCL2 has emerged to be complicated.  Collagen-
induced arthritis in CCR2-/- mice is more severe with increased macrophage and neutrophil 
infiltrates (Quinones et al., 2004, Rampersad et al., 2011), whereas in other arthritis models, 
inhibition of CCL2 ameliorated disease (Gong et al., 1997, Shahrara et al., 2008).  CCR2 deficiency 
was associated with reduced monocyte/macrophage infiltration in some settings (Boring et al., 
1997, Popivanova et al., 2009, Sawanobori et al., 2008), but not others (Fujii et al., 2012, Quinones 
et al., 2004).  More neutrophil infiltrates were seen in CCR2-/- mice in certain settings (Fujii et al., 
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2012, Quinones et al., 2004, Montgomery et al., 2007), unchanged in some (Dunay et al., 2010), 
less in others (Souto et al., 2011).  For dengue and influenza infections in CCR2-/- mice, the viral 
load was unchanged, and the pathology was attenuated (Guabiraba et al., 2010, Lin et al., 2011).  In 
contrast, cytomegalovirus and West Nile virus infections in these mice resulted in increased viral 
loads and pathology (Hokeness et al., 2005, Lim et al., 2011).  
Given the recent outbreak of CHIKV and the interest in using CCR2/CCL2 blockers for 
alphaviral arthritides and other diseases, this study sought to determine the effect of CCR2 
deficiency in CHIKV arthritis using a recently established mouse model, which mimics many 
aspects of human disease (Gardner et al., 2010).  Herein, we showed that arthritic disease was 
substantially increased and prolonged in CCR2-/- mice, with no changes in viral load or RNA 
persistence and only marginal changes in anti-viral immunity.  CHIKV infected CCR2-/- mice also 
showed clear evidence of cartilage damage, a feature not normally associated with CHIKV arthritis.  
Although recruitment of CCR2+ monocyte/macrophages can contribute to inflammation, they can 
also be critical for preventing excessive pathology and resolving inflammation. 
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3.2 Results 
 
3.2.1 CCR2-/- mice had more severe foot swelling than WT mice  
Consistent with previous report (Gardner et al., 2010), after CHIKV inoculation into adult 
wild-type (WT) mice, a clearly discernible foot swelling is observed (Figure 3.1), which peaks on 
day 6/7 and largely resolves by day 10-14 (Figure 3.1A).  The same CHIKV inoculation into CCR2-
/- mice resulted in a nearly 2 times higher mean peak foot swelling than that seen in WT mice 
(Figure 3.1A, day 6), with differences clearly observable by eye (Figure 3.1B).  The swelling in 
CCR2-/- mice also resolved much more slowly, returning to values not significantly different from 
day zero after day 40 days, whereas in WT mice this occurred after day 14 (Figure 3.1A).  Foot 
swelling in CCR2-/- mice was significantly higher than WT mice for all time points from day 3 to 32 
(Figure 3.1A).  These observations indicate that the absence of CCR2 gene resulted in a more 
severe viral arthritis, indicating a protective role for the CCR2 gene in this viral arthritis.   
 
3.2.2 WT and CCR2-/- mice had a similar level of CHIKV viraemia and 
CHIKV RNA persistence in feet 
To investigate the possible cause of the more severe foot swelling seen in CCR2-/- mice, 
replication of CHIKV was analysed in WT and CCR2-/- mice.  No consistent and/or significant 
differences in viraemia (Figure 3.2A) or tissue virus titres (Figure 3.2B) were seen between WT and 
CCR2-/- mice, illustrating that CCR2 deficiency did not have a major effect on CHIKV replication.  
Chronic alphaviral rheumatic disease is believed to be due to the persistence of virus in 
joint tissues, with virus shown primarily to persist in macrophages (Labadie et al., 2010).  As the 
longevity of disease is clearly increased in CCR2-/- mice (Figure 3.1A), the levels of viral RNA in 
these mice were analysed over time.  Real time qRT-PCR using CHIKV E1 primers showed no 
consistent or significant differences in the levels of CHIKV RNA in the feet of CCR2-/- and WT 
over time (Figure 3.3).  The data in Figure 3.2 and Figure 3.3 collectively suggest that the increased 
clinical disease seen in CCR2-/- mice (Figure 3.1), was not due to increased viral replication or 
persistence in these mice.  
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Figure 3.1: Foot swelling in CHIKV infected WT and CCR2-/- mice. 
6-8-week old mice were infected with 104 CCID50 CHIKV into the dorso-lateral metatarsal region 
of the foot.  Feet were measured at the time points indicated.  Foot swelling is expressed as a mean 
percentage increase (compared to uninfected mice feet). (A) The mean percentage increase in foot 
swelling over time for WT mice (n = 16 feet, 8 mice) and CCR2-/- mice (n = 14 feet, 7 mice) (A 
single experiment, representative of 3 repeat experiments is shown).  Asterisks indicate significant 
differences (p < 0.01) by the t test or Kolmogorov-Smirnov test; the choice of test at each time 
point was dependent on skewness, kurtosis, and variance of the data being compared (see section 
2.26).  (Repeat-measures ANOVA tests were not appropriate as data distribution was mostly non-
parametric).  (B) Images of WT and CCR2-/- feet on day 0 and day 6 (peak arthritis).  (n = 16 feet, 8 
mice, mean ± SE is presented; data are derived from 2 independent experiments).  
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Figure 3.2: Virus replication in WT and CCR2-/- mice. 
6-8-week old mice were infected with 104 CCID50 CHIKV into the dorso-lateral metatarsal region 
of the foot.  At the indicated time points, sera or tissue samples were collected and virus levels 
measured using a CCID50 assay.  (A) Peripheral blood viraemia.  (n = 7 mice for CCR2-/-, n = 8-14 
WT mice, mean ± SE is presented; data are derived of 2 independent experiments for CCR2-/- mice, 
and 3 independent experiments for WT mice).  (B) Virus titres in the indicated tissues (n = 3-6 per 
time point, mean ± SE is presented) (NT – not tested).  
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Figure 3.3: qRT-PCR analyses of CHIKV RNA in CHIKV infected WT and CCR2-/- 
mice. 
6-8-week old mice were infected with 104 CCID50 CHIKV into the dorso-lateral metatarsal region 
of the foot.  At the indicated time points, feet were excised and analysed by qRT-PCR and primers 
specific for E1 (a major CHIKV structural protein); data was normalised to RPL13A mRNA levels.  
(n = 3-6 feet from different mice per time point, mean ± SE is presented; data is derived from 2 
independent experiments).  *p < 0.05 by Mann-Whitney U test. 
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3.2.3 Histology and immunohistochemistry of the cellular infiltrates in 
the arthritic feet of WT and CCR2-/- mice 
Since the virus replication and persistence are similar in WT and CCR2-/- mice while the 
foot swelling was more severe in CCR2-/- mice, the infiltrating cells in the joint were analysed.  
Histological examination of arthritic feet in WT mice showed a predominance of mononuclear cell 
infiltrates on day 6 (the day of peak arthritis) as described previously (Gardner et al., 2010).  This 
could be clearly seen by H&E staining of muscle (compare Figure 3.4A with B and C).  Staining of 
foot sections with F4/80 antibody (a monoclonal antibody recognising mouse 
monocyte/macrophages), also showed a large number of infiltrating F4/80+ cells (Figure 3.4D) as 
reported previously (Gardner et al., 2010).  Leder staining (Figure 3.4E) showed that neutrophils 
were largely absent from infiltrates in day 6 feet of WT mice (Figure 3.4E).  ApoTag staining 
revealed some apoptosis, primarily in cells with monocytic and fibroblastic morphology (Figure 
3.4F).  Chromotrope2R staining showed that eosinophils were largely absent (Figure 3.4G).   
The cellular infiltrates in the feet of CCR2-/- mice were quite distinct from those seen in 
WT mice.  H&E staining showed a predominance of neutrophils (compare Figure 3.4H with I and 
J), (many with hyper-segmented nuclei), with few F4/80+ cells detected in the infiltrates (Figure 
3.4K).  Prodigious neutrophil infiltrates were also clearly seen by Leder staining (Figure 3.4L).  
ApoTag staining was more widespread, with frequent staining of cytoplasmic debris (Figure 3.4M, 
left), suggestive of secondary necrosis.  ApoTag staining was often also present in cells with 
polymorphonuclear morphology (Figure 3.4M, right).  The latter suggests inflammatory neutrophils 
undergoing apoptosis, a well described phenomena in inflammation biology (Ariel and Serhan, 
2012).  Chromotrope2R staining also revealed a large number of eosinophils were present in the 
arthritic infiltrates in CCR2-/- feet on day 21 post-infection (Figure 3.4N). 
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Figure 3.4: Histology and immunohistochemistry of rheumatic lesions in CHIKV 
infected WT and CCR2-/- mice.   
A-G, WT mice.  H-N, CCR2-/- mice.  (A) and (H), H&E staining of muscle from uninfected mice.  
(B) and (I), H&E staining of muscle day 6 post infection.  (C) and (J), high magnification of H&E 
staining of muscle day 6 post-infection.  (D) and (K), F4/80 antibody (monocyte/macrophage) 
staining of connective tissue day 6 post-infection.  (E) and (L), Leder staining (neutrophils) of 
connective tissue day 6 post-infection.  (F) and (M), ApoTag staining (apoptotic cells) day 6 post-
infection (F, two images, M, two images).  (G) and (N), Chromotrope 2R staining (eosinophils) of 
connective tissue day 21 post-infection. 
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3.2.4 Quantitation of histology and immunohistochemistry of the 
cellular infiltrates in the arthritic feet of WT and CCR2-/- mice.   
To quantitate the features described above, slides were digitally scanned (Aperio) and 
analysed using the Positive Pixel Count algorithm.  F4/80 staining increased substantially in WT 
feet on day 6 post-infection (as reported previously (Gardner et al., 2010)) and was significantly 
higher than F4/80 staining in CCR2-/- feet at this time (Figure 3.5A).  F4/80 staining did not increase 
significantly in CCR2-/- feet on day 6, but did increase significantly on days 21 and 29 (Figure 
3.5A).  However, these latter increases were likely associated with infiltrating eosinophils, which 
also stain with F4/80 antibody (Figure 3.6).  Leder staining showed a dramatic increase in CCR2-/- 
feet on day 6 post-infection and was still significantly elevated on day 14 (Figure 3.5B), consistent 
with the increase in neutrophils seen by H&E staining.  In WT mice, Leder staining was slightly 
elevated day 6, but was substantially lower than in CCR2-/- feet on days 6 and 14 (Figure 3.5B).  
Immunohistochemistry using the neutrophil-specific anti-Ly6G antibody confirmed the stark and 
significant contrast in neutrophil infiltrate between WT and CCR2-/- feet on day 6 (Figure 3.7A, B 
and C).  ApoTag staining of apoptotic cells was also significantly higher in CCR2-/- feet on day 6, 
and was also significantly elevated on day 14, whereas, in WT mice, there was no significant 
difference between any of the time points shown (Nakaya et al., 2012) (Figure 3.5C).  Chromotrope 
2R staining (eosinophils) was slightly elevated on days 6 and 14 in WT mice, but was substantially 
elevated in CCR2-/- mice on day 21 and 29 (Figure 3.5D). 
These data illustrate that the prodigious monocyte/macrophage infiltrate seen in WT mice 
at this time (Gardner et al., 2010) is likely dependent on CCR2 expression, with its ligand CCL2 
strongly induced during CHIKV arthritis (Gardner et al., 2010, Labadie et al., 2010).  In addition, 
the increased and prolonged arthritic disease seen in CCR2-/- mice was associated with a severe 
neutrophil infiltrate followed by an eosinophil infiltrate, with more apoptotic cells also seen during 
peak disease. 
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Figure 3.5: Histology quantitation.  
(A) Image analysis (strong brown) of F4/80 staining of whole foot sections from WT and CCR2-/- 
mice at the indicated times post-infection.  Dotted line indicates the upper limit of non-specific 
staining in control slides.  (n = 3-5 feet from different per time point and mouse strain, mean ± SE is 
presented; p values by Kolmogorov-Smirnov test).  (B) Image analysis (strong red) of Leder 
staining of whole foot sections of WT and CCR2-/- mice at the indicated times post-infection.  (n as 
above; p values by Kolmogorov-Smirnov, Mann Whitney U and t tests).  (C) Image analysis (strong 
brown) of ApoTag staining of whole foot sections of WT and CCR2-/- mice at the indicated times 
post-infection.  (n as above; p values by Kolmogorov-Smirnov tests).  (D) Image analysis (strong 
red) of Chromotrope 2R staining of whole foot sections of WT and CCR2-/- mice at the indicated 
times post-infection.  (n as above: p values by Kolmogorov-Smirnov and Mann Whitney U tests) 
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Figure 3.6: F4/80 staining of cells in foot sections from WT and CCR2-/- mice day 21 
post CHIKV infection. 
(A) In WT mice F4/80 staining was predominantly associated with mononuclear cells (e.g. 
macrophages), with mononuclear infiltrate largely resolved by day 21 (Figure 3.5A).  (B) In feet of 
CCR2-/- mice the increase F4/80 staining seen at this time (Figure 3.5A) was associated with 
polymorphonuclear cells (likely eosinophils - see Figure 3.5D).  Murine eosinophils are known to 
stain with F4/80 antibody (McGarry and Stewart, 1991, Gouon-Evans et al., 2000). 
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Figure 3.7: Anti-Ly6G staining of feet from CCR2-/- and WT mice. 
Immunohistochemistry using anti-Ly6G neutrophil specific antibody.  (A) Image analysis (strong 
brown) of anti-Ly6G staining of whole foot sections from WT and CCR2-/- mice at day 6 post-
infection (n = 4 mice, mean ± SE is presented; p value by Kolmogorov-Smirnov test).  (B) Example 
of a whole foot section from CCR2-/- mouse stained with anti-Ly6G.  (C) Example of whole foot 
section from WT mouse stained with anti-Ly6G. 
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3.2.5 Antibody-based depletion of neutrophils did not ameliorate foot 
swelling in CCR2-/- mice 
Since neutrophils were associated with the more pronounced arthritis in CCR2-/- mice, the 
role of neutrophils in this model was investigated.  Anti-neutrophil antibody was injected into 
CCR2-/- mice and resulted in the reduction of neutrophils (Figure 3.8B).  However, this antibody-
based depletion of neutrophils did not ameliorate foot swelling in CCR2-/- mice (Figure 3.8A), and 
instead resulted in widespread haemorrhage and edema (Figure 3.8C) (reminiscent of the pathology 
seen in mice with diminished IFN-α/β responses (Rudd et al., 2012)), complicating any analysis of 
the arthritogenic role of neutrophils using this approach  
 
3.2.6 Cartilage damage in CHIKV infected CCR2-/- mice.  
In contrast with most autoimmune arthritides, alphaviral arthritides (and most viral 
arthritides (Suhrbier and Mahalingam, 2009)) are generally not associated with joint damage 
(Suhrbier et al., 2012).  Joint damage was also not seen in CHIKV-infected WT mice in the current 
study (in 6/6 feet examined) (Figure 3.9A) (or in CHIKV-infected monkeys (Labadie et al., 2010)).  
However, H&E staining of joints from CHIKV-infected CCR2-/- mice day 45 post-infection often 
showed (in 6/6 feet examined) loss of chondrocytes with empty lacunae in multiple foot joints 
(Figure 3.9B, arrows).  Clear signs of cartilage damage at the articular surfaces (never seen in WT 
mice) were also occasionally observed in CCR2-/- mice (2 joint in 6 feet) (Figure 3.9B, arrowhead).  
Loss of cartilage collagen (as revealed by Safranin O staining) was not observed in WT mice 
(Figure 3.9C), but was clearly seen in at least 1, occasionally 2, joints per foot in CCR2-/- mice (6 
feet examined) (Figure 3.9D, blue areas indicated by arrows).  CCR2 deficiency thus increased the 
severity of CHIKV arthritis, with cartilage damage clearly apparent. 
 
3.2.7 ANA levels in CCR2-/- and WT mice 
ANA are antibodies that are reactive against autologous cell nucleus.  Joint damage is a 
feature of rheumatoid arthritis (Hu et al., 2013) and CHIKV infected CCR2-/- mice showed clear 
signs of joint damage (Figure 3.9B and D).  Since high level of ANA in humans and in mice have 
been associated with autoimmune disorders includes rheumatoid arthritis (De Rycke et al., 2005), 
the ANA titres in the CCR2-/- mice were analysed.  No detectable ANA was observed in the sera of 
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either WT or CCR2-/- mice post CHIKV infection  (Figure 3.10).  This observation suggests that 
CCR2-/- mice did not develop autoimmunity.  
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Figure 3.8: Foot swelling after neutrophil depletion in CCR2-/- mice. 
Depletion of neutrophils in CCR2-/- mice did not reduce foot swelling.  (A) Mice were treated with 
anti-Ly6G antibody or IgG2a control antibody i.p. on days 4, 5 and 6 (arrows).  Foot measurements 
were taken at the indicated time points after CHIKV infection.  (n = 5 mice, mean ± SE is 
presented).  (B) Blood neutrophils were determined by blood smears and are presented as a 
percentage of total white blood cells as described previously (Challacombe et al., 2006).  (n as 
above).  (C) Widespread of haemorrhage (dotted line circle) and edema (*) were observed in tissue 
of anti-neutrophil antibody treated CCR2-/- mice 6 days post infection. 
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Figure 3.9: Cartilage damage in CCR2-/- feet.   
(A) H & E staining of joint from WT mouse day 45 post-infection (SS – synovial space).  (B) H&E 
staining of joint from CCR2-/- mouse day 45 post-infection.  Arrows indicate empty chondrocytic 
lacunae within the hyaline cartilage.  Arrowheads show cartilage damage at the articular surface.  
(C) Safranin O staining (cartilage) of joint from WT mouse day 45 post-infection.  (D) Safranin O 
staining (cartilage) of joint from CCR2-/- mouse day 45 post-infection.  Arrows show loss of red 
collagen staining (replaced by blue staining) at the articular surfaces. 
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Figure 3.10: ELISA for detection of mouse ANA. 
Naïve, day 29 and 45 post-CHIKV infection mice’s sera were tested for ANA - an indicator of 
autoimmune disease.  (n = 3-4 mice per group, mean ± SE is presented). 
Data for Figure 3.10 was prepared with assistance of Thuy Le.  
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3.2.8 Anti-viral Th1/Th2/Th17 responses in CHIKV-infected WT and 
CCR2-/- mice.   
CHIKV infections induce a strongly Th1-biased immune response (Gardner et al., 2010, 
Labadie et al., 2010), with CCR2-/- mice reported having impaired Th1 responses (Boring et al., 
1997, Sato et al., 2000, Iijima et al., 2011).  However, analysis of the anti-CHIKV IgG2c (Th1) and 
IgG1 (Th2) titres (Wang et al., 2011a, Schroder et al., 2010), illustrated that the dominant IgG2c 
responses were not significantly different in CCR2-/- mice (Figure 3.11A, IgG2c).  Anti-CHIKV-
specific IgG1 levels were, however, significantly elevated in CCR2-/- mice (Figure 3.11A, IgG1), 
perhaps consistent with the increased eosinophilia seen in these mice (Figure 3.5D).  Serum IFN-γ 
levels (Figure 3.11C) and neutralising antibody levels (Figure 3.11D) were not significantly 
different between WT and CCR2-/- mice.   
qRT-PCR analysis of T-bet, a key transcription factor for Th1 cells (Lipscomb et al., 
2009), showed a clear increase in WT mice on day 6 (peak arthritis) (Figure 3.11B, T-bet).  
However, T-bet mRNA induction and levels were not significantly different (from WT mice) in 
CCR2-/- mice (Figure 3.11B, T-bet), supporting the view that anti-CHIKV Th1 responses were not 
significantly impaired in CCR2-/- mice. 
Expansion of Th17 cells were reported to be responsible for the increase in neutrophil 
infiltration and exacerbated arthritic disease seen in collagen-induced arthritis in CCR2-/- mice 
(Rampersad et al., 2011).  However, no significant increases in RORγT mRNA were observed in 
either mouse strain on day 6 post-infection (Figure 3.11B, RORγT).  RORγT is a key transcription 
factor for Th17 cells (Ruan et al., 2011). 
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Figure 3.11: Immune responses in WT and CCR2-/- mice post CHIKV infection.  
(A) Anti-CHIKV IgG2c and IgG1 titres 7 weeks post-infection as determined by ELISA.  (n = 4 
mice per group, mean ± SE is presented; p value by Mann Whitney U test).  (B) qRT-PCR analysis 
of T-bet (Th1 transcription factor) and RORγT (Th17 transcription factor) at the indicated times 
post-infection.  (n = 4-6 feet and mice per group, mean ± SE is presented; p values by Mann 
Whitney U test).  (C) Serum IFN-γ analysed by cytometric bead array (n = 6-8 mice per group, 
mean ± SE is presented).  (D) Serum neutralisation titres post CHIKV infection (n = 3-7 mice per 
group, mean ± SE is presented). 
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3.2.9 Changes in inflammatory mediators in the arthritic feet and sera of 
CCR2-/- mice 
Increased neutrophil infiltrates in CCR2-/- mice have been associated with elevated levels 
of (i) neutrophil-attracting chemokines CXCL1 (keratinocyte chemoattractant) and/or CXCL2 (also 
known as macrophage inflammatory protein 2-alpha) (Fujii et al., 2012, Quinones et al., 2004, 
Montgomery et al., 2007), and/or (ii) granulocyte colony-stimulating factor (G-CSF) (Sawanobori 
et al., 2008), a key growth factor for neutrophil development and recruitment involved in 
inflammatory arthritis (Eyles et al., 2008).  IL-1β can also promote neutrophil recruitment (Sadik et 
al., 2012), and IL-10 can inhibit neutrophil recruitment (Ajuebor et al., 1999).  qRT-PCR analyses 
showed that significantly more CXCL1, CXCL2, G-CSF and IL-1β, and less IL-10, was present in 
the arthritic feet of CCR2-/- mice (Figure 3.12A), suggesting multiple mediators were involved in 
the switch from the predominantly monocyte/macrophage to neutrophil infiltrates.  Serum IL-10 
was also elevated earlier in the course of infection in WT mice (Figure 3.12B).  qRT-PCR analysis 
also showed that Arg-1 expression (a marker of M2 macrophages), although up-regulated in WT 
feet as expected (Stoermer et al., 2012), was not up-regulated in CCR2-/- feet (Figure 3.12, Arg-1).  
M2 macrophages are associated with resolution of inflammation (Ariel and Serhan, 2012).   
 
3.2.10 CHIKV infection in IL-10-/- mice 
Induction of IL-10 in feet (Figure 3.12A, day 6, IL-10) and sera (Figure 3.12B, day 1 and 
2) was significantly higher in WT mice compared to CCR2-/- mice.  This observation is consistent 
with the view that IL-10 can inhibit neutrophil recruitment (Ajuebor et al., 1999), with WT mice 
showed a lower level of neutrophil infiltration (Figure 3.5B).  To study the role of IL-10 in CHIKV 
infection, IL-10-/- mice were infected with CHIKV.  IL-10-/- mice had significantly higher foot 
swelling at day 5 and 6 compared to WT mice (Figure 3.13A), despite lower viraemia at day 1 
(Figure 3.13B).  Immunohistochemistry using the neutrophil-specific anti-Ly6G antibody showed 
that IL-10-/- mice had higher (but not significantly different) levels of infiltrating neutrophils 
(Figure 3.13C). 
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Figure 3.12: qRT-PCR of selected genes in feet and IL-10 in sera of WT and CCR2-/- 
post CHIKV infection.  
(A) qRT-PCR analysis of the indicated species at the indicated times post-infection.  (n = 3-5 mice 
per group, mean ± SE is presented; p values by Kolmogorov-Smirnov and t tests).  (B) Serum IL-10 
analysed by cytometric bead array.  (n = 6-8 mice per group, mean ± SE is presented; p value by 
Kolmogorov-Smirnov test). 
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Figure 3.13: Foot swelling, viraemia and neutrophil staining in CHIKV 
infected IL-10-/- mice. 
Increased foot swelling and decreased viraemia in IL-10-/- mice.  (A) The mean percentage increase 
in foot swelling over time for WT (n = 16 feet, 8 mice) and IL-10-/- mice (n = 10 feet, 5 mice) 
(mean ± SE is presented).  (p values by Mann-Whitney U test).  (B) Viraemia.  (n = as above, mean 
± SE is presented; p value by Mann-Whitney U test).  (C) Immunohistochemical staining using 
neutrophil-specific anti-Ly6G antibody (n = 4 feet and mice per mouse strain) quantitated as in 
Figure 3.7A (not significantly different). 
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3.2.11 Global gene expression changes induced by CHIKV infection.   
Microarray analysis was undertaken to determine what genes were up- and down-regulated 
in the arthritic feet of CHIKV-infected WT and CCR2-/- mice.  The genes up- or down-regulated on 
day 7 post-infection (one day after peak arthritis to capture genes associated with resolution 
initiation) relative to day 0 were determined for both mouse strains.  A total of 2406 genes were up- 
or down-regulated following CHIKV infection in WT and/or CCR2-/- mice.  When the fold up- or 
down-regulation of these differentially expressed genes (DEGs) was compared between WT and/or 
CCR2-/- mice, 81% showed less than 2 fold difference, illustrating that most genes were similarly 
regulated in feet day 7 post-infection in the two mouse strains.  However, consistent with the 
histological analyses, monocyte/macrophage-associated genes and pathways were more 
upregulatedin WT feet (Figure 3.14, green), and neutrophil-associated genes and pathways were 
more upregulated in CCR2-/- feet (Figure 3.14A, blue).  Consistent with the higher induction of IL-
10 (by qRT-PCR) in the WT mice (Figure 3.12A, IL-10), M2 and resolving macrophage associated 
genes were more upregulated in WT mice (Figure 3.14A). 
To gain a better understanding of the differences in infection-associated gene regulation 
between CCR2-/- and WT mice, the differences in fold changes in gene expression between the two 
strains for all 2406 DEGs was expressed as a ratio.  For 181 genes (7.5% of all DEGs) the “the fold 
change in CCR2-/- feet” divided by “the fold change in WT feet” was >1.5 (Figure 3.15A).  For 920 
genes (38% of all DEGs) “the fold change in WT feet” divided by “the fold change in CCR2-/- feet” 
was >1.5 (Figure 3.15D).  The former 181 genes thus represent genes that were more induced in 
CCR2-/- mice than in WT mice, and the latter 920 genes represent genes that were less induced in 
CCR2-/- mice than in WT mice.  IPA analysis of the 181 genes more induced in CCR2-/- mice, 
revealed canonical pathways associated with granulocyte, IL-17A in autoimmunity, RA and 
inflammation (Figure 3.15B).  Although autoimmune pathways were identified (consistent with the 
worse pathology), CCR2-/- mice did not develop ANAs (Figure 3.10).  IPA analysis of the 920 
genes less induced in CCR2-/- feet revealed canonical pathways associated with 
monocyte/macrophage, pattern recognition, autoimmunity, B and T cell (mostly Th cell), NK cell, 
muscle and inflammation pathways (Figure 3.15C).  Many of these pathways are consistent with the 
aforementioned changes in infiltrates and inflammation.  The identification of muscle pathways 
likely reflects increased muscle damage (Nakaya et al., 2012) in CCR2-/- feet (Figure 3.15C).  The 
identification of NK, T and B cell pathways in this gene set (Figure 3.15C) also suggests reduced 
recruitment of these cells (Gardner et al., 2010) into the infected feet in CCR2-/- mice; T cells can 
also express CCR2 (Bruhl et al., 2004). 
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Figure 3.14: Monocyte/macrophage, M2/resolving macrophages and neutrophils 
profiles in the feet of CHIKV infected WT and CCR2-/- mice.  
(A) Microarray expression data (fold change) of up-regulated genes associated with 
monocyte/macrophage (green), M2/resolving macrophages (brown) and neutrophils (blue).  Fold 
changes for DEGs from CCR2-/- d0 vs d7, and WT d0 vs d7 are shown with their q significance 
values (red values - not significant; values of q<0.05 were considered significance; statistics by 
IPA).  (B) Up-regulated pathways associated with monocytes/macrophages (green) and neutrophils 
(blue) on day 7 post infection in WT and CCR2-/- mice.  -log(<1.3) represents p<0.05. 
Data for Figure 3.14 was prepared with assistance of Helder Nakaya and Andreas Suhrbier.
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Figure 3.15: Microarray analysis of arthritic feet from WT and CCR2-/- mice.   
Genes differentially expressed on day 7 post infection (compared to day 0) for WT and CCR2-/- feet 
were determined by microarray analysis.  2406 differentially expressed genes were up or down-
regulated in WT and/or CCR2-/- feet.  (A) For 181 of these genes “fold change in CCR2-/- 
mice”/“fold change in WT mice” was >1.5 fold; (for 603 DEGs this ratio was >1).  (B) IPA 
canonical pathway analyses of the 181 genes more induced in CCR2-/- feet are shown, with 
pathways grouped into themes.  Pathways details are shown in Appendix I.  (C) As in (B) but with 
the 920 genes less induced in CCR2-/- feet.  (D) For 920 of these genes the “fold change in WT 
mice”/“fold change in CCR2-/- mice” was >1.5 fold (bottom right); (for 1794 genes this ratio was 
>1, for 9 the ratio was =1).  Pathways details are shown in Appendix II.  -log(<1.3) represents p < 
0.05.  
Data for Figure 3.15 was prepared with assistance by Helder Nakaya and Andreas Suhrbier. 
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3.3 Discussion 
This chapter describes the first analysis of a viral arthritis in CCR2-/- mice and illustrates 
that deficiency in this gene results in a more severe, prolonged and erosive arthritis.  The prodigious 
monocyte/macrophage infiltrate seen in WT mice was almost entirely replaced by a neutrophil 
infiltrate in CCR2-/- mice, with this switch associated with dysregulation of a range of inflammatory 
and anti-inflammatory pathways.  Recruitment of CCR2+ monocytes during CHIKV arthritis, 
although likely contributing to acute inflammatory disease (Suhrbier et al., 2012, Suhrbier and 
Mahalingam, 2009), thus also protects against even worse neutrophil-mediated pathology.   
CXCL1, CXCL2, G-CSF, and IL-1β were increased in the arthritic feet of CCR2-/- mice, 
whereas IL-10 was decreased, suggesting multiple mediators were involved in promoting neutrophil 
recruitment (Fujii et al., 2012, Quinones et al., 2004, Montgomery et al., 2007, Sawanobori et al., 
2008, Eyles et al., 2008, Sadik et al., 2012, Ajuebor et al., 1999).  The reduction in IL-10 and lack 
of Arg-1 induction, also suggests a paucity of (CCR2+ derived) M2 and resolving macrophages and 
their anti-inflammatory activities in CCR2-/- mice.  This contention is supported by array data that 
shows less up-regulation of a number of M2 and resolving macrophage markers in CCR2-/- feet 
(e.g. TGF-β, Ym1, Msr1) (Figure 3.14A, brown).  M2 macrophages have high efferocytosis 
activity, with efferocytosis a key driver of inflammation resolution (Ariel and Serhan, 2012).  The 
increase in ApoTag staining in CCR2-/- mice also suggests that efferocytosis is compromised in 
these mice, with CCL2 having previously been shown to promote efferocytosis (Tanaka et al., 
2010).  Evidence for secondary necrosis is also present in CCR2-/- feet (Figure 3.4M, left), and 
usually occurs when efferocytosis is compromised.  Secondary necrosis itself promotes 
inflammation by releasing a number of soluble inflammatory mediators (Miyake and Yamasaki, 
2012).   
The eosinophil infiltration that follows the neutrophil infiltration in CCR2-/- mice may be 
promoted by the tissue damage induced by the neutrophils and/or secondary necrosis, and may help 
down-regulate the inflammatory response in these animals (Lotfi et al., 2009).  Eosinophilic 
arthritis has been reported previously, and is usually associated with a benign course of disease 
(Vazquez-Trinanes et al., 2013).   
Treatment of WT mice with clodronate (one day prior to CHIKV infection) to deplete 
monocyte/macrophages was previously shown to reduce foot swelling, but extended the viraemia, 
after CHIKV infection (Gardner et al., 2010); data that would seem at odds with the observations 
presented herein.  However, the recent recognition that CD4 T cells and IFN-γ play important roles 
in driving arthritis in this CHIKV mouse model (Nakaya et al., 2012), and the ability of clodronate 
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treatment to suppress Th1 responses (Brewer et al., 1994), might suggest the observation above 
(Gardner et al., 2010) has more to do with reduced Th1 responses than reduced 
monocyte/macrophage infiltration (Cote et al., 2013).  (Th1 responses were not significantly 
affected in CHIKV infected CCR2-/- mice).  Clodronate treatment was also recently shown to affect 
germinal centers (Nikbakht et al., 2013), with compromised antibody responses perhaps explaining 
the extended viraemia seen after clodronate treatment (Gardner et al., 2010). 
Exactly how CCR2+ monocytes recruited during CHIKV infection, and/or the 
macrophages that develop from them, might prevent excessive neutrophil infiltration and pathology 
in WT mice remains unclear.  IL-10 may be involved (Ajuebor et al., 1999), but is unlikely to be the 
only player as neutrophil infiltration was not substantially or significantly increased in IL-10-/- mice 
(Figure 3.13C).  Anti-inflammatory macrophages can also suppress neutrophil recruitment by inter 
alia secreting (i) a series of proresolving lipid mediators (Serhan, 2010) and/or (ii) proteases that 
cleave neutrophil-attracting chemokines (Ortega-Gomez et al., 2013).  Regulatory T cells (Tregs) 
may be involved as (i) depletion of CCR2+ Tregs has been shown to exacerbate collagen-induced 
arthritis (Bruhl et al., 2004), (ii) anti-inflammatory macrophages can promote Treg expansion via 
TGF-β and IL-10 (Ortega-Gomez et al., 2013, London et al., 2013), (iii) T cells are important in 
driving CHIKV arthritis (Nakaya et al., 2012), and (iv) Th cell pathways were decreased in CCR2-/- 
mice (Figure 3.15C), with the microarray analysis unable to differentiate between Th and Treg 
cells.  The increased IgG1 responses in CCR2-/- mice also support the view that T cell activities 
were altered in CHIKV-infected CCR2-/- mice.  Further work is needed before the mechanisms and 
cells involved and their relative importance are fully elucidated, with other cell types (e.g. myeloid-
derived suppressor cells (Ortega-Gomez et al., 2013)) potentially also involved.  What does emerge 
from these studies is that in CHIKV arthritis (and perhaps other viral arthritides (Suhrbier and 
Mahalingam, 2009)), inflammation-recruited CCR2+ monocyte/macrophages appear to be 
important for limiting neutrophil recruitment into the infected and inflamed joint tissues.  This 
contrasts with observations in other arthritis models where these cells promote neutrophil 
recruitment (Wang et al., 2012a). 
The increase in IL-17 pathway activation in CHIKV infected CCR2-/- feet did not appear to 
be due to increased levels of Th17 cells (as was reported for in collagen-induced arthritis 
(Rampersad et al., 2011)).  Recently, immune complexes present during acute arthritis were shown 
to induce IL-17 production by neutrophils (Katayama et al., 2013).  Given antibody responses are 
raised against CHIKV (Figure 3.11A), immune complexes are likely to be present in CCR2-/- mice 
and may thus be responsible for triggering IL-17 production by the infiltrating neutrophils.  
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The widespread dysregulation of inflammatory processes observed in CHIKV infected 
CCR2-/- mice suggests considerable care might be warranted when using therapeutic agents that 
target CCR2/CCL2 for treating alphaviral arthritides (Rulli et al., 2011) (and perhaps other 
arthritides (Fujii et al., 2012)).  Patients who are being treated with CCR2/CCL2-targeting agents 
(for other conditions) may also be at risk of exacerbated arthritic disease following an alphaviral 
infection.   
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Chapter 4: The contribution of B, T, NK cells and IFN-γ  
in the control of viraemia and mediation of arthritis 
during CHIKV infection  
 
4.1 Introduction 
Infection of adult humans with arthritogenic alphaviruses results in a 5-7 day viraemia and 
symptomatic infection is nearly always associated with rheumatic disease, primarily polyarthralgia 
and/or polyarthritis, which can be chronic and debilitating (Suhrbier et al., 2012).  Antibodies are 
well known to provide protection against infections with alphaviruses (Burdeinick-Kerr et al., 2007, 
Brooke et al., 2010) including CHIKV (Eckels et al., 1970), with several studies demonstrating the 
antiviral efficacy of other antibody-based interventions (Fric et al., 2013, Selvarajah et al., 2013, Pal 
et al., 2013).  However, the contribution of B cells to alphaviral arthritic disease is less clear, with 
some studies indicating that B cells have no role in RRV disease (Morrison et al., 2007, Morrison et 
al., 2006), while another study showed that B cell deficiency leads to more severe arthritic disease 
in CHIKV-infected mice (Lum et al., 2013). 
The role of T cells in controlling alphaviral infection remains controversial.  Some studies 
suggest that T cells play no protective role in controlling viraemia during, for example, CHIKV 
(Chu et al., 2013), RRV (Morrison et al., 2007, Morrison et al., 2006) and ONNV (Seymour et al., 
2013) infections.  In contrast, other studies have suggested a protective role for T cells in control of 
RRV (Linn et al., 1998), SINV (Binder and Griffin, 2001, Burdeinick-Kerr et al., 2007) and VEEV 
infections (Brooke et al., 2010). 
Cytokines are well known to contribute to viral control and the pathology of alphaviral 
infection.  IFN-α/β has been shown to be critical for protection against infection, disease and 
mortality caused by CHIKV and other alphaviruses, with IFN-α/β induced rapidly, but transiently, 
early in response to viral infection (Rudd et al., 2012, Schilte et al., 2010, Ryman et al., 2007, 
Labadie et al., 2010).  IFN-γ has been shown to be involved in control of SINV (Binder and Griffin, 
2001, Burdeinick-Kerr et al., 2007) and VEEV infections (Brooke et al., 2010).  TNF has also been 
shown to have anti-alphaviral properties (Zaid et al., 2011), but has also been implicated in the 
pathology of CHIKV (Rudd et al., 2012).   
79 
Herein an adult mouse model of CHIKV infection and arthritis was used, where this mouse 
model mimics many aspects of human CHIKV disease (Gardner et al., 2010).  Mice deficient in B 
cells (µMT mice), B and T cells (Rag-1-/- mice), B, T and NK cells (Rag2/Il2rg-/- mice), CD4+ T 
cells (MHC-IIΔ/Δ mice) and IFN-γ (IFN-γ-/- mice) were infected with CHIKV, and viraemia and 
disease were monitored.  B cells appear to be critical for control of CHIKV viraemia (consistent 
with a previous report by Lum et al. (2013)), with all B cell deficient mice showing a persistent 
steady-state viraemia.  B cells may have an indirect role in promoting CHIKV arthritis.  T cells 
were found to have a minor but significant role in controlling viraemia.  Importantly, CD4+ T cells 
(possibly via the action of IFN-γ) were shown to be a major driver of CHIKV arthritis.  This is in 
contrast to previous reports that suggested that T cells play no role in alphaviral arthritis (Morrison 
et al., 2007, Morrison et al., 2006). 
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4.2 Results 
 
4.2.1 Viraemia in WT and B cell deficient mice (µMT, Rag-1-/- and 
Rag2/Il2rg-/- mice) infected with CHIKV 
To determine which immune cells are critical for the control of CHIKV viraemia, WT, 
µMT (B cell deficient), Rag-1-/- (B and T cell deficient) and Rag2/Il2rg-/- (B, T and NK cell 
deficient) mice were infected with CHIKV via s.c. injection into each foot (Gardner et al., 2010). 
At the indicated time points, viraemia was measured using CCID50 assay.  Viraemia in the 
B cell deficient mouse strains (µMT, Rag-1-/- and Rag2/Il2rg-/-) peaked on days 2-3 post infection, 
stayed significantly higher than WT mice on days 3, 4 and 5, and then settled to relatively steady-
state levels (Figure 4.1, µMT, Rag-1-/- and Rag2/Il2rg-/-).  This minor-fluctuating infection pattern is 
also seen in macrophage cell line that persistently infected with RRV (Linn et al., 1998, Way et al., 
2002).  In contrast, viraemia in WT mice was cleared by day 5 (Figure 4.1, WT).  This elevated and 
persistent viraemia in B-cell deficient mice suggests that B cells are critical for the clearance of 
CHIKV viraemia. 
The steady-state viraemias observed in B cell deficient mice are reminiscent of peripheral 
blood set point viraemias described for human immunodeficiency virus (HIV), in which the set 
point levels are deemed to be a reflection of functional anti-viral immunity (Prentice and Tang, 
2012).  Using a similar approach, the set point viraemias in CHIKV infected mice were determined 
by taking the mean of all viraemia measurements taken ≥ 10 days post infection (Figure 4.1, red 
values ± SD).  Rag2/Il2rg-/- and Rag-1-/- mice, which both lack B and T cells, had a viraemia that 
was significantly higher (≈2 logs) than µMT mice that lack B cells (Figure 4.1, see p values).  
These results suggest that T cells contribute to the control of CHIKV viraemia.  NK cells do not 
appear to play a significant role in the control of CHIKV viraemia, as Rag-1-/- mice (B and T cell 
deficient) had a similar set point viraemia as Rag2/Il2rg-/- mice (B, T and NK cell deficient) (Figure 
4.1). 
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Figure 4.1: Viraemia in CHIKV infected WT mice and B cell deficient mouse strains 
(µMT, Rag-1-/- and Rag2/Il2rg-/- mice). 
WT, µMT (deficient in B cells), Rag-1-/- (deficient in B and T cells) and Rag2/Il2rg-/- mice 
(deficient in B, T and NK cells) were infected with CHIKV.  Viraemia was measured at the 
indicated time points.  Set point viraemia (in red) is the mean of all viraemia measurements taken ≥ 
10 days post infection (n = 3-10 mice per time point, mean ± SE is presented; data are derived from 
2-3 independent experiments).  **p < 0.01 and *p < 0.05 (compared to WT mice) by Mann-
Whitney U test. 
Data for Rag2/Il2rg-/- mice was prepared with assistance of Penny Rudd and Joy Gardner.  
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4.2.2 Vaccination of µMT mice 
The results in section 4.2.1 demonstrate that CHIKV infected µMT mice (B cell deficient) 
had a lower set point viraemia than the Rag-1-/- mice (B and T cell deficient).  This observation 
suggests that the µMT mice generate CHIKV specific T cells that contribute to the control of 
CHIKV viraemia.  CD8+ cytotoxic T lymphocytes (hereafter referred as CD8+ T cells), have been 
shown not to influence viraemia in a Ross River virus mouse model (Linn et al., 1998) and not to 
influence viraemia and disease in a CHIKV mouse model (Teo et al., 2012b), suggesting CD4+ T 
cells are likely involved.  To test whether µMT mice are able to produce protective CHIKV specific 
T cells, µMT mice were vaccinated with an inactivated (non-adjuvanted) CHIKV whole-virus 
vaccine, which provides complete protection against CHIKV viraemia and foot swelling in WT 
mice (Gardner et al., 2010) (see section 2.9 for methods).  Vaccinated µMT mice (21 days post 
vaccination) were found to generate T cell responses to the CHIKV vaccine that were comparable 
to those seen in WT mice (Figure 4.2A), as measured by T cell proliferation assays using 
inactivated virus as antigen (see section 2.22 for methods).  An enzyme-linked ImmunoSpot assay 
was attempted, but failed to detect any significant increase of CD8+ T cell activity in vaccinated 
mice compared to non-vaccinated mice (data not shown).  This result is not surprising as 
unadjuvanted, killed, whole-virus vaccines are generally poor at inducing CD8+ T cell responses 
(Foged et al., 2012).  These data suggest that µMT and WT mice primarily produced CHIKV-
specific CD4+ T cells post vaccination. 
To examine the efficacy of these vaccine-induced CHIKV-specific T cells in controlling 
CHIKV viraemia, vaccinated and non-vaccinated µMT mice were challenged with CHIKV.  The 
vaccinated µMT mice had a ≈1 and ≈1.5 log lower viraemia on days 3 and 4 post infection, 
respectively, when compared with mock-vaccinated µMT mice (Figure 4.2B, *).  This effect was 
lost at later time points (Figure 4.2B), by which time the control µMT mice would presumably have 
generated their own CHIKV-specific T cells.  This experiment supports the view that T cells 
contribute to viraemia control.  
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Figure 4.2: Viraemia and T cell proliferation assay in vaccinated WT and µMT mice. 
µMT and WT mice were vaccinated with inactivated CHIKV antigen.  (A) Splenocytes derived 
from mock-vaccinated WT, vaccinated WT, mock-vaccinated 0µMT and vaccinated µMT mice 
were subjected to a T cell proliferation assay.  Counts per minute correlates with the proliferation of 
CHIKV specific T cells.  (n = 5 mice per group; p values by Mann-Whitney U test).  (B) 
Vaccinated and mock-vaccinated µMT mice were challenged with CHIKV.  Viraemia was 
measured at the indicated time points.  (n = 7-10 mice per group; data is derived from 2 
independent experiments).  *p < 0.01 by Mann-Whitney U test. 
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4.2.3 Treatment of Rag-1-/- and µMT mice with anti-CHIKV antibodies 
Adoptive transfer of antibodies has been suggested as a prophylactic and therapeutic 
intervention for CHIKV (Fric et al., 2013, Selvarajah et al., 2013, Pal et al., 2013).  Persistently 
infected Rag-1-/- and µMT mice, which lack antibody producing B cells, were treated with 200 µl of 
hyperimmune sera containing high levels of CHIKV neutralising antibodies (1 in 1250 
neutralisation titre).  Viraemia in the treated mice became undetectable for 10 and 30 days in Rag-1-
/- and µMT mice (Figure 4.3), respectively, but then reappeared to levels seen prior to antibody 
administration (Figure 4.3).  Therefore, passive transfer of antibody was unable permanently to 
clear the virus from these persistently viraemic mice.  
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Figure 4.3: Viraemia in persistently infected Rag-1-/- and µMT mice treated with anti-
CHIKV hyperimmune sera.  
Rag-1-/- mice (deficient in B and T cells) and µMT mice (deficient in B cells), with an established 
persistent viraemia, were treated with hyperimmune sera containing high levels of CHIKV 
neutralising antibodies.  At the indicated time points, viraemia was measured (n = 4 mice per time 
point). 
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4.2.4 CHIKV arthritis in µMT mice 
To investigate the role of B cells in the development of arthritis, µMT and WT mice were 
infected with CHIKV and foot swelling was measured over time (Figure 4.4A and B).  Foot 
swelling was significantly higher in µMT mice than WT mice on days 4, 5, 7, 8, 9, 10 and 11 
(Figure 4.4B) consistent with a previous report using a different CHIKV isolate (Lum et al., 2013).  
However, there was no significant difference in peak foot swelling (day 6) between µMT and WT 
mice.  
The infected joint tissues were also examined by histology (Figure 4.5).  Peak swelling of 
WT and µMT mice (Figure 4.4B, day 6) showed a clear infiltrate of mononuclear cells (Figure 4.5A 
and B).  The density of infiltrating cells during peak arthritis was quantified using the Aperio 
Positive Pixel Count algorithm, which determined the amount of blue nuclear stain per µm2.  The 
density of infiltrating mononuclear cells did not differ between WT and µMT mice (Figure 4.5F), 
illustrating that the increased foot swelling (in µMT mice) was due to the increased levels of 
arthritis. 
 
4.2.5 CHIKV arthritis in Rag-1-/- mice 
To investigate the role of T cells in CHIKV arthritis, Rag-1-/- mice (deficient in B and T 
cells) were infected with CHIKV.  Rag-1-/- mice displayed two distinct peaks in foot swelling, one 
on day 3 (that was significantly higher than that seen in WT mice) and one on day 6 (Figure 4.4C).  
Foot swelling in Rag-1-/- mice on day 6 was comparable to that seen in WT mice (Figure 4.4C). 
Histological analysis revealed that Rag-1-/- mouse feet had a significantly lower density of 
infiltrating cells on both day 3 and 6 (Figure 4.5F, Rag-1-/-) as quantified by Aperio Positive Pixel 
Count analysis, when compared to that seen in WT mice (Figure 4.5F, WT).  These results 
illustrated that foot swelling in Rag-1-/- mice was not due to the influx of inflammatory cells but 
rather was largely attributable to oedema (Figure 4.5C and D, * indicates of oedema).  The higher 
density of inflammatory infiltrates in WT (and µMT mice) when compared with Rag-1-/- mice, 
further supports the view that T cells are required for the development of CHIKV arthritis. 
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Figure 4.4: Foot swelling in CHIKV infected WT, µMT and Rag-1-/- mice. 
WT, µMT (deficient in B cells) and Rag-1-/- mice (deficient in B and T cells) were infected with 
CHIKV and monitored for foot swelling.  (A) Images of uninfected WT mice feet (-ve CHIKV) and 
infected WT mice feet (+ve CHIKV) on day 6 post infection (peak swelling).  (B) Foot swelling, 
expressed as percent increase (compared to pre-infection measurements), in infected WT and µMT 
mice.  (n = 10-16 feet, 5-8 mice per time point; data are derived from 3 independent experiments for 
WT mice and 2 independent experiments for µMT mice).  *p < 0.01 by Mann-Whitney U test.  (C) 
Foot swelling in WT and Rag-1-/-.  (n = 10-16 feet, 5-8 mice per group; data are derived from 3 
independent experiments for WT mice and 2 independent experiments for Rag-1-/- mice).  **p < 
0.01 by Mann-Whitney U test.  
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Figure 4.5: Histological analysis and quantification of feet from CHIKV infected WT, 
µMT, Rag-1-/- and MHC-IIΔ/Δ mice. 
WT, µMT (deficient in B cells), Rag-1-/- (deficient in B and T cells) and MHC-IIΔ/Δ (deficient in 
CD4+ T cells) mice were infected with CHIKV s.c. into the feet.  At the indicated time points, the 
infected mice were sacrificed, the feet removed and examined by histology.  (A), (B), (C), (D) and 
(E) H&E staining of skeletal muscle in CHIKV infected mice feet; * indicates oedema.  (F) Aperio 
Positive Pixel Count quantification of digitally scanned H&E stained whole foot sections.  Area of 
nuclear staining (blue) per unit area is used as a measure of the density of infiltrating cells.  (n = 4 
feet, 4 mice per group).  P values by Mann-Whitney U (WT day 6 vs MHC-IIΔ/Δ day 6) and 
Kolmogorov Smirnov tests (WT day 6 vs Rag-1-/- day 6). 
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4.2.6 Investigation of the role of CD4+ T cells in CHIKV viraemia and 
arthritis using MHC-II Δ/Δ mice  
Previous results (sections 4.2.1, 4.2.2, and 4.2.4) suggested that T cells may play a role in 
the control of CHIKV viraemia and the development of CHIKV arthritis. CD4+ T cells are also 
important drivers of rheumatoid arthritis (Yamada et al., 2011, Snir et al., 2011).  To determine 
whether CD4+ T cells are involved in CHIKV viraemia control and arthritis, MHC-IIΔ/Δ mice that 
are deficient in CD4+ T cells were infected with CHIKV.  Compared with WT mice, the MHC-IIΔ/Δ 
mice had a slight delay in viraemia clearance that approached significance on day 4 (Figure 4.6A), 
again supporting the view that CD4+ T cells play a significant but secondary role in controlling 
CHIKV viraemia. 
To elucidate the role of CD4+ T cells in CHIKV arthritis, foot swelling in CD4+ T cell 
deficient MHC-IIΔ/Δ mice was compared with WT mice following CHIKV infection.  MHC-IIΔ/Δ 
mice had significantly lower foot swelling compared to WT mice on day 6, 7 and 8 post infection 
(Figure 4.6B, *), and H&E staining revealed that the feet of MHC-IIΔ/Δ mice had lower densities of 
infiltrating cells compared to WT mice during peak arthritis (day 6 post infection) (Figure 4.5A and 
E; Figure 4.5F, WT and MHC-IIΔ/Δ).  These data suggest that CD4+ T cells play an important role 
in the development of CHIKV arthritis.  
 
4.2.7 Vaccination of µMT mice – foot swelling  
µMT mice produced CHIKV-specific CD4+ T cells following vaccination (section 4.2.2).  
Since result in section 4.2.6 suggested that CD4+ T cells may play a pathogenic role in acute 
CHIKV arthritis, foot swelling in vaccinated µMT mice was compared with non-vaccinated µMT 
mice following CHIKV infection.  Vaccinated µMT mice had a significantly higher foot swelling 
on day 2, 3 and 4 compared to mock-vaccinated µMT mice when challenged with CHIKV (Figure 
4.7, *).  This observation suggests that the pre-existing CHIKV-specific CD4+ T cells present in the 
vaccinated mice were responsible for the early foot swelling seen in vaccinated mice.  Taken 
together, these data suggest that CD4+ T cells act to reduce CHIKV viraemia but exacerbate 
CHIKV arthritis. 
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Figure 4.6: Viraemia and foot swelling in CHIKV infected WT and MHC-IIΔ/Δ mice.  
WT and MHC-II Δ/Δ mice (CD4+ deficient) were infected with CHIKV.  (A) Viraemia in WT and 
MHC-IIΔ/Δ mice post CHIKV infection.  (n = 6-10 mice per group, mean ± SE is presented; data are 
derived from 3 independent experiments for WT mice and 2 independent experiments for MHC-
IIΔ/Δ  mice.  P value by t-test.  (B) Foot swelling in WT and MHC-IIΔ/Δ mice post CHIKV infection.  
(n = as above, with both feet; data are derived as above).  *p < 0.05 by Mann-Whitney U test. 
99 
 
Days post CHIKV infection
Foot swelling
WT
MHC-IIΔ/Δ
%
 in
cr
ea
se
 in
 fo
ot
 
w
id
th
 x
 b
re
at
h 
± 
SE
0 2 4 6 8 10 12 14
0
10
20
30
40
50
60B
Days of post CHIKV infection
A
Vi
ra
em
ia
, l
og
10
 C
C
ID
50
/m
l ±
 S
E
*
*
*
Viraemia
p = 0.056
0 2 4 6 8 10 12 14
0
1
2
3
4
5
6
7
WT
MHC-IIΔ/Δ
100 
 
Figure 4.7: Foot swelling in vaccinated µMT mice and mock-vaccinated µMT mice 
following CHIKV infection. 
µMT mice were vaccinated with inactivated CHIKV antigen or mock.  After 3 weeks, mice were 
infected with CHIKV s.c. in the feet.  Foot swelling was measured at the indicated time points and 
values are expressed as percent increase in foot width x breadth (compared to day 0) (n = 10 feet, 5 
mice per time point; data are derived from 2 independent experiments).  *p < 0.05 by Mann-
Whitney U test. 
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4.2.8 MHC-IIΔ/Δ mice produce IgG2c antibodies independent of CD4+ T 
cells  
MHC-IIΔ/Δ mice are deficient in CD4+ T cells, which are known to facilitate B cell IgG 
class switching (Swain et al., 2012).  However, MHC-IIΔ/Δ mice were able to control viraemia 
effectively (Figure 4.6A) and did not display persistent viraemia as seen in B cell deficient mice 
(Figure 4.1).  Analysis of the antibody responses in these mice showed that following CHIKV 
infection, MHC-IIΔ/Δ mice generated no anti-viral IgG1 responses (Figure 4.8A), but they did 
produce anti-viral IgG2c responses, albeit at about 100 fold lower titres compared to WT mice 
(Figure 4.8B).  This reduced, yet significant, virus-specific IgG2c is likely responsible for the 
control of CHIKV seen in these mice.  These observations indicate that MHC-IIΔ/Δ mice control 
viraemia via CD4+ T cell-independent production of IgG2c. 
  
4.2.9 CHIKV arthritis and viraemia in IFN-γ-/- mice 
Activated CD4+ T cells can produce high levels of IFN-γ (Foulds et al., 2006).  During 
CHIKV infection, serum IFN-γ is consistently up regulated in human patients, monkeys and mice 
(Gardner et al., 2010, Labadie et al., 2010, Hoarau et al., 2010).  To examine whether IFN-γ 
contributes to CHIKV arthritis, IFN-γ-/- mice were challenged with CHIKV.  Following infection, 
CHIKV-infected IFN-γ-/- mice showed a significantly lower foot swelling on days 2-3 and 6-8 when 
compared with WT mice (Figure 4.9A; p<0.01).  Viraemia in IFN-γ-/- mice was not significantly 
different from WT mice (Figure 4.9B, see p values), indicating that the reduced foot swelling in 
IFN-γ-/- mice was not due to any major reduction in viraemia.  These data suggest that IFN-γ is 
involved in promoting CHIKV arthritis.  The likely source of IFN-γ may be CD4+ T cells.  
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Figure 4.8: The presence of anti-CHIKV antibody in CHIKV infected WT and MHC-IIΔ/Δ 
mice.  
WT and MHC-IIΔ/Δ mice were infected with CHIKV.  Sera from WT and MHC-IIΔ/Δ mice were 
collected on day 21 post-CHIKV infection and assayed for anti-CHIKV antibodies by standard 
ELISA.  (A) Anti-CHIKV IgG1.  (n = 4 mice per group).  (B) Anti-CHIKG IgG2c.  (n = 4 mice per 
group).  
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Figure 4.9: Viraemia and foot swelling in WT and IFN-γ-/- mice during CHIKV 
infection. 
WT and IFN-γ-/- mice were infected with CHIKV.  (A) Foot swelling in WT and IFN-γ-/- mice post 
CHIKV infection.  (n = 10-16 feet, 5-8 mice per group; data are derived from 3 independent 
experiments for WT mice and 2 independent experiments for IFN-γ -/- mice).  **p < 0.01 by Mann-
Whitney test.  (B) Viraemia in WT and IFN-γ-/- mice post CHIKV infection.  (n = 5-10 mice per 
time point).  P values by Kolmogorov Smirnov test. 
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4.2.10 Histological analysis of persistently infected Rag-1-/- mice 
Previous data (Eckels et al., 1970, Metz et al., 2013a, Lum et al., 2013) (Figure 4.1) 
suggest that B cells are critical for control of CHIKV viraemia and CD4+ T cells are implicated in 
the development of CHIKV arthritis (Figure 4.6B).  Rag-1-/- mice, which lack both B and T cells, 
had relatively high viraemia (Figure 4.1, compare day 1-5), but a lower density of infiltrating cells 
in the feet compared to WT mice (Figure 4.5A, C and D; Figure 4.5F, Rag1-/-).  After CHIKV 
infection, Rag-1-/- mice developed a persistent viraemia (Figure 4.1).  This persistent viraemia 
resulted in surprisingly little overt pathology with mice appearing and behaving normally post 
infection for up to day 500 (data not shown).   
To determine whether persistent CHIKV infection results in any pathology in mice, the 
liver, lungs, brain, spleen, lymph nodes, muscle, skin, and feet of persistently viraemic (430 days 
post infection) and uninfected Rag-1-/- mice were examined by histology.  H&E analysis revealed 
that the spleen, kidney and liver of chronically infected Rag-1-/- mice had minor but discernible 
pathology (Figure 4.10B, D and F) compared to non-infected Rag-1-/- mice (Figure 4.10A, C and 
E).  The spleens of chronically infected Rag-1-/- mice displayed marked increases in 
polymorphonuclear leukocytes (Figure 4.10B), features that are consistent with chronic infection 
(Borojevic et al., 1983, Murray et al., 1998, Furze and Selkirk, 2005).  In the kidney and liver of 
persistently viraemic Rag-1-/- mice, an increased cell density was observed (for kidney, compare 
Figure 4.10C with D, black arrowheads; for liver, compare Figure 4.10E with F, black arrowheads), 
which is also indicative of chronic inflammation (Emamghorashi et al., 2011).  Liver tissue from 
infected Rag-1-/- mice clearly displayed an increased number of apoptotic cells compared to 
uninfected Rag-1-/- mice (Figure 4.10F, white arrows), again indicating the presence of chronic 
inflammation (Ishak, 2000).  Together, these histological observations indicate that the persistent 
viraemia observed in Rag-1-/- mice generates a pathology consistent with mild but chronic 
inflammation. 
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Figure 4.10: Histological analysis of persistently viraemic Rag-1-/- mice. 
Rag-1-/- mice were infected with CHIKV.  On day 430 post infection, two viraemic Rag-1-/- mice 
were sacrificed.  A, C, E, uninfected Rag-1-/- mice.  B, D, F, Rag-1-/- mice day 430 post infection.  
(A) and (B), H&E staining of spleen.  (C) and (D), H&E staining of kidney.  Black arrowheads 
indicate increased cell density.  (E) and (F), H&E staining of liver.  Black arrowheads indicate 
increased cell density; white arrows indicate apoptotic cells.  
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4.2.11 Cytokine profile in the sera of persistently infected Rag-1-/- mice  
Histological analysis of chronically infected Rag-1-/- mice provided evidence of an 
ongoing local inflammatory response (section 4.2.10).  To further investigate the presence of 
ongoing systemic inflammation, serum cytokine levels were measured in uninfected Rag-1-/- mice 
and persistently viraemic Rag-1-/- mice, by using cytometric bead array and IFN-alpha 
FlowCytomix assay.  IFN-γ, TNF and IL-6 levels peaked on day 1-3, and then dropped, but 
remained persistently up-regulated (Figure 4.11), with IFN-γ and TNF previously shown to have 
anti-alphaviral activities (Ryman et al., 2007, Zaid et al., 2011).  The initial induction of these pro-
inflammatory cytokines in Rag-1-/- mice was similar to the induction of these cytokines in WT mice 
during acute infection (Gardner et al., 2010).  However, in WT mice the levels of these cytokines 
returned to pre-infection levels after 14 days (Gardner et al., 2010). 
IFN-α levels, which were up-regulated during acute infection in Rag-1-/- mice (Figure 
4.11, day 1-3), did not remain elevated, despite ongoing viraemia in these mice (Figure 4.1, Rag-1-/-
).  Production of IFN-α/β  is well characterised and known to be tightly controlled and usually 
transient (Bonjardim et al., 2009, Komuro et al., 2008).  This pattern of IFN-α/β  production 
appeared to be largely retained in Rag-1-/- mice after CHIKV infection despite ongoing viraemia.  
These data suggest that IFN-γ, TNF and IL-6, but not IFN-α, were associated with viraemia control 
in persistently infected Rag-1-/- mice. 
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Figure 4.11: Serum cytokine levels in persistently viraemic Rag-1-/- mice. 
Rag-1-/- mice were infected with CHIKV s.c. in the feet.  Sera were collected at the indicated time 
points and analysed for IFN-γ, TNF, IL-6 and IFN-α levels using cytometric bead array (IFN-γ, 
TNF, IL-6) and Mouse IFN-alpha FlowCytomix assay (IFN-α).  (n = 2-4 mice per time point). 
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4.2.12 Persistent virus recovered from Rag1-/- mice 
The ability of alphaviruses to acquire mutations and better evade the antiviral effects of 
IFNα/β have been reported (Lidbury et al., 2011, Stoermer Burrack et al., 2014) with CHIKV and 
other alphaviruses having evolved strategies to counter the host’s type I and II interferon responses  
(Ryman and Klimstra, 2008, Fros et al., 2010).  Virus isolated from Rag-1-/- mice on 100 and 429 
days post-infection behaved no differently from parental virus (with respect to viraemia and foot 
swelling) when isolated from blood, expanded in C6/36 cells, and used to infect WT mice (data not 
shown).  CHIKV thus appears unable (via mutations) to evade further the innate factors that 
maintain the viraemia at the set-point level in Rag1-/- mice.  One might speculate that TNF (Zaid et 
al., 2011) (rather than IFN-γ (Fros et al., 2010)) plays a dominant role in viraemia suppression in 
these mice (Figure 4.11), and that the evolution of entirely new protein domains that can counter the 
anti-viral effects of TNF is unrealistic in the limited time frame.  
 Despite the low fidelity of RNA replication (Coffey et al., 2011), sequencing of virus 
isolated day 100 from Rag-1-/- mice (and expanded in C6/36 cells) showed only a limited number of 
mutations (see Appendix VI), perhaps suggesting constraints on error accumulation (Crotty et al, 
2001).  (Alternatively, other viral species did arise in Rag-1-/- mice, but expanded poorly in C6/36 
cells). 
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4.3 Discussion 
This chapter investigated the role of B cells, T cells, NK cells and IFN-γ in controlling 
CHIKV viraemia and mediating arthritis using a mouse model of CHIKV disease.  WT mice and 
mice deficient in B cells (µMT mice), B and T cells (Rag-1-/- mice), B, T and NK cells (Rag2/Il2rg-
/- mice), CD4+ T cells (MHC-IIΔ/Δ mice) and IFN-γ (IFN-γ-/- mice) were infected with CHIKV.  The 
viraemia and arthritis seen in these CHIKV infected mouse strains are summarised in Table 4.1, 
along with the implications of the results. 
Table 4.1: Viraemia and arthritis in WT and knock-out mice infected with CHIKV.  
The conclusions were derived by comparing the viraemia and arthritis of knock-out mice with WT 
mice. 
Mice  Deficiency Viraemia  Arthritis  Conclusions 
WT None  Resolved day 5 p.i.  Peak at day 6 - 
µMT B cells Persistent 
(Figure 4.1) 
• Similar to WT 
mice 
(Figure 4.4B) 
• B cells are critical for 
viraemia clearance 
Rag-1-/- B and T 
cells 
Persistent and higher 
than µMT mice 
(Figure 4.1) 
• Higher than 
WT mice on day 
3-5 (Figure 4.4C) 
• With oedema  
(Figure 4.5C,D)  
• B cells are critical for 
viraemia clearance 
• T cells are associated 
with CHIKV arthritis 
and played a minor role 
viraemia control 
Rag2/Il2rg-/- B, T and 
NK cells 
Persistent and higher 
than µMT mice; 
similar to Rag-1-/- 
mice 
(Figure 4.1) 
• Lower than WT 
(& µMT) mice^  
• Similar to Rag-
1-/- mice^ 
• No oedema^ 
• B cells are critical for 
viraemia clearance 
• NK cells are less 
critical in controlling 
CHIKV viraemia  
• NK cells do not 
mediate CHIKV arthritis 
MHC-IIΔ/Δ CD4+ T 
cells 
Resolved day 5 p.i.  
(Figure 4.6A) 
Lower than WT 
(Figure 4.5E,F & 
Figure 4.6B) 
• CD4+ T cells promote 
CHIKV arthritis  
IFN-γ-/- IFN-γ Resolved day 5 p.i.  
(Figure 4.9B) 
Lower than WT 
(Figure 4.9A) 
• IFN-γ promotes 
CHIKV arthritis 
*p.i. = post infection; ^ = data not shown (by others from Suhrbier Group). 
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4.3.1 Role of T cells in viraemia control 
CHIKV infection triggers a strong T cell response in humans and mice (Hoarau et al., 
2010, Wauquier et al., 2011, Gardner et al., 2010), suggesting the involvement of T cells in the 
immune control of CHIKV.  The data presented in this chapter demonstrated that T cells play a role 
(although secondary to antibodies) in the control of CHIKV viraemia.  The evidences presented 
herein are (i) Rag-1-/- mice had a higher set point viraemia compared to µMT mice (Figure 4.1), and 
Rag-1-/- mice also had a viraemia relapse 20 days earlier than µMT mice after both strains of mice 
were treated with an equal amount of adoptively transferred anti-CHIKV antibody (Figure 4.3).  (ii) 
Vaccination of µMT mice induced a T cell response (Figure 4.2A) that was sufficient to reduce 
viraemia on day 3 and 4 post infection (Figure 4.2B, *).  As unadjuvanted, killed, whole-virus 
vaccines are generally poor at inducing CD8+ T cells (Foged et al., 2012) and CD4+ T cell recall 
responses usually peak at around day 4 (Wuthrich et al., 2005), this observation provides further 
evidence for an antibody-independent role of CD4+ T cells in CHIKV viraemia suppression.  (iii) 
CHIKV infected MHC-IIΔ/Δ displayed a delay in viraemia control when compared to WT mice 
(Figure 4.6A).  Taken together, the evidence presented in this chapter indicates that T cells play a 
minor but significant role in controlling CHIKV viraemia.  
 
4.3.2 Role of T cells in arthritis 
Previous reports indicated that T cells are not implicated in RRV-induced (another 
alphavirus) arthritis (Morrison et al., 2007, Morrison et al., 2006).  However, investigation of 
CHIKV associated arthritis in this chapter clearly implicates T cells, specifically CD4+ T cells, in 
the development of CHIKV-induced arthritis.  A lower density of infiltrating cells was observed in 
Rag-1-/- and MHC-IIΔ/Δ mice following infection (Figure 4.5C, D and E), and there was an early 
exacerbation of foot swelling observed in vaccinated µMT mice following infection (Figure 4.7, *).  
The microarray analyses conducted by Nakaya et al. (2012) also showed evidence for strong T cell 
signals during peak CHIKV arthritis.  Similarly, the pathogenic role of T cells demonstrated herein 
are also consistent with the findings of another study that used CD4-/- mice to demonstrate an 
arthritic role of CD4+ T cells in CHIKV disease (Teo et al., 2012b). 
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4.3.3 Role of B cells in viraemia control  
 B cells are well known in clearing the viraemia of alphaviruses including CHIKV and 
SINV (Lum et al., 2013, Teo et al., 2012b, Burdeinick-Kerr et al., 2007, Hawman et al., 2013, 
Brooke et al., 2010).  The results presented in this chapter also suggest that clearance of CHIKV 
viraemia was critically dependent on B cells, as mice deficient in B cells failed to clear CHIKV 
viraemia (Figure 4.1).  Altogether, the findings by others and data presented herein clearly support 
the view that B cells are essential for viraemia clearance. 
The clearance of viraemia in MHC-IIΔ/Δ mice (Figure 4.6A) was likely due to the generation 
of anti-CHIKV IgG2c antibody responses (Figure 4.8B).  This finding is in agreement with a study 
of CHIKV infection in CD4-/- mice that also produced anti-CHIKV antibody that effectively cleared 
the virus (Lum et al., 2013).  CD4+ T cells are well known to facilitate the B cell isotype switching 
that results in IgG2c production (Mitchison, 2004).  However, CD4+ T cell-independent production 
of IgG2c has been reported (Lee et al., 2005, Swanson et al., 2010), where class switching is 
induced by IFN-α/β (Swanson et al., 2010).  CHIKV infection triggers a high level of IFN-α/β in 
humans and mice (Rudd et al., 2012, Hoarau et al., 2010), suggesting that IFN-α/β might have 
contributed to the CD4+ T cell independent production of IgG2c observed in MHC-IIΔ/Δ mice 
following CHIKV infection.    
 
4.3.4 Viraemia levels are not correlated to arthritis severity 
Data in this chapter indicate that a higher level of viraemia does not necessarily result in a 
more severe level of arthritis.  The higher viraemia observed in Rag-1-/- and Rag2/Il2rg-/- mice did 
not lead to a more severe arthritis (compare Figure 4.1 and Figure 4.4C for Rag-1-/- mice; data not 
shown for Rag2/Il2rg-/- mice).  Similarly, the more severe arthritis seen in vaccinated µMT mice 
(Figure 4.7; *) was not associated with a higher viraemia in the same period (Figure 4.2B).  
Additionally, µMT, Rag-1-/- and Rag2/Il2rg-/- mice did not exhibit any ongoing arthritic disease 
(data not shown), despite the presence of persistent viraemia.  Therefore, viraemia is required but 
not sufficient for inducing arthritic disease in CHIKV infected mice.  
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4.3.5 Role of IFN-γ in viraemia control and arthritis 
Given that IFN-γ may protect against CHIKV infection (Figure 4.11, IFN-γ), one might 
expect that IFN-γ-/- mice would experience a more severe infection (i.e. higher viraemia); however, 
IFN-γ-/- mice did not show any significant increase in viraemia when compared with WT mice 
(Figure 4.9B).  It is possible that the contribution of IFN-γ may be minimal during acute infections 
when IFN-α/β levels are also high (Rudd et al., 2012).  Furthermore, CHIKV infected IFN-γ-/- mice 
have been previously shown to be capable of producing anti-CHIKV antibodies, which would also 
contribute to the control of viraemia in these mice (Lum et al., 2013). 
IFN-γ producing CD4+ T cells are implicated in RA (Snir et al., 2011, Yamada et al., 2011); 
IFN-γ levels are elevated in synovial fluid of RRV-infected patients (Lidbury et al., 2008), and 
serum IFN-γ is up-regulated in CHIKV infected patients (Wauquier et al., 2011, Hoarau et al., 
2010), monkeys (Labadie et al., 2010) and mice (Gardner et al., 2010).  The data presented herein 
shows that IFN-γ is implicated in CHIKV arthritis, with IFN-γ-/- mice displaying a lower foot 
swelling compared to WT mice (Figure 4.9A).  This observation contradicts the finding of another 
study that suggested that IFN-γ had no role in CHIKV arthritis (Teo et al., 2012b).  This 
discrepancy might be attributable to the different isolates of CHIKV used (LR2006-OPY1 used in 
this study vs SGP11), as different isolates of CHIKV have previously been shown to induce a 
differing severity of arthritis (Gardner et al., 2010).  
 
4.3.6 TNF and IFN-γ  (not IFN-α) were associated with persistently 
viraemic Rag-1-/- mice 
On-going up regulation of IFN-γ and TNF in Rag-1-/- mice suggested that these cytokines 
might be associated with the control of persistent CHIKV viraemia (Figure 4.11).  These data are 
consistent with the anti-alphaviral role of IFN-γ and TNF (Zaid et al., 2011, Ryman et al., 2007) 
and the dysregulation of IFN-γ and TNF in macrophages persistently infected with RRV in vitro 
(Way et al., 2002).  IFN-γ also up-regulates protein kinase R (PKR), which is known to inhibit viral 
protein synthesis (Schroder et al., 2004).  PKR also facilitates the maturation of functional TNF 
(Schroder et al., 2004).   
 
 
115 
4.3.7 Conclusion 
In summary, this study described a likely role for CD4+ T cells in mediating the onset of 
CHIKV arthritis (possibly via the production of IFN-γ) and a critical role for B cells in clearing 
CHIKV viraemia (via antibody production).  While adoptively transferred antibodies were seen to 
clear viraemia in B cell deficient mice, viral clearance occurred for only a brief period (Figure 4.3).  
This observation suggests that CHIKV might persist in the tissues until the transferred antibodies 
have lost their bioactivity, resulting in relapses.  The persistence of CHIKV in the tissues of CHIKV 
infected mice is the subject of the next chapter. 
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Chapter 5: Long-term persistence of CHIKV RNA in WT 
mice is associated with signs of chronic inflammation  
 
5.1 Introduction 
While acute symptoms of CHIKV disease (characterised by polyarthritis/polyarthralgia, 
fever, rash and/or myalgia) generally resolve within 1-2 weeks, chronic arthritic disease can persist 
for months and sometimes over a year (Suhrbier et al., 2012).  Recent studies indicate that a high 
percentage of CHIKV infected patients (ranging from 4.7-75.4%), especially the elderly 
(Chaaitanya et al., 2011, Sissoko et al., 2009, Gerardin et al., 2013), experience long-term (3-36 
months) unresolved arthritic symptoms (see Table 1.2).  These symptoms include arthralgia, 
myalgia, joint stiffness and rheumatic musculoskeletal pain (see Table 1.2).  Consistent with the 
chronic symptoms, these patients were found to have elevated levels of (i) anti-CHIKV IgG 
antibodies (Kelvin et al., 2011, Gerardin et al., 2013) and (ii) proinflammatory cytokines IL-6 and 
IL-12 in serum (Chow et al., 2011, Chopra et al., 2012).   
Given that most alphaviral viraemias usually last no longer than 7-10 days, how alphaviral 
infections lead to these chronic symptoms is unclear.  Viral persistence in tissues has long been 
thought to contribute to symptoms, since viral antigen and/or viral RNA of RRV and CHIKV have 
been detected in the joints of affected patients (Soden et al., 2000, Hoarau et al., 2010).  Hoarau et 
al. (2010) showed that CHIKV RNA and antigen could be detected in the synovial macrophages of 
a patient that experienced chronic rheumatic manifestations at the 18-months post onset of disease.  
This was consistent with a CHIKV study in primates showing the persistence of CHIKV RNA in 
splenic macrophages up to 97-days post infection (Labadie et al., 2010).  The mechanisms of 
CHIKV persistence were not investigated in these studies; however, it has been proposed that 
CHIKV-induced apoptosis and phagocytosis could facilitate CHIKV persistence in macrophages 
(Krejbich-Trotot et al., 2011, Joubert et al., 2012, Suhrbier and La Linn, 2004).  In addition, 
CHIKV could be transmitted to neighbouring cell via tight junction, where this mode of 
transmission could also facilitate CHIKV persistence (Lee et al., 2011).  To gain more insights into 
long-term persistence of CHIKV RNA and its role in driving chronic arthritic disease, the mouse 
model of CHIKV infection and disease was investigated.  The data obtained from this model clearly 
showed that both CHIKV RNA, including negative-strand RNA, can persist in the feet up to day 
100 post infection, despite the presence of neutralising antibody.  Interferon stimulated gene 54 
(ISG-54), a factor that is up-regulated in response to viral infection and double stranded RNA 
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(dsRNA), was found to be persistently up-regulated in these feet, suggesting ongoing viral RNA 
replication.  Microarray analysis of persistently infected feet (day 30 post infection) and subsequent 
Ingenuity’S Upstream Regulator Analysis revealed a profile very similar to that seen in a 
chronically infected human (Hoarau et al., 2010).  This data also clearly revealed the presence of an 
ongoing local inflammatory response that is dominated by type I IFN responses, as well as by 
responses associated with apoptosis, autophagy, M2 macrophages, cytokines (IL-6, IL-12 and IFN-
γ) and T cells. 
118 
5.2 Results  
 
5.2.1 Isolation of infectious CHIKV from feet 
Chronic CHIKV arthritis might be triggered by the persistence of CHIKV in the affected 
tissues.  To examine viral persistence in the feet, WT mice were infected with CHIKV.  Feet were 
excised and subjected to three different methods to attempt recovery of infectious virus (Table 5.1, 
see section 2.6 for detailed procedures).  Using either the mortar-pestle or homogeniser method, 
infectious CHIKV could be isolated from the feet of infected mice up to day 9 post infection, but 
not day 14 post infection (Table 5.1).  Using the collagenase digestion method, infectious CHIKV 
was successfully isolated from the feet up to day 14 post infection, but not day 21 post infection 
(Table 5.1).  Infectious CHIKV can thus be recovered from feet of mice infected with CHIKV for at 
least 14 days post infection, even when viraemia was cleared at 4-5 days post infection (Figure 4.1, 
WT). 
Table 5.1: Isolation of infectious CHIKV from the infected feet using 3 different 
methods. 
*For detailed method, see section 2.6.  n.t. = not tested  
Methods* 
Virus detection  (no. positive / no. tests) 
Day 1-6  Day 9  Day 14  Day 21 
1. Mortar and pestle  6/6 3/3 0/2 0/2 
2. Homogeniser  n.t. 3/3 0/2 n.t. 
3. Collagenase digestion n.t. 3/3 2/2 0/2 
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5.2.2 Quantification of CHIKV RNA levels in the feet of CHIKV-infected 
mice  
Infectious CHIKV was found to persist in the feet up to 14 days post infection, indicating 
that CHIKV continues to replicate in the feet well after the viraemia has been cleared (typically day 
4-5).  To further examine whether CHIKV RNA can persist and replicate in the feet of infected 
mice beyond the viraemic period, CHIKV RNA levels were analysed by qRT-PCR.  Total RNA 
from infected feet was extracted, and CHIKV RNA levels were quantified by qRT-PCR using 
primers targeting the E1 structural protein of CHIKV.  Negative strand-specific qRT-PCR was used 
to quantify nsP1 portion of negative strand CHIKV RNA using a modification of the tagged-primer 
system described previously (Plaskon et al., 2009).  Briefly, the process used tagged-primer to 
generate cDNA incorporated with tag, a unique 20 nucleotides sequence that improve accuracy and 
specificity of subsequent quantification by qRT-PCR (Plaskon et al., 2009).  Another tagged-primer 
was then used in qRT-PCR to ensure that only tag-incorporated cDNA was amplified and 
quantified.  During alphavirus infections, negative strand RNA is synthesised from positive strand 
RNA and provides a template for positive strand RNA synthesis, with negative strand RNA 
comprising 2-5% of total RNA (Wang et al., 1991, Sawicki and Sawicki, 1980).  The presence of 
negative strand CHIKV RNA is thus indicative of active CHIKV RNA replication.  Significant 
levels of both total RNA (Figure 5.1A) and negative stranded RNA (Figure 5.1B) were detected up 
to 100 days post infection, suggesting ongoing RNA replication.  This observation is consistent 
with earlier reports showing that RRV can persistently infect macrophages in vitro for at least 148 
days post infection (Way et al., 2002, Linn et al., 1996).  The qRT-PCR shown in Figure 5.1A 
yielded a PCR product, shown by gel electrophoresis (Figure 5.2), that matches the predicted size of 
168 base pair.  Together, these data suggest that actively replicating CHIKV can persist in the 
infected foot tissues long after the viraemic period. 
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Figure 5.1: Quantification of CHIKV RNA in CHIKV infected feet and spleens. 
Mice were infected with CHIKV.  At the indicated time points, total RNA was extracted from 
infected spleens and/or feet.  (A) Total RNA was reverse transcribed into cDNA then qRT-PCR 
was used to quantify total CHIKV RNA using primers specific for the E1 structural protein of 
CHIKV.  Data was normalised using mRNA levels of housekeeping gene, RPL13A.  Y axis values 
are relative only.  *p < 0.05 (compared to uninfected mice) by Mann-Whitney U test.  (B) Negative 
strand-specific cDNA was generated then qRT-PCR was used to quantify negative strand RNA 
using primers specific for nsP1 portion of negative strand CHIKV RNA.  Method for B is distinct 
from the method for A.  (n = 3-7 feet from different mice per time point, mean ± SE is presented; 
data are derived from 2 independent experiments).  **p < 0.01 and *p < 0.05 (compared to 
uninfected mice) by Mann-Whitney U test. 
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Figure 5.2: Gel electrophoresis image of the RNA E1 qRT-PCR product. 
Total RNA was extracted from infected feet, reverse transcribed into cDNA then analysed by qRT-
PCR using primers targeting the E1 structural protein of CHIKV E1 protein.  The qRT-PCR 
products were run on a 2% agarose gel and visualised by ethidium bromide staining.  The no 
template control (no cDNA) and cDNA from uninfected feet did not produce any bands, indicating 
an absence of CHIKV RNA.  Samples from infected feet on day 29 and 21 post infection produced 
bands that matched the predicted size (168 base pair in length), suggesting the signals detected by 
qRT-PCR are CHIKV specific. 
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5.2.3 Curve fit of the decline in CHIKV RNA levels in feet 
To gain insights into the decline of CHIKV RNA levels, a curve fit of the reduction of 
CHIKV RNA levels over time was sought (Figure 5.3A) based on data shown in Figure 5.1A and 
B.  The curve fits of both total and negative strand CHIKV RNA after the end of the viraemic 
period emerged to represent simple exponential decays approximating to y=e-0.06/0.07x (Figure 
5.3A), suggesting that both total and negative strand CHIKV RNA levels decline at a similar rate 
(see below, *).  The rate of decline in RNA levels suggest a decay with a constant half-life of 10-11 
days.  
* y=e-0.065x 
• “y” is CHIKV RNA level  
•  “x” is the days of post infection  
 
5.2.4 Relative ratio of the levels of total CHIKV RNA to negative strand 
CHIKV RNA  
To gain further insights into the decline of CHIKV RNA levels, relative ratios of total 
RNA to negative strand CHIKV RNA were calculated (Figure 5.3B).  The ratios were higher during 
the initial viraemic period (days 1-2), with ratios settling to a relative constant level thereafter 
(Figure 5.3B).  The decline of this ratio may reflect a reduction of sub-genomic RNA levels (see 
Figure 1.3E2) following the initial viraemic period, with sub-genomic RNAs are known to be the 
dominant RNA species during alphavirus replication (Perri et al., 2000).   
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Figure 5.3: Curve fit of reduction in RNA levels over time and ratio of total CHIKV 
RNA to negative strand CHIKV RNA. 
Viral RNA data shown in Figure 5.1A and B at different times post-infection were used for 
preparation of (A) the curve fit of reduction in total and negative RNA levels over time starting 
after the end of the viraemic period (B) the ratio of total CHIKV RNA to negative strand CHIKV 
RNA at different times post-infection.  SE was derived from the variance in the values obtained for 
total CHIKV RNA.  The Y-axis represents relative units only and does not represent a specific 
quantity of viral RNA, as methods for quantitation of total CHIKV RNA and –RNA are distinct.  (n 
= 3-7 feet from different mice per time point, mean ± SE is presented; data are derived from 2 
independent experiments) 
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5.2.5 Quantification of CHIKV RNA levels in the spleen of CHIKV-
infected mice  
Previous study shows that CHIKV RNAs persist in the spleens of macaques up to day 97 
post infection (Labadie et al., 2010).  To determine if CHIKV RNAs also persist in the spleens of 
mice, total CHIKV RNA levels in the spleens were analysed by qRT-PCR as in section 5.2.2.  In 
contrast with the findings in macaques (Labadie et al., 2010, Messaoudi et al., 2013), qRT-PCR 
analysis of total RNA levels in the spleen showed that levels of persistent viral total RNA dropped 
to levels below detection by day 14 (Figure 5.1A).  This observation indicates that the site of 
CHIKV persistence is different between macaques and mice.  
 
5.2.6 Neutralising antibody response post CHIKV infection  
Data in chapter 4 showed that antibodies are critical for the clearance of CHIKV viraemia.  
However, data in this chapter indicate that infected feet contain actively replicating CHIKV up to 
day 100 post infection.  This persistence of CHIKV prompted us to examine the time course of 
antibody levels in infected mice.  Mice were infected with CHIKV and serum neutralising antibody 
titres were measured over time.  A neutralising antibody response could be detected as early as day 
4 post infection (Figure 5.4).  The neutralising antibody titre peaked around day 20-30 post 
infection, and then dropped but remained evident until at least day 150 post infection (Figure 5.4).  
These data suggest that CHIKV persists, despite rapid up-regulation, attainment of high levels and 
long-term maintenance of neutralising antibody responses. 
 
5.2.7 Quantification of ISG-54 expression in CHIKV infected feet  
CHIKV infection induces robust IFN-α/β responses, with a number of IFN-α/β-stimulated 
genes induced (Nakaya et al., 2012) including ISG-54 (Thon-Hon et al., 2012).  To determine 
whether the observed persistent viral RNA in the feet was associated with ongoing stimulation of 
interferon responses, qRT-PCR was used to determine ISG-54 mRNA levels over time post 
infection with CHIKV.  Significant levels of ISG-54 mRNA were detected in feet for up to 100 
days post infection of mice (Figure 5.5), indicating ongoing stimulation of interferon responses.  
These data further support the view that persistent CHIKV RNA is replicating thereby stimulating 
anti-viral and inflammatory responses (Ohl and Tenbrock, 2011).   
127 
 
Figure 5.4: Neutralising antibody titres in CHIKV infected mice over time.  
Mice were infected with CHIKV and at the indicated time points sera were collected and tested for 
neutralising antibody titres (n = 3-6 per time point, mean ± SE is shown; data are derived from 2 
independent experiments). 
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Figure 5.5: ISG-54 mRNA levels in feet of CHIKV-infected mice over time. 
Mice were infected with CHIKV, and at the indicated time points, total RNA was extracted from 
infected feet, reverse transcribed into cDNA then quantified for ISG-54 RNA by qRT-PCR using 
primers specific to murine ISG-54.  ISG-54 mRNA levels were normalised to RPL13A mRNA 
levels (n = 3-7 mice per time point, mean ± SE is presented; data are derived from 2-3 independent 
experiments).  ** = p < 0.01 (compared to uninfected mice).  All statistics by Mann-Whitney U test. 
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5.2.8 Comparison of global gene expression between CHIKV-infected 
feet on day 0 and day 30 post infection  
Using microarray analysis, a previous study revealed that pathways related to T cell, 
autoimmunity, antigen presentation, NK cell, innate sensing, monocytes/macrophage, apoptosis, B 
cell, cytokines/chemokines and complement were up-regulated in the feet of CHIKV infected mice 
during peak arthritis (day 6-7 post infection) (Nakaya et al., 2012).  The same study also revealed 
that CHIKV arthritis shares many inflammatory pathways with RA (Nakaya et al., 2012).  Given 
that CHIKV RNA (Figure 5.1) and signs of inflammation (Figure 5.5) persisted for extended 
periods post infection, a similar microarray analysis was undertaken to analyse global gene 
expression changes in persistently infected feet on day 30 post infection.  With bioinformatics 
assistance of Dr Helder Nakaya, microarray analysis was conducted as described (Nakaya et al, 
2012) by Ramaciotti Centre (Sydney, Australia) comparing feet from day 0 and day 30.  Probe sets 
with no annotations were removed, only expressed genes with a mean log2 expression ≥ 6 across all 
samples were included, and t-tests were performed between day 0 and day 30 samples for 4,805 
filtered genes.  Genes where p < 0.05 were included.  No false discovery rate corrections were 
undertaken.  Fold changes ranged from 1.05-1.55.  A total of 547 DEGs were identified, of these 
192 genes were up-regulated, and 355 genes were down-regulated on day 30 following CHIKV 
infection.   
 
5.2.8.1 Ingenuity’s Canonical Pathway Analysis of up-regulated genes  
To gain a better understanding of the pathways stimulated by the persistence of CHIKV 
RNA in feet, the up-regulated genes were analysed using IPA.  Canonical pathways analysis of the 
192 up-regulated genes induced on day 30 post infection, revealed activation of pathways 
associated with T cells, autoimmunity, antigen presentation, NK cells, innate sensing, 
monocytes/macrophages, apoptosis and cytokines (Figure 5.6).  These up-regulated pathways were 
broadly similar to the pathways described for day 7 post infection (Nakaya et al., 2012), suggesting 
that many of the inflammatory pathways are retained on day 30 post infection.  However, there 
were some apparent differences.  B cell and complement-associated pathways were present on day 
7, but were not identified on day 30.  However, it should be noted that the low fold change (1.05-
1.55) and the low number of up-regulated genes (192) limit the conclusions that can be reached by 
such comparisons.  
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The continued activation of IFN-α/β signalling pathways on day 30 post infection (Figure 
5.6, innate sensing and cytokines) is consistent with the view that persistent replicating CHIKV 
dsRNA continues to stimulate IFN-α/β responses (section 5.2.7).  The up-regulation of genes in 
monocyte/macrophage pathways is consistent with the view that macrophages remain involved in 
chronic disease (Suhrbier et al., 2012), consistent with the observation that macrophages are the 
main cellular reservoirs of persistent RRV and CHIKV RNA (Soden et al., 2000, Labadie et al., 
2010).  The up-regulation of T cell pathways suggests ongoing involvement of T cells in chronic 
CHIKV arthritis, with their key role in acute arthritis described in Chapter 4 (Figure 4.6B).  Taken 
together, the pathways shown to be activated on day 30 post infection suggest that persistence of 
CHIKV may contribute to an ongoing CHIKV-induced arthritic disease.  
 
5.2.8.2 Ingenuity’s Canonical Pathway Analysis of down-regulated 
genes 
To gain a better understanding of the pathways inhibited by the persistence of CHIKV 
RNA in feet, the down-regulated genes were analysed using IPA.  Canonical pathways analysis of 
the 355 down-regulated genes induced on day 30 post infection, revealed inhibition of signalling 
pathways associated with mammalian target of rapamycin, regulation of eukaryotic initiation factor 
4, p70S6 kinase, eukaryotic initiation factor 2 and aryl hydrocarbon receptor with molecules largely 
associated with protein translation (only pathways with p < 0.05 and at least 3 molecules assigned 
were selected) (pathway details are shown in Appendix IV).  Alphavirus infections are well known 
for inducing shutdown of host cell translation processes (Jose et al., 2009).  Therefore, inhibition of 
protein translation-associated pathways would suggest ongoing CHIKV infections. 
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Figure 5.6: IPA of canonical pathways active in CHIKV-infected feet on day 30 post 
infection.  
Ingenuity’s Canonical Pathway Analysis of the 192 genes differentially expressed in feet of mice at 
day 30 post infection, with pathways grouped into themes.  A higher -log (p value) denotes a more 
significant overlap between the analysed DEGs and genes in the IPA knowledge database.  -log 
(<1.3) represents p < 0.05.  Pathways shown here have a -log (>1.5) and have at least three 
molecules assigned to the pathway.  Pathway details are shown in Appendix III.  
Data for Figure 5.6 was prepared with assistance from Helder Nakaya. 
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5.2.8.3  Ingenuity’s Upstream Regulator Analysis of up-regulated genes 
The same 192 up regulated genes analysed above were analysed using Ingenuity’s 
Upstream Regulator Analysis (Figure 5.7).  This analysis identified multiple upstream regulators 
involved in type I IFN responses, with other upstream regulators associated with apoptosis, 
autophagy, M2 macrophages, cytokines and T cells also identified (Figure 5.7).  Identification of 
type I IFN pathways as dominant upstream regulators is consistent with the increase of interferon 
signalling pathways identified by canonical pathway analysis (Figure 5.6; innate sensing) and the 
up-regulation of ISG-54 mRNA in the feet on day 30 post infection (Figure 5.5).  Importantly, IFN-
α was also detected in the synovial tissues of a patient with chronic CHIKV arthritis (Hoarau et al., 
2010).   
The upstream regulator analysis also identified DDX58 (also known as retinoic acid-
inducible gene 1 (RIG-I)) (Figure 5.7, see *), an observation consistent with a previous study 
suggesting DDX58 might be a cytoplasmic sensor for CHIKV RNA that triggers IFN-
α/β production (Schilte et al., 2010) via interferon promoter stimulator-1 (IPS-1) (Rudd et al., 
2012).  Tripartite motif-containing 24 (TRIM24) and microRNA 21 (mir-21) were identified as 
upstream regulators but were assigned negative activation Z-scores.  These two molecules have a 
negative regulatory role in type I IFN responses (Chen et al., 2013, Tisserand et al., 2011), and their 
predicted negative activations are again consistent with the observed up-regulation of IFN-
α/β responses.   
The upstream regulator analysis also identified Activation of Poly(ADP-ribose) polymerase-
1 (PARP-1) (Figure 5.7, apoptosis), an enzyme that is associated with apoptosis.  This observation 
is consistent with previous reports demonstrating that alphavirus infection, including CHIKV 
infection, is associated with induction of PARP-1 (Nargi-Aizenman et al., 2002, Krejbich-Trotot et 
al., 2011).  Importantly, PARP-1 was also detected in the synovial tissues of a patient with chronic 
CHIKV arthritis (Hoarau et al., 2010).   
The analysis assigned immunity-related GTPase M (IRGM) with a negative activation Z 
score (Figure 5.7, autophagy).  IRGM is a protein that interferes with autophagy during infection 
with RNA viruses, including viruses from the togaviradae family (Gregoire et al., 2011).  
Autophagy plays a protective role in CHIKV infection, with inhibition of autophagy genes 
enhancing CHIKV replication in vitro (Joubert et al., 2012). Thus, negative activation of IRGM 
would suggest an increase in autophagy and suppression of CHIKV replication.  
133 
Signal transducer and activator of transcription 3 (STAT3) is another factor that was 
identified as an upstream regulator (Figure 5.7, M2 macrophages).  STAT3 is a critical transcription 
factor for M2 macrophage differentiation (Tang et al., 2013, Wang et al., 2012b).  Recently, M2 
macrophage differentiation was shown to be associated with CHIKV persistence (Stoermer et al., 
2012).  The identification of STAT3 would suggest activation of M2 macrophages and suggests the 
persistence of CHIKV RNA (shown in Figure 5.1) promotes M2 differentiation. 
The identification of IL-6 as an upstream regulator suggests an ongoing arthritic pathology 
(Figure 5.7, other cytokines), as previous reports have shown that serum IL-6 was up-regulated in 
patients with chronic arthritic symptoms (Chow et al., 2011, Chopra et al., 2012), with elevated IL-
6 also expressed in the synovial tissues of a patient with chronic CHIKV arthritis (Hoarau et al., 
2010).  Moreover, IL-6 is a key cytokine implicated in RA (Shoda and Yamamoto, 2007) and 
several other viral arthritides (Suhrbier and Mahalingam, 2009).   
Similarly, IL-12 that was identified here (Figure 5.7, other cytokines) also found to be 
elevated in the sera of patients experiencing chronic CHIKV arthritis (Hoarau et al., 2010).  IL-12 is 
a key driver of Th1 response.  Therefore, the up-regulation of IL-12 is consistent with the up-
regulation of IFN-γ, a key Th1 cytokine (Figure 5.7, other cytokines).  Up-regulation of IFN-γ is 
also consistent with previous clinical studies showing that IFN-γ was detected in the sera and 
synovial tissue of patients that experienced chronic CHIKV and RRV arthritis, respectively (Schilte 
et al., 2013, Soden et al., 2000); perhaps, this observation is also in agreement with the pathogenic 
role of IFN-γ in acute arthritis (Figure 4.9A).  
 
5.2.8.4 Ingenuity’s Upstream Regulator Analysis of down-regulated 
genes 
Ingenuity’s Upstream Regulator Analysis of the 355 down-regulated genes on day 30 post 
infection, identified only one significant upstream regulator (selection criteria: p < 1010) that is 
glutathione S-transferases P1.  The glutathione S-transferases P1 has previously been shown to 
prevent inflammation by inhibiting the production of inflammatory factors TNF-α, IL-1β, MCP-1 
and nitric oxide (Luo et al., 2009).  Thus, suppression of glutathione S-transferases P1 would 
suggest an ongoing promotion of inflammation in the feet. 
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Figure 5.7: Ingenuity’s Upstream Regulator Analysis of differentially expressed 
genes identified in CHIKV-infected feet on day 30 post infection. 
Ingenuity’s Upstream Regulator Analysis of the 192 genes up-regulated genes identified in feet of 
mice at day 30 post infection.  A positive z-score indicates that the identified pathway normally up 
regulates specific genes found in the 192 gene set.  A negative z-score indicates that the identified 
pathway normally down regulates specific genes in the 192 gene set.  Upstream regulators details 
are shown in Appendix V.  
Data for Figure 5.7 was prepared with assistance from Helder Nakaya. 
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5.3 Discussion 
Many CHIKV patients experience chronic arthritic symptoms (Suhrbier et al., 2012).  The 
results in Chapter 5 provide evidence that chronic inflammation is triggered by persistence of 
CHIKV RNA.  Firstly, CHIKV RNA and negative strand RNA (indicative of RNA replication) 
were shown to persist in the feet of infected mice (Figure 5.1) well after the viraemic period and 
despite the presence of neutralising antibodies (Figure 5.4).  Secondly, the persistent CHIKV RNA 
in the feet of infected mice was associated with signs of ongoing stimulation of type I IFN 
responses, with ISG-54 persistently up-regulated (Figure 5.5).  Finally, microarray gene expression 
analysis of chronically infected feet illustrated pronounced type I IFN responses (Figure 5.6, innate 
sensing and Figure 5.7, type I IFN responses).  Taken together these data suggest that CHIKV RNA 
continues to replicate in foot tissues of mice for extended periods, with the replicating dsRNA 
continuing to induce type I IFN responses.  These data are consistent with human (Hoarau et al., 
2010) and primate studies (Labadie et al., 2010), which show that viral RNA and protein persist, 
despite robust immune responses.  The mouse studies here now extend these data and suggest that 
the persistent RNA may be replicating, even after live virus can no longer be recovered from feet 
(Table 5.1). 
 
5.3.1 Evidence of ongoing CHIKV replication in vivo 
  CHIKV RNA replication begins with synthesis of negative strand RNA from positive 
strand genomic RNA (Figure 1.4F1).  The negative strand RNA serves as a template for the 
generation of new positive strand RNA, which includes both genomic and subgenomic viral RNAs 
(Figure 1.4F2 and F3).  Both the former and latter processes generate viral dsRNA intermediates, 
which are known to trigger type I IFN responses (Bowie and Unterholzner, 2008).  In this study, 
significant levels of CHIKV RNA (and negative strand RNA) were present in the feet up to 100 
days post infection (Figure 5.1), with up-regulation of type I IFN responses (Figure 5.7, type I IFN 
responses) and ISG-54 (Figure 5.5).  These data suggest that ongoing viral RNA replication 
continues to induce type I IFN responses (Plaskon et al., 2009, Sawicki and Sawicki, 1980).  
 
5.3.2 Decline in viral RNA    
 The curves fits of CHIKV RNA decline indicate that the decline after the viraemic period 
follows a simple exponential decay with a half life of 10-11 days (Figure 5.3A).  Future studies may 
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utilise these curves as a basis for comparing the decay rate of CHIKV RNA under diferent 
conditions.  For example, if an anti-CHIKV treatment leads to a higher magnitude of decline, the 
treatment might be considered aneffective treatment as it would take a shorter time to reduce a 
given amount of CHIKV RNA.   
 Given the high error rates usually associated with the replication of RNA viruses (Crotty et 
al., 2001) and the loss of infectious virus and the subsequent steady decline in viral RNA levels, one 
might speculate that CHIKV RNA first becomes too mutated to generate replication competent 
virus (Crotty et al., 2001) and eventually becomes too mutated to maintain CHIKV RNA replication 
(Figure 5.1).  These progressive failures in generating replication competent virus may account for 
the lack of live virus recovery from the mouse feet at chronic stage (Table 5.1).  The high 
neutralising antibodies appear at chronic stage (Figure 5.4) could also hinder the live virus recovery 
from the mice tissue.  In contrast to mice, live virus could be recovered from the macaque spleens, 
lymph nodes and livers at chronic stage (Labadie et al., 2010).   This difference suggests that the 
CHIKV infection in mice is distinct from CHIKV infection in monkey.  However, it is important to 
note that, despite numerous attempts, there was no successive live virus recovery from synovial 
biopsies of chronic CHIKV and RRV patients (Soden et al., 2000, Hoarau et al., 2010).    
 
5.3.3 Immune responses that control CHIKV persistence  
 The obvious up-regulation of type I IFN responses clearly indicate that type I IFN play a 
substantial antiviral role in controlling CHIKV persistence (sections 5.2.7, 5.2.8.1 and 5.2.8.3).  T 
cell responses also appear to be crucial in controlling CHIKV persistence:  (i) up-regulation of IL-
12 and IFN-γ suggests ongoing Th1 responses (Figure 5.7, other cytokines); (ii) up-regulation of T 
cell receptor and dedicator of cytokinesis 8 (DOCK8) would suggest ongoing CD8+ T cell 
responses (Randall et al., 2011) that are perhaps important for clearance of persistent viral CHIKV 
RNA.  One might speculate that the persistence of anti-CHIKV antibodies seen in patients (Kelvin 
et al., 2011, Gerardin et al., 2013) and mice (Figure 5.4) might facilitate the persistence of CHIKV 
via antibody-dependent enhancement (ADE) of infection (Suhrbier and Linn, 2004) a process 
whereby virus infectivity is increased due to the uptake of antibody-virus complex into cells via Fc 
gamma receptors (FcRγ).  Although previous study showed that ADE increased the infectivity of 
RRV in monocytes and macrophages (Linn et al., 1996, Mahalingam and Lidbury, 2002), CHIKV 
viraemia was unaffected in mice deficient for the FcRγ (deficient in FcRγRI and FcRγRIII) (Poo et 
al., submitted).   
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5.3.4 CHIKV-induced chronic inflammation in mice versus humans  
The microarray analysis showed that many of the pathways up-regulated during peak 
arthritis (day 6/7) (Nakaya et al., 2012) were retained in persistently infected feet (day 30 post 
infection) (Figure 5.6).  This may suggest that many of the drivers of acute inflammation are 
maintained during chronic disease.  Importantly, the upstream regulator analysis identified 
pathways (Figure 5.7; specifically type I IFN, PARP-1, IL-6 and IFN-γ) that activated in our mouse 
model have also been shown to be activated in chronic human alphavirus infections (Hoarau et al., 
2010, Soden et al., 2000).  Hoarau et al. (2010) also demonstrated that T cells persisted in the 
synovial tissue of a patient that experienced chronic CHIKV arthritis.  Recently, Hoarau et al. 
(2013) showed peripheral blood mononucleated cell derived T cells isolated from convalescent 
CHIKV patients were able to produce IFN-γ after challenged with CHIKV peptides ex vivo.  Both T 
cell related observations from chronic CHIKV patients are in line with the T cell and IFN-γ 
signatures identified here in mice (Figure 5.6 and Figure 5.7).  
 
5.3.5 Conclusion 
 In conclusion, this mouse model of CHIKV infection and disease recapitulates not only 
acute disease (Gardner et al., 2010) but also chronic CHIKV arthritic disease, with key pathways 
identified in mice also found in chronic disease in humans.  The findings obtained using this model 
also support the notion that persistence of replicating CHIKV RNA contributes to chronic arthritic 
symptoms.  To ameliorate the chronic arthritic disease cause by CHIKV infection, future studies 
might focus on factors that can clear persistent CHIKV RNA in the tissues or ameliorate the 
inflammatory responses without compromising the host’s control of persistent viral RNA. 
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Chapter 6: Summary 
 The unprecedented size of the recent and ongoing CHIKV outbreak has highlighted the 
necessity for improved interventions.  As this thesis goes to press, ≈3,700 cases of CHIKV disease 
have been reported in the Caribbean (Robles, 2014).  A good understanding of CHIKV 
immunobiology is necessary for the development of such interventions.  Although the 
understanding of CHIKV disease has advanced considerably in recent years, the role of several 
immune factors in CHIKV disease remained poorly defined.  The findings in this thesis contribute 
to an improved understanding of the role of several immune factors in CHIKV disease.  
 
6.1 Summary of Chapter 3:  CCR2 deficiency promotes exacerbated 
chronic erosive neutrophil-dominated chikungunya virus arthritis  
 
6.1.1 Major findings  
The main findings of this chapter are: 
1) The predominantly monocyte/macrophage infiltrate seen in wild-type mice was replaced by a 
pronounced neutrophil infiltrate in CCR2-/- mice, which resulted in an enhanced and 
prolonged arthritis and was associated with cartilage damage.  
2) Changes in the expression of multiple inflammatory mediators accounted for this switch in 
the arthritic infiltrates, with the loss of M2 macrophages and associated anti-inflammatory 
activities (e.g. efferocytosis, see Figure 6.1) also likely to be involved in the prolonged 
inflammatory response. 
3) Although infiltrating CCR2+ monocytes/macrophages contribute to inflammation, they also 
appear to be important for resolving inflammation and preventing excessive pathology 
(manifesting as more severe and prolonged arthritis and cartilage damage).  
 
6.1.2 Major implications 
Implications for treatment   
These results argue that therapeutic targeting of inflammatory monocytes/macrophages 
may not be without risk.  For instance, considerable care might be warranted when targeting 
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chemokines like CCL2 using anti-CCL2 antibody or bindarit for the treatment of alphaviral 
arthritides (Rulli et al., 2009, Rulli et al., 2011).  Patients being treated with anti CCL2/CCR2 drugs 
may also be at risk of adverse pathology following an alphaviral infection.   
 
A role for monocytes or macrophages for inhibiting neutrophil recruitment during 
CHIKV arthritis 
During infection, CCL2 recruits CCR2+ monocytes to the site of infection (Figure 6.1).  
The recruited monocytes then develop into classically activated M1 macrophages that promote 
inflammation, trigger anti-viral defence and contribute to arthritic inflammation (Figure 6.1) 
(Suhrbier and Mahalingam, 2009).  Macrophages can then also polarise into M2 and/or resolving 
macrophages populations, which are usually required for effective inflammation resolution (Figure 
6.1).  
Unresolved is how recruitment of CCR2+ monocytes inhibits infiltration of neutrophils, 
either the CCR2+ monocytes themselves and/or macrophages derived from them are likely to be 
involved (Figure 6.1; see question marks).  Anti-inflammatory macrophages may prevent neutrophil 
infiltration by secreting proresolving lipid mediators (Serhan, 2010) and/or proteases that anti-
inflammatory macrophages (Ortega-Gomez et al., 2013).  IL-10, which anti-inflammatory 
macrophages secrete, may be marginally involved, with foot swelling and neutrophil infiltration 
only slightly elevated (the latter not significantly) in CHIKV infected IL-10-/- mice (Figure 3.13A 
and C).  The IL-10 can also promote the expansion of CCR2+ T-regulatory cells, which play a 
protective role in collagen-induced arthritis (Ortega-Gomez et al., 2013).  
 
Implications for the cell type harbouring persistent CHIKV RNA 
CHIKV is reported to persist in macrophages found in spleen (monkeys) (Labadie et al., 
2010, Messaoudi et al., 2013) and synovial fluid in humans (Hoarau et al., 2010).  RRV is also 
reported to be able to establish persistent infection in cell cultures of murine macrophage cell line 
(RAW 264.7) (Linn et al., 1998, Way et al., 2002) and human synovial cells (with macropahge-like 
feature) (Journeaux et al., 1987).  Prolific infiltration of CCR2+ macrophages in joints was 
observed in WT mice, but not in CCR2-/- mice.  Despite the difference in the levels of macrophage 
infiltration, WT and CCR2-/- mice had similar levels of persistent CHIKV RNA, suggesting that 
CHIKV RNA is unlikely to persist in recruited macrophages derived from CCR2+ monocytes.  
Conceivably, CHIKV RNA persistence is restricted to resident tissue macrophages.  Such 
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macrophages tend to have an M2 phenotype (Davies et al., 2013), with a recent study suggesting 
that CHIKV persists in M2 macrophages (Stoermer et al., 2012) (Figure 6.1).  The overall reduction 
in M2 macrophage markers seen in the array (Figure 3.14, brown) likely largely relates to CCR2+ 
monocyte-derived macrophages, with the tissue-resident macrophages not specifically analysed.   
 
   
Figure 6.1: Relationship of monocytes/macrophages and neutrophils in CHIKV 
arthritis.   
CHIKV infection in the joints triggers the induction of CCL2 that leads to the recruitment of 
CCR2+ monocytes from the circulating blood into CHIKV infected joints.  The recruited CCR2+ 
monocytes then develop into classically activated M1 macrophages that promote inflammation, 
trigger anti-viral defence and arthritic inflammation.  Macrophages can also differentiate into a M2 
and/or resolving macrophages populations.  These macrophages are usually required for effective 
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inflammation resolution but are also implicated in harbouring persistent CHIKV RNA (Stoermer et 
al., 2012).  It remains unclear that how monocytes and/or macrophages derived from them could 
suppress the infiltration of neutrophils.  * Stoermer et al. (2012) 
6.1.3 Future directions 
1) Treating WT mice with CCR2 inhibitors 
CCR2 deficiency exacerbates CHIKV arthritis in mice.  To determine whether this means 
that treatment with CCR2 inhibitors would also exacerbate disease, WT mice might be treated with 
CCR2 inhibitors.  There are several commercial available CCR2 inhibitors, namely RS504393 
(Berkhout et al., 2003, Pevida et al., 2012), INCB3344 (Brodmerkel et al., 2005, Chan et al., 2012) 
and MK-0812 (Min et al., 2010, Butora et al., 2007, Wisniewski et al., 2010).  MK-0812 has been 
used to treat patients with rheumatoid arthritis, although initial trial results were disappointing 
(Lebre et al., 2011).  Therefore, future experiment should use MK-0812 to treat WT mice as this 
treatment will not only provide insights on CCR2 inhibition in CHIKV arthritis but also assist the 
understandings of CCR2 drugs in treating arthritic disease.   
 
2) Adoptively transfer of CCR2+ monocytes to CCR2-/- mice 
Recruitment of CCR2+ monocytes appears to be crucial in preventing the infiltration of 
neutrophils that then promote severe CHIKV arthritis (Figure 6.1).  How these cells achieve this 
remains unclear.  To gain further insights WT CCR2+ monocytes might be adoptively transferred 
into CCR2-/- mice to see whether this would inhibit neutrophil infiltration.  It may also be useful to 
titrate the number of adoptively transferred CCR2+ monocytes, to determine how many cells are 
required to inhibit neutrophil infiltration.  Once established, CCR2+ monocytes from various other 
knockout mice (e.g. IL-10-/- and IL-1β-/-) might be tested to see whether the effect was lost.   
 
3) Targeting resident tissue macrophages  
 CHIKV can persist in macrophages (Hoarau et al., 2010, Labadie et al., 2010), with a 
recent study proposing that M2 macrophages promote CHIKV persistence (Figure 6.1) (Stoermer et 
al., 2012).  Thus targeting macrophages, specifically M2 macrophages, during the chronic stage of 
infection and disease may be useful in preventing CHIKV persistence and thus chronic disease.  
Preliminary studies in our group demonstrate that depleting macrophages population during the 
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chronic stage can change the levels of persistent viral RNA in feet.  When mice day 30 post-
infection were treated with 15 µg macrophage-depleting anti-F4/80 antibody s.c., a ≈ 5 fold 
reduction of qRT-PCR detectable viral RNA as measured 4 days post-treatment (data not shown). 
6.2 Summary of Chapter 4: The contribution of B, T and NK cells and 
IFN-γ in the control of viraemia and mediation of arthritis during CHIKV 
infection 
 
6.2.1 Major findings   
The main findings of this chapter are: 
1) CD4+ T cells play an important role in mediating CHIKV arthritis. 
2)  T cells play a significant role, albeit minor, in controlling viraemia. 
3)  IFN-γ plays an important role in mediating CHIKV arthritis. 
 
6.2.2 Major implication 
Implications for the understandings of CHIKV arthritis    
Previous studies indicated T cells are not implicated in triggering alphaviral arthritis 
(Morrison et al., 2007, Morrison et al., 2006).  However, the results herein clearly suggest that 
CD4+ T cells are implicated in CHIKV arthritis.  This contention is also supported by (i) the strong 
T cells signals detected during peak arthritis (Nakaya et al., 2012) and (ii) findings by another group 
demonstrating the involvement of CD4+ T cells in CHIKV arthritis (Teo et al., 2012b).  Results 
herein also suggest that IFN-γ (likely produced by CD4+ T cells) is involved in promoting CHIKV 
arthritis, with IFN-γ previously found to be elevated in synovium fluid of acute RRV patients 
(Lidbury et al., 2008) and synovial tissue of chronic RRV patients (Soden et al., 2000).  Anti-IFN-γ 
also ameliorated disease in a mouse model of RRV disease (Lidbury et al., 2008), suggesting that 
therapeutic targeting of this cytokine might be considered.  Viraemia was not increased in IFN-γ-/- 
mice, suggesting the anti-viral activities of IFN-γ are not critical for CHIKV control (see below).   
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6.2.3 Future directions 
1) To investigate the role of IFN-γ  in arthritis caused by different isolates of CHIKV  
In contrast to the findings in this thesis, Teo et al. (2012b) reported that IFN-γ had no 
significant role in CHIKV arthritis.  This discrepancy might be attributable to the different isolates 
of CHIKV used.  To further investigate this issue, IFN-γ-/- mice (and control WT mice on the same 
background) might be infected with various CHIKV isolates (including LR2006-OPY1 and SGP11) 
and the disease severity directly compared.   
 
2) Assessing the effectiveness of anti-IFN-γ  antibodies in treating CHIKV arthritis  
IFN-γ deficiency reduced acute arthritis and did not lead to increased viraemia in CHIKV 
infected mice (Figure 4.9A and B).  In addition, microarray analysis reveals that IFN-γ signature is 
still active in persistently infected feet during the chronic stage of disease (Figure 5.7, other 
cytokines).  Therefore, treatment that inhibits IFN-γ may be a viable therapeutic option to 
ameliorate CHIKV arthritis, as suggested previously for RRV (Lidbury et al., 2008).  Since IFN-γ 
affects acute arthritis and associates with chronic arthritis, anti-IFN-γ treatment will be administered 
during acute (days 2-6), chronic (days 10-30) and overall period (days 2-30) to test the effectiveness 
of anti-IFN-γ antibodies in treating CHIKV arthritis at different stages of the disease.  Disease 
severity (arthritis and viraemia), viral persistence (CHIKV RNA levels) and anti-CHIKV antibody 
levels (antiviral antibody titres and IgG isotypes) in these mice might be monitored, to determine 
what other potentially detrimental effects such treatment may have.  
 
6.3 Summary of Chapter 5: Long-term persistence of CHIKV RNA in WT 
mice is associated with signs of chronic inflammation 
 
6.3.1 Major findings  
The main findings of this chapter are: 
1) CHIKV RNA, including negative strand viral RNA, persisted for up to 100 days post-
infection in joint tissues, long after the end of the viraemic period (day 4-5).  
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2) Infectious CHIKV can be recovered from feet of mice for at least 14 days post-infection, 
even when viraemia was cleared at 4-5 days post infection.  
3) Although antibodies were essential for clearance of the CHIKV viraemia, antibodies 
appeared unable to prevent persistence of CHIKV and CHIKV RNA in tissue.  The 
persistent CHIKV RNA in the feet may account for the persistent arthritis because:  
(i) IFN pathways and ISG (e.g. ISG-54) were persistently up- regulated, suggesting on-
going inflammation, with these responses perhaps involved in controlling CHIKV 
persistence; and (ii) many of the pathways induced during the acute phase were maintained 
in the chronic phase. 
4) PARP-1, an enzyme that is associated with apoptosis, was identified as an up-stream 
regulator during the chronic stage of CHIKV infection.  This result is consistent with 
findings on apoptosis-facilitated CHIKV persistence, which show that the up-regulation of 
PARP-1 in chronic CHIKV patients (Hoarau et al., 2010) and CHIKV infected cells 
(Krejbich-Trotot et al., 2011). 
5) The mouse model of CHIKV infection and disease, which was used in this study, 
recapitulates not only acute disease but also chronic CHIKV arthritic disease, with key 
pathways identified in mice also found in chronic disease in humans (Hoarau et al., 2010).  
 
6.3.2 Major implications 
Implications for the utilisation of mouse model to study chronic CHIKV infection   
This study reveals the remarkable similarity between chronic CHIKV infection in humans 
and mice, with both sharing similar inflammatory signatures and both showing persistence of 
CHIKV RNA.  These observations indicate that this mouse model is useful for studies that seek to 
better understand chronic CHIKV disease.  The model may thus also find utility for testing 
interventions that aim to ameliorate chronic CHIKV arthritic disease.  
 
6.3.3 Future directions 
1) To better characterise the inflammatory signatures and identify potential viral 
genomes associated with chronic CHIKV arthritis 
Although results herein indicate that CHIKV infection leads to the persistence of CHIKV 
and chronic inflammation, the factors that are associated with, and regulate, CHIKV persistence and 
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chronic inflammation are not comprehensively understood.  A better understanding of these factors 
will facilitate the development of better treatments for chronic CHIKV.  Further evaluation may use 
RNA-sequencing to study the total RNA population in mice feet with persistent CHIKV RNA.  
This approach should identify more DEGs than the microarray study, as background subtraction 
issues are less of an issue with this technology.  Background subtraction issues tend to compromise 
the ability to find significantly differentially regulated genes in microarray studies when fold 
changes are low.  This approach will not only help identifying more comprehensively the factors 
that are associated with CHIKV persistence and inflammation, but may also give insights into the 
viral genome changes associated with persistence.  The insights arising from such mouse studies 
might also guide further analyses of patient samples (e.g. synovial samples).  
 
2) CD8+ T cells role in controlling CHIKV persistence 
Studies suggest that CD8+ T cells do not appear to play a role in controlling acute viraemia 
(Linn et al., 1998, Chu et al., 2013, Teo et al., 2012b), but these studies did not examine whether 
CD8+ T cells could play a role in controlling CHIKV persistence in vivo.  Further studies might 
focus on evaluating the role T cells, specifically CD8+ T cells, in controlling CHIKV persistence in 
the tissue.  This evaluation can be achieved by infecting mice with deficient in CD8+ T cells (e.g. 
B6.129S2-Cd8atm1Mak/J) and other components of CD8+ T cells like perforin (e.g. C57BL/6-
Prf1tm1Sdz/J) and granzyme B (B6;129S2-Gzmbtm1Ley/J).  These studies would provide insights on 
whether cytolytic activities are involved in clearing persistent CHIKV RNA.  If CD8+ T cells are 
shown to be crucial, future therapeutics may look into ways for enhancing CD8+ T cells, for 
example, by inhibiting programmed cell death protein 1 that are highly expressed in CD8+ T cells 
that have been exhausted during chronic viral infection (Barber et al., 2006).  
 
3) Evaluating the effect of anti-IL-6 therapeutics on CHIKV arthritis   
 Targeting IL-6 may be worth exploring as a therapeutic intervention given that IL-6 was (i) 
implicated in RA (Shoda and Yamamoto, 2007), (ii) up-regulated in CHIKV patients with chronic 
arthritic symptoms (Chow et al., 2011, Chopra et al., 2012, Hoarau et al., 2010), and (iii) was 
identified as an upstream regulator during chronic infection of CHIKV infection in mice (Figure 
5.7; other cytokines).  Interventions targeting IL-6, such as siltuximab/sirukumab and tocilizumab 
(IL-6 and IL-6 receptor targeting agents, respectively), have been clinically proven to ameliorate a 
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range of inflammatory autoimmune diseases, including RA, juvenile idiopathic arthritis and 
Castleman’s disease (Tanaka et al., 2014, Yoshida and Tanaka, 2014). 
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Appendices 
Appendix I  
Table 7.1: Details of the IPA pathways shown in Figure 3.15B. 
Ingenuity Canonical Pathways -log(p-value) Molecules 
Granulocyte    
Granulocyte Adhesion and Diapedesis  7.52  CXCL3,IL36G,MMP3,CXCL13,CXCR2,PPBP,C
CL3L1/CCL3L3,CCL20,IL1B,CXCL6,CCL19  
Agranulocyte Adhesion and Diapedesisa  7.27  CXCL3,IL36G,MMP3,CXCL13,CXCR2,PPBP,C
CL3L1/CCL3L3,CCL20,IL1B,CXCL6,CCL19  
IL-17A in autoimmunity    
Role of IL-17A in Psoriasis  7.78  CXCL3,S100A9,CCL20,S100A8,CXCL6  
Role of IL-17A in Arthritis  4.41  CXCL3,CCL20,PTGS2,NOS2,CXCL6  
Rheumatoid arthritis    
Altered T Cell and B Cell Signaling in 
Rheumatoid Arthritis  
2.55  IL36G,CXCL13,LTB,IL1B  
Role of Osteoblasts, Osteoclasts and 
Chondrocytes in Rheumatoid Arthritis  
1.73  IL36G,SFRP2,MMP3,IL1B,Bmpr1b  
Role of Macrophages, Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis  
1.71  IL36G,SFRP2,MMP3,LTB,IL1B,NOS2  
Inflammation    
Acute Phase Response Signaling  3.77  IL36G,HP,C1S,RBP2,IL1B,SERPINA3,OSMR  
Communication between Innate and 
Adaptive Immune Cells  
3.41  IL36G,HLA-B,CCL3L1/CCL3L3,IL1B,CD8A  
Atherosclerosis Signaling  2.83  CCR3,IL36G,MMP3,IL1B,S100A8  
Dendritic Cell Maturation  2.13  STAT4,IL36G,HLA-B,LTB,IL1B  
Aryl Hydrocarbon Receptor Signaling  1.76  GSTM3,ALDH1A2,NQO1,IL1B  
LPS/IL-1 Mediated Inhibition of RXR 
Function  
1.74  IL36G,GSTM3,ALDH1A2,IL1B,SMOX  
Other    
LXR/RXR Activation  2.77  IL36G,IL1B,S100A8,PTGS2,NOS2  
Retinoate Biosynthesis I  2.73  SDR16C5,ALDH1A2,RBP2  
Cholecystokinin/Gastrin-mediated 
Signaling  
2.23  IL36G,IL1B,EPHA4,PTGS2  
Xenobiotic Metabolism Signaling  1.85  GSTM3,ALDH1A2,NQO1,IL1B,SMOX,NOS2  
 
Details of the IPA pathways shown in Figure 3.15 for the 181 genes where “the fold change in 
CCR2mice” divided by “the fold change in WT mice” was >1.5; i.e. pathways associated withgenes 
more induced in CCR2-/ feet. aSame genes as in “Granulocyte Adhesion and Diapedesis”. Only 
pathways with (i) a -log(p value) > 1.5 and (ii) 4 or more molecules are shown 
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Table 7.2: Details of the IPA pathways shown in Figure 3.15C. 
Ingenuity Canonical Pathways -log(p-value) Molecules 
Monocyte/macrophage    
Dendritic Cell Maturation  12.4  PLCB2,LEP,NFKBIE,PIK3R5,HLA-DQA1,HLA-
DRB1,HLA-DMB, 
CD83,HLADQB1,FCGR2B,TREM2,FCGR1A,PI
K3CG,COL10A1,TNFRSF1B,FCGR3A,HLA-
DMA,TYROBP,IL10,MYD88,HLA-B, 
IL15,CD40,PLCG2,PIK3R6,FCER1G,CD86,ST
AT2,PIK3CD, IRF8,TNF  
Fcγ Receptor-mediated Phagocytosis in 
Macrophages and Monocytes  
7.87  RAC2,PXN,TLN1,FYB,FCGR1A,INPP5D,PLD4,
NCF1,PIK3CG,SYK,LYN,HCK,VAV1,FGR,FCG
R3A,ACTA1,LCP2,PRKCB  
Production of Nitric Oxide and Reactive 
Oxygen Species in Macrophages  
7.74  PTPN6,PPP1R3C,NFKBIE,PIK3R5,PPP1R3A,
APOC2,NCF4, 
SPI1,IRF1,NCF1,ALB,RHOG,PLCG2,PIK3CG,
CYBA,NCF2, 
PIK3R6,CYBB,PIK3CD,SERPINA1,IRF8,TNFR
SF1B,TNF,SIRPA,PRKCB  
MSP-RON Signaling Pathway  6.24  CSF2RB,ITGB2,ITGAM,CCL12,PIK3CG,PIK3R
6,PIK3R5,PIK3CD,CCR2,TNF,ACTA1  
IL-12 Signaling and Production in 
Macrophages  
4.36  IL10,MYD88,PIK3R5,APOC2,SPI1,IRF1,ALB,C
D40,TGFB1, 
PIK3CG,PIK3R6,SERPINA1,PIK3CD,IRF8,TNF
,PRKCB  
Pattern recognition    
Role of Pattern Recognition Receptors in 
Recognition of Bacteria and Viruses  
8.01  Tlr11,NLRP3,IL10,MYD88,PIK3R5,C1QC,C1Q
A,C1QB,IRF7,PLCG2,PIK3CG,SYK,TLR1,PIK3
R6,PIK3CD,TNF,C3AR1,PRKCB  
Autoimmunity    
Altered T Cell and B Cell Signaling in 
Rheumatoid Arthritis  
7.96  HLA-DMA,Tlr11,CD79B,IL10,IL15,HLA-
DQA1,HLA-DRB1,HLA-
DMB,HLADQB1,CD79A,CD40,TGFB1,TLR1,FC
ER1G,CD86, Tlr13,TNF  
Type I Diabetes Mellitus Signaling  7.88  HLA-
DMA,SOCS3,CASP3,MYD88,NFKBIE,HLA-
B,HLA-DQA1, APAF1,HLA-DRB1,HLA-
DMB,HLA-DQB1,IRF1,PRF1,FCER1G, 
CD86,BID,TNFRSF1B,HLA-F,TNF  
Autoimmune Thyroid Disease Signaling  6.88  HLA-DMA,PRF1,CD40,IL10,HLA-B,HLA-
DQA1,FCER1G,HLA-DRB1,CD86,HLA-
DMB,HLA-DQB1,HLA-F  
Systemic Lupus Erythematosus Signaling  4.07  PTPN6,CD79B,IL10,HLA-
B,PIK3R5,FCGR2B,FCGR1A, 
CD79A,INPP5D,CD40,PIK3CG,CD72,PLCG2,P
IK3R6,FCER1G, LYN,CD86,PIK3CD,HLA-
F,TNF,FCGR3A  
B and T cells    
Role of NFAT in Regulation of the 
Immune Response  
9.55  PLCB2,NFKBIE,PIK3R5,HLA-DQA1,HLA-
DRB1,HLA-DMB,  
HLA-
DQB1,FCGR2B,FCGR1A,CD79A,GNB4,PIK3C
G, FCGR3A,HLA-
DMA,CD79B,ITPR1,GNAI2,BTK,SYK,PLCG2, 
PIK3R6,FCER1G,LYN,CD86,MEF2C,PIK3CD,L
CP2  
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T Helper Cell Differentiation  8.5  HLA-DMA,IL2RG,IL10,HLA-DQA1,HLA-
DRB1,HLA-DMB,HLA-
DQB1,CD40,TGFB1,FCER1G,IL10RB,IL10RA,
CD86,IL2RA, TNFRSF1B,TNF  
FcγRIIB Signaling in B Lymphocytes  8.36  BTK,CD79B,SYK,PIK3CG,PLCG2,LYN,PIK3R6
,PIK3R5,PIK3CD,DOK1,FCGR2B,CD79A,INPP
5D  
iCOS-iCOSL Signaling in T Helper Cells  7.68  HLA-DMA,IL2RG,NFKBIE,CSK,HLA-
DQA1,PIK3R5,HLA-DRB1,HLA-DMB,HLA-
DQB1,ITPR1,INPP5D,CD40,PIK3CG, 
PIK3R6,FCER1G,VAV1,IL2RA,PIK3CD,LCP2  
Antigen Presentation Pathway  7.3  PSMB9,NLRC5,HLA-DMA,HLA-B,HLA-
DQA1,CIITA,HLA-DRB1,HLA-DMB,CD74,HLA-
F,TAP1  
B Cell Receptor Signaling  6.87  RAC2,PTPN6,CD79B,POU2F2,NFKBIE,CSK,PI
K3R5,FCGR2B, 
CD79A,INPP5D,BTK,SYNJ1,DAPP1,SYK,PIK3
CG,PLCG2,PIK3R6,LYN,VAV1,PIK3AP1,PIK3C
D,PRKCB  
PI3K Signaling in B Lymphocytes  6.45  PLCB2,CD79B,NFKBIE,ITPR1,FCGR2B,INPP5
D,CD79A,BTK,DAPP1,CD40,CD180,SYK,PIK3
CG,PLCG2,LYN,VAV1,PIK3AP1, 
PIK3CD,PRKCB  
CD28 Signaling in T Helper Cells  6.41  HLA-DMA,PTPN6,NFKBIE,CSK,HLA-
DQA1,PIK3R5,HLA-DRB1,HLA-DMB,HLA-
DQB1,ITPR1,PIK3CG,SYK,PIK3R6, 
FCER1G,CD86,VAV1,PIK3CD,LCP2  
Graft-versus-Host Disease Signaling  6.14  HLA-DMA,PRF1,HLA-B,HLA-
DQA1,FCER1G,HLA-DRB1,CD86, HLA-
DMB,HLA-DQB1,HLA-F,TNF  
Tec Kinase Signaling  5.86  PIK3R5,ITGA5,BTK,GNAI2,GNB4,RHOG,PLC
G2,PIK3CG,LYN, 
FCER1G,PIK3R6,HCK,VAV1,STAT2,PIK3CD,T
NF,FGR,ACTA1, ITGA4,PRKCB  
B Cell Development  5.85  HLA-DMA,CD79B,CD40,HLA-DQA1,HLA-
DRB1,CD86, HLA-DMB, HLA-DQB1,CD79A  
Allograft Rejection Signaling  5.72  HLA-DMA,PRF1,H2-T24,CD40,IL10,HLA-
B,FCER1G,HLA-DQA1, CD86,HLA-DRB1,HLA-
DMB,HLA-DQB1,HLA-F,TNF  
IL-4 Signaling  5.49  HLA-DMA,IL2RG,PTPN6,HLA-
DQA1,PIK3R5,HLA-DRB1,  
HLA-DMB,HLA-
DQB1,INPP5D,SYNJ1,PIK3CG,PIK3R6,PIK3C
D  
CTLA4 Signaling in Cytotoxic T 
Lymphocytes  
5.24  HLA-DMA,PTPN6,HLA-DQA1,PIK3R5,HLA-
DRB1,HLA-DMB,  
HLA-
DQB1,PIK3CG,SYK,PIK3R6,FCER1G,CD86,PI
K3CD,LCP2 
Cytotoxic T Lymphocyte-mediated 
Apoptosis of Target Cells  
5.17  HLA-DMA,PRF1,H2-T24,CASP3,HLA-
B,FCER1G,APAF1,  
HLA-DQA1,BID,HLA-DRB1,HLA-DMB,HLA-
DQB1,HLA-F  
PKCθ Signaling in T Lymphocytes  5.13  HLA-DMA,RAC2,NFKBIE,HLA-
DQA1,PIK3R5,HLA-DRB1,HLA-DMB,HLA-
DQB1,PLCG2,PIK3CG,PIK3R6,FCER1G,CD86
, VAV1,PIK3CD,LCP2  
Communication between Innate and 
Adaptive Immune Cells  
4.61  Tlr11,CD40,IL10,TLR1,IL15,HLA-
B,FCER1G,CD86,Tlr13,  
HLA-DRB1,CD83,HLA-F,TNF  
NK cells    
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Natural Killer Cell Signaling  9.02  RAC2,PTPN6,Klra4 (includes 
others),LAIR1,TYROBP,PIK3R5, 
SH3BP2,INPP5D,SYNJ1,SYK,KLRC4-
KLRK1/KLRK1,PLCG2, 
PIK3CG,PIK3R6,FCER1G,VAV1,PIK3CD,SH2
D1B,LCP2,FCGR3A,PRKCB  
Crosstalk between Dendritic Cells and 
Natural Killer Cells  
8.4  IL2RG,TYROBP,CD69,IL15,HLA-B,HLA-
DRB1,TLN1,CD83, 
TREM2,CSF2RB,PRF1,CD40,KLRC4-
KLRK1/KLRK1, CD86,TNFRSF1B,HLA-
F,TNF,ACTA1  
Muscle    
Actin Cytoskeleton Signaling  4.79  RAC2,PXN,MYLPF,CSK,ACTN2,PIK3R5,ITGA
5,MYH7,TLN1,  
IQGAP2,MYH2,PIK3CG,PIK3R6,MYH3,VAV1,P
IK3CD,NCKAP1L,TMSB10/TMSB4X,PIP4K2A,
ACTA1,MYH1,ITGA4  
Calcium Signaling  4.74  RAP2B,TNNT1,CHRNA1,ATP2B1,TNNC2,TNN
C1,TNNT2,TRDN,CHRNB1,Tpm1,MYH7,ITPR1
,MYH2,MYH3,RYR1,MEF2C,TNNI1,SLC8A1,A
CTA1,MYH1  
Paxillin Signaling  4.76  ITGB2,PXN,ITGAM,PIK3CG,ACTN2,CSK,PIK3
R6,PIK3R5,ITGA5,PIK3CD,TLN1,ITGA7,ACTA
1,ITGA4  
Inflammation    
TREM1 Signaling  9.57  Tlr11,TYROBP,IL10,MYD88,LAT2,ITGA5,CD83
,FCGR2B,CD40, 
CCL12,CCL7,PLCG2,TLR1,CD86,Tlr13,TNF  
Leukocyte Extravasation Signaling  8.81  RAC2,MMP14,PIK3R5,MMP25,PIK3CG,CYBA,
CYBB,ACTA1, 
ITGA4,PXN,CXCR4,ACTN2,ARHGAP4,ITGA5,
NCF4,SELPLG, 
GNAI2,BTK,ITGB2,NCF1,WIPF1,ITGAM,PLCG
2,NCF2,PIK3R6, VAV1,PIK3CD,PRKCB  
Atherosclerosis Signaling  6.36  ALOX12B,MSR1,CXCR4,APOC2,PLA2G7,F3,T
NFRSF14, 
SELPLG,ITGB2,ALB,CD40,CCL12,TGFB1,COL
10A1,SERPINA1, CCR2,TNF,ITGA4  
Fc Epsilon RI Signaling  5.38  RAC2,PIK3R5,INPP5D,BTK,SYNJ1,PLCG2,PIK
3CG,SYK,LYN, 
FCER1G,PIK3R6,VAV1,PIK3CD,TNF,LCP2,PR
KCB  
Integrin Signaling  4.96  RAP2B,RAC2,PXN,ARHGAP26,ACTN2,PIK3R
5,ITGA5,TLN1, 
PARVB,ITGB2,WIPF1,RHOG,ITGAM,PIK3CG,
PLCG2,PIK3R6, 
ZYX,PIK3CD,ITGA7,ACTA1,ITGA4  
Role of JAK1 and JAK3 in γc Cytokine 
Signaling  
4.13  SOCS3,IL2RG,FES,PIK3CG,SYK,IL15,PIK3R6,
PIK3R5,IL2RA, PIK3CD  
NF-κB Activation by Viruses  4.09  ITGB2,CCR5,PIK3CG,NFKBIE,PIK3R6,PIK3R5
,ITGA5,PIK3CD, TNFRSF14,ITGA4,PRKCB  
Other    
Virus Entry via Endocytic Pathways  4.4  RAC2,HLA-
B,PIK3R5,ITGA5,ITGB2,FLNC,PLCG2,PIK3CG
, PIK3R6,PIK3CD,ACTA1,PRKCB,ITGA4  
Induction of Apoptosis by HIV1  4.32  CASP3,CXCR4,NFKBIE,APAF1,BID,BAX,TNF
RSF1B,NAIP,TNF,BAK1  
LXR/RXR Activation  4.26  TTR,MSR1,VTN,AHSG,NR1H3,APOC2,ABCG1
,ALB,CCL12,CCL7,SERPINA1,PLTP,GC,TNFR
SF1B,TNF  
Role of Tissue Factor in Cancer  4.21  F10,ARRB2,CASP3,PIK3CG,LYN,HCK,PIK3R6
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,PIK3R5,PLAUR, 
FGB,PIK3CD,RPS6KA2,F3,FGR  
ILK Signaling  4.2  PXN,FBLIM1,CASP3,ACTN2,PIK3R5,MYH7,PA
RVB,ITGB2, 
RHOG,MYH2,FLNC,PIK3CG,PIK3R6,MYH3,PI
K3CD,TMSB10/TMSB4X,TNF,ACTA1,MYH1  
Phospholipase C Signaling  4.1  PLCB2,CD79B,MYLPF,ITGA5,ITPR1,FCGR2B,
CD79A,BTK, 
PLD4,TGM2,GNB4,RHOG,SYK,PLCG2,FCER1
G,LYN,MEF2C,ARHGEF2,ADCY7,LCP2,ITGA4
,PRKCB  
 
Details of the IPA pathways shown in Figure 3.15 for the 920 gene where “the fold change in WT 
mice” divided by “the fold change in CCR2-/- mice” was >1.5; i.e. pathways associated with the 
genes less induced in CCR2-/- feet. Only pathways with a -log(p value) > 4 are shown. 
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Table 7.3: Details of the IPA pathways shown in Figure 5.6. 
Ingenuity Canonical Pathways -log(p-value) Molecules 
T cells   
Allograft Rejection Signaling 2.35 HLA-G,CD40,H2-K2/H2-Q9,HLA-B 
Cytotoxic T Lymphocyte-mediated 
Apoptosis of Target Cells 1.57 HLA-G,H2-K2/H2-Q9,HLA-B 
OX40 Signaling Pathway 1.5 HLA-G,H2-K2/H2-Q9,HLA-B 
Autoimmunity 
  Type I Diabetes Mellitus Signaling 2.75 HLA-G,HLA-B,HSPD1,STAT1,IRF1 
Systemic Lupus Erythematosus Signaling 2.67 
HLA-G,PTPRC,PIK3R3,CD40,HLA-
B,FCGR1A,FCGR3A 
Autoimmune Thyroid Disease Signaling 2.2 HLA-G,CD40,HLA-B 
Altered T Cell and B Cell Signaling in 
Rheumatoid Arthritis 1.5 CD40,TLR1,Tlr13 
Antigen presentation 
 
 
Antigen Presentation Pathway 4.97 HLA-G,NLRC5,HLA-B,CANX,PSMB8 
Communication between Innate and 
Adaptive Immune Cells 4.05 CXCL10,HLA-G,CD40,HLA-B,TLR1,Tlr13 
Dendritic Cell Maturation 3.24 
PIK3R3,CD40,HLA-
B,STAT1,TREM2,FCGR1A,FCGR3A 
NK cell 
 
 
Crosstalk between Dendritic Cells and 
Natural Killer Cells 2.23 HLA-G,CD40,HLA-B,TREM2 
Innate sensing 
  Activation of IRF by Cytosolic Pattern 
Recognition Receptors 4.96 IFIH1,CD40,DDX58,ZBP1,STAT1,IFIT2 
Role of Pattern Recognition Receptors in 
Recognition of Bacteria and Viruses 2.98 IFIH1,PIK3R3,DDX58,TLR1,C1QB 
Role of PKR in Interferon Induction and 
Antiviral Response 2.4 STAT1,FCGR1A,IRF1 
PI3K/AKT Signaling 1.77 PIK3R3,YWHAH,LIMS1,ITGA4 
Monocytes macrophages 
 
 
Fcγ Receptor-mediated Phagocytosis in 
Macrophages and Monocytes 3.01 PIK3R3,HCK,FYB,FCGR1A,FCGR3A 
TREM1 Signaling 1.93 CD40,TLR1,Tlr13 
Agranulocyte Adhesion and Diapedesis 1.79 CXCL10,CXCL9,CCL13,Ccl8,ITGA4 
IL-12 Signaling and Production in 
Macrophages 1.64 PIK3R3,CD40,STAT1,IRF1 
Apoptosis 
 
 
Retinoic acid Mediated Apoptosis Signaling 1.78 PARP9,IRF1,PARP14 
Cytokines 
  Interferon Signaling 3.82 IFIT3,PSMB8,STAT1,IRF1 
GM-CSF Signaling 1.85 PIK3R3,HCK,STAT1 
Other 
  Neuroprotective Role of THOP1 in 
Alzheimer's Disease 2.4 HLA-G,NFYA,HLA-B 
Glucocorticoid Receptor Signaling 2.29 
PIK3R3,CCL13,HMGB1,YWHAH,STAT1,HSPA5,
FCGR1A 
UVA-Induced MAPK Signaling 2.21 PIK3R3,STAT1,PARP9,PARP14 
Granulocyte Adhesion and Diapedesis 1.89 CXCL10,CXCL9,CCL13,Ccl8,ITGA4 
Protein Ubiquitination Pathway 1.77 USP18,HLA-B,PSMD1,PSMB8,HSPD1,HSPA5 
Reelin Signaling in Neurons 1.59 PIK3R3,HCK,ITGA4 
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Details of the IPA pathways shown in Figure 5.7 for the 192 genes more induced in the feet of day 
30 post infected mice. Only pathways with a -log(p value) > 1.5 are shown. Pathways with a -log(p 
value) > 1.3 (means p  < 0.05) and at least 3 molecules assigned are shown. 
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Table 7.4: Details of the IPA pathways for section 5.2.8.2 
Ingenuity Canonical Pathways -log(p-value) Molecules 
mTOR Signaling 2.09 RPS29,ULK1,RPS27,RHOG,IRS1,RPS8,RPS21 
Regulation of eIF4 and p70S6K Signaling 2.06 RPS29,RPS27,EIF4EBP2,IRS1,RPS8,RPS21 
EIF2 Signaling 1.64 RPS29,RPS27,RPS8,RPS21,RPL13A,RPL13 
Aryl Hydrocarbon Receptor Signaling 1.58 MYC,DCT,RXRB,MGST3,HSPB1 
Details of the IPA pathways described in section 5.2.8.2 of day 30 post infected mice. Pathways 
with a -log(p value) > 1.3 (means p  < 0.05) and at least 3 molecules assigned are shown. 
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Table 7.5: Details of the ingenuity upstream regulator analysis of the 192 more 
induced in the feet of day 30 post infected mice shown in Figure 5.7.   
Red = type I IFN responses; green = Th1 responses; blue = T cells responses; orange = apoptosis; 
purple = autophagy; grey = others.  Only p values < 1E10 are shown.  
Uspstream 
Regulator 
Activatio
n z-score Type 
p-value of 
overlap Target molecules in dataset 
IKBKE 0.101 kinase 9.65E-10 
Ccl2,CXCL10,HLA-
B,IFIH1,IFIT2,IFIT3,Irg1,STAT1 
IFNK 3.134 cytokine 1.59E-10 CD40,CXCL10,CXCL9,IFIH1,IRF1,STAT1,ZBP1 
IFNE 2.449 cytokine 8.28E-11 CD40,CXCL10,CXCL9,IFIH1,IFIT2,STAT1,USP18,ZBP1 
DDX58 
(RIG-I 
gene) 
2.039 enzyme 4.01E-11 CXCL10,DDX58,IFI44,IFIH1,IFIT1B,IFIT2,IFIT3,IRF1,STAT1 
IFN type 1 2.911 group 2.22E-11 Ccl2,CXCL10,CXCL9,DDX58,IFIH1,IFIT1B,IFIT2,IRF1,STAT1 
TLR4 3.324 transmembrane receptor 1.26E-11 
Ccl2,CCR5,CD274,CD40,CXCL10,CXCL9,H
MGB1,IFIT1B,IFIT2,IFIT3,Iigp1,IRF1,IRGM,P
LEK,RGS1,STAT1,TREM2 
IFNA1/IFNA
13 2.925 cytokine 8.54E-12 
CD40,CXCL10,CXCL9,IFIH1,IFIT2,IRF1,STA
T1,Tgtp1/Tgtp2,USP18,ZBP1 
IFN 
alpha/beta 3.264 group 5.57E-12 
CCR2,CD40,CXCL10,CXCL9,IFIT2,IFIT3,IRF
1,IRGM,STAT1,Tgtp1/Tgtp2,TLR1 
IFNA2 3.655 cytokine 1.97E-12 
CXCL10,CXCL9,DDX58,DDX60,EMR1,HERC
6,HLA-
B,IFI44,IFIH1,IFIT2,IFIT3,IRF1,PARP9,STAT1
,USP18,ZBP1 
IFN Beta 3.412 group 6.48E-13 
CD274,CD40,CXCL10,DDX58,HLA-B,HLA-
G,IFIH1,IFIT1B,IFIT2,IRF1,STAT1,USP18,ZB
P1 
IFNAR1 2.75 transmembrane receptor 3.57E-13 
CD40,CXCL10,CXCL9,HLA-
B,IFI44,IFIH1,IFIT1B,IFIT2,IFIT3,Irg1,Oasl2,S
TAT1,USP18 
IFNL1 3.44 cytokine 7.49E-14 CD40,CXCL10,CXCL9,DDX58,DDX60,HERC6,IFI44,IFIH1,IFIT2,IFIT3,STAT1,USP18 
Interferon 
alpha 4.357 group 5.06E-14 
CCR5,CD40,CXCL10,CXCL9,DDX58,FCGR1
A,HLA-B,HLA-
G,IFIH1,IFIT1B,IFIT2,IFIT3,IRF1,ITGA4,PSM
B8,STAT1,Tgtp1/Tgtp2,TLR1,USP18,ZBP1 
TLR3 3.558 transmembrane receptor 2.44E-14 
Ccl2,CD274,CD40,CXCL10,CXCL9,DDX58,G
BP4,IFI44,IFIH1,IFIT2,IFIT3,Iigp1,Irg1,Oasl2,
PIK3R3,RGS1,STAT1,USP18 
IRF3 3.632 transcription regulator 7.44E-16 
Ccl2,CXCL10,CXCL9,DDX58,FCGR1A,IFI44,I
FIH1,IFIT1B,IFIT2,IFIT3,IRGM,Oasl2,PARP14
,STAT1,Trim30a/Trim30d,USP18,ZBP1 
STAT1 4.265 transcription regulator 2.42E-17 
Ccl2,Ccl8,CD274,CD40,CXCL10,CXCL9,FCG
R1A,Gbp6 (includes 
others),HERC6,IFIT1B,IFIT2,IFIT3,IRF1,Irg1,I
RGM,PSMB8,PTN,Rnf213,STAT1,Tgtp1/Tgtp
2,USP18 
IFNB1 3.754 cytokine 1.39E-23 
Ccl2,CCR5,CD274,CD40,CXCL10,CXCL9,DD
X58,GBP4,Gbp6 (includes 
others),GBP7,Gbp8,Gvin1 (includes 
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others),IFIH1,IFIT1B,IFIT2,IFIT3,IRF1,Irg1,IR
GM,STAT1,Tgtp1/Tgtp2,Tlr13,Trim30a/Trim30
d,USP18,VCL,ZBP1 
Ifnar 4.518 group 1.39E-27 
Ccl2,CD274,CD40,CXCL10,CXCL9,DDX58,H
LA-B,HLA-
G,IFIH1,IFIT1B,IFIT2,IFIT3,IRF1,IRGM,ITGA4
,NLRC5,PSMB8,Rnf213,STAT1,USP18,ZBP1 
IRF7 4.345 transcription regulator 5.94E-20 
CD40,CXCL10,CXCL9,DDX58,FCGR1A,GBP
4,IFI44,IFIH1,IFIT1B,IFIT2,IFIT3,IRF1,IRGM,
Oasl2,PARP14,PSMB8,STAT1,Trim30a/Trim3
0d,USP18,ZBP1 
mir-21  -3.769 microRNA 9.95E-18 
AOAH,CD180,CD274,CXCL10,CXCL9,FCGR
1A,Gbp6 (includes others),GBP7,Gbp8,Gvin1 
(includes 
others),Iigp1,IRF1,IRGM,NLRC5,STAT1,Tgtp
1/Tgtp2,TLR1,TREM2 
TRIM24 -4.054 transcription regulator 9.42E-20 
CXCL10,DDX58,DDX60,GBP4,HERC6,IFI44,I
FIH1,IFIT1B,IFIT2,IFIT3,Iigp1,IRF1,IRGM,PS
MB8,STAT1,Tgtp1/Tgtp2,USP18 
SOCS1 -3.908 other 4.58E-20 
Ccl2,CD40,CXCL10,CXCL9,DDX58,Gbp6 
(includes others),GBP7,Gvin1 (includes 
others),IFI44,IFIH1,IFIT1B,IFIT2,IFIT3,Iigp1,I
RF1,Irg1,Oasl2,STAT1 
PARP1 2.646 enzyme 2.19E-10 
Ccl2,CD274,CXCL10,CXCL9,GBP4,Gbp6 
(includes 
others),GBP7,Iigp1,STAT1,Tgtp1/Tgtp2 
IRGM -2.828 other 3.81E-10 CCNB2,CXCL10,CXCL9,IFIT1B,IFIT2,IFIT3,Iigp1,USP18 
STAT3 2.317 transcription regulator 2.52E-10 
Ccl8,CCR5,CD274,CD40,CXCL10,CXCL9,FC
GR1A,GLIPR1,HLA-
B,IFI44,IFIH1,IFIT1B,IFIT3,IRF1,Lyz1/Lyz2,P
SMB8,PTN,STAT1 
IFNG 6.301 cytokine 1.10E-21 
BST1,C1QB,Ccl2,Ccl8,CCR2,CCR5,CD274,C
D40,CTSS,CXCL10,CXCL9,CYBB,DDX58,DT
X3L,FCGR1A,FCGR3A,GBP4,Gbp6 (includes 
others),GBP7,Gbp8,Gvin1 (includes 
others),HCK,HERC6,HLA-B,HLA-
G,HMGB1,HSPD1,IFI44,IFIH1,IFIT2,IFIT3,Iig
p1,IRF1,Irg1,IRGM,NLRC5,PARP9,PLEK,PS
MB8,PTN,STAT1,Tgtp1/Tgtp2,TLR1,TREM2,
USP18 
IL12 
(complex) 1.822 complex 5.69E-11 
Ccl2,CCR2,CCR5,CXCL10,CXCL9,EMR1,IFI
H1,IFIT1B,IFIT2,Iigp1,IRF1,ITGA4,Tgtp1/Tgtp
2,Trim30a/Trim30d 
IL6 3.886 cytokine 6.68E-10 
Ccl2,CCNB2,CCR2,CCR5,CD40,CXCL10,CX
CL9,CYBB,EMR1,FCGR1A,HLA-
B,HSPA5,IFIT1B,IFIT2,IRF1,LY86,Lyz1/Lyz2,
MAD2L1,PSMB8,PTPRC,STAT1,TLR1 
DOCK8 3.162 other 3.57E-11 CD40,CXCL10,CXCL9,IFIT1B,IFIT2,IFIT3,Iigp1,IRF1,RGS1,STAT1 
TCR 0.467 complex 5.27E-11 
CCR2,CCR5,CXCL10,CXCL9,DDX58,GBP4,
HSPA5,HSPD1,IFI44,IFIH1,IFIT2,IFIT3,IRF1,
PIK3R3,PTPRC,STAT1 
     
FZD9 2.425 G-protein coupled receptor 9.19E-10 Ccl2,CXCL10,IFI44,IFIT1B,Oasl2,STAT1 
PLK2 2.646 kinase 2.98E-10 CD40,CXCL10,CXCL9,IFIT2,Iigp1,IRF1,RGS1 
PLK4 2.646 kinase 2.19E-10 CD40,CXCL10,CXCL9,IFIT2,Iigp1,IRF1,RGS1 
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Table 7.6: Mutations identified in CHIKV recovered from Rag-1-/- mice day 100 post 
infection.  
Parental Reunion Island isolate LR2006 OPY1 (passaged twice in C6/36 cells) used herein 
(Gardner et al., 2010) and virus isolated from Rag-1-/- mice at day 100 post infection (Rag100) were 
grown in C6/36 cells, partially purified (0.22 µM filtration, DNase/RNase treated, and 100,000 g 1 
h centrifugation), RNA isolated (QIAamp Viral RNA Mini Kit) and reverse transcribed, with the 
resultant viral cDNA amplified using the Illustra GenomiPhi V2 DNA Amplification Kit (GE 
Healthcare).  The sequence of the viral genome was then determined using semi-conductor 
sequencing (Ion Torrent PGM) at the Lotterywest State Biomedical Facility Genomics (University 
of Western Australia).  Ion 314 chips were used to generate >200,000 reads of ≈100 bp.  The 
sequence was assembled using Geneious Pro software and aligned with LR2006 OPY1 (Accession: 
DQ443544.2).  Sequence changes are indicated below, changes highlighted in red.  Three coding 
changes were identified. 
 
Nucleotide position Virus Nucleotide Amino Acid 
776 LR2006 OPY1 A K 
Parental G E 
Rag100 G E 
1052 LR2006 OPY1 A and G M/V 
Parental G V 
Rag100 G V 
4167 LR2006 OPY1 A and G D/G 
Parental A D 
Rag100 A D 
4302 LR2006 OPY1 A Y 
Parental A Y 
Rag100 G C (nsP31409) 
5049 LR2006 OPY1 G and T R/I 
Parental T I 
Rag100 T I 
5903 LR2006 OPY1 C L 
Parental C L 
Rag100 T L 
8978 LR2006 OPY1 A Q 
Parental A Q 
Rag100 G R(E2471) 
185 
9203 LR2006 OPY1 A K 
Parental A K 
Rag100 G and A R and K (E2346) 
11073 LR2006 OPY1 A L 
Parental A L 
Rag100 G L 
3’ UTR; 11395, 11421 
and 11455 
LR2006 OPY1 C - 
Parental C - 
Rag100 T - 
 
Data was prepared with assistance of Helle Bielefeldt-Ohmann and Penny Rudd. 
 
